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Summary
Laboratory medicine has undergone a spectacular evolution in the last deca-
des and has become today of crucial importance for supporting diagnostic
and therapeutic decisions. The increase of the volume of laboratory analy-
ses has not gone without an emerging risk of measurement errors that may
have far-reaching consequences, even on the patient’s life. External Qual-
ity Assessment (EQA), already established since several decades in various
countries and often running on an international level, aim at going further
than the "internal quality control" procedures of every laboratory and at im-
proving laboratory quality by inter-laboratory comparisons. An EQA round
generally consists of sending aliquots of the same sample to various labo-
ratories for assaying selected tests. After finishing the assays, results are
reported back to the EQA organizer. Subsequently these results are subject
to a statistical analysis, which is performed globally, for all the participants,
or for each analytical technique separately. Finally, a report is sent to every
participant that informs about the acceptability of the individual results,
with respect to predefined limits, and with respect to the group of peers.
This thesis, structured in five chapters, focuses on the External Quality Con-
trol of clinical laboratories by a critical analysis of existing methods and by
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creating new approaches that permit to improve the current procedures.
The first chapter of this work emphasizes the evolution of the role of the
clinical laboratory and EQA in the quality improvement. After the report
’To Err is Human: Building a Safer Health System’, numerous scientists
became interested in investigating the frequency, source and impact of lab-
oratory errors. The Total Testing Process (TTP) became recognized as the
best framework to investigate laboratory errors. The three different phases
of the TTP - respectively, the pre-analytical, analytical and post-analytical
phases - are described in detail and the nature and frequency of errors in
each phase explained. For each phase, possible improvements are described
and the role of EQA is suggested. Today, EQA principally focuses on the
assessment and improvement of the analytical phase. Proposals are made to
improve the role of EQA for assessing and improving pre- and post-analytical
error as well, by using specific sample material and by automating the report-
ing of data and laboratory reports to the EQA participants. The principle
of the comparison of results of a laboratory with those obtained by the other
laboratories is traditionally based on the calculation of "z-scores". An in-
depth study comparing different techniques has been made, shedding new
light on the shortcomings and strong points of the different approaches. We
concluded that robust techniques may exhibit weak performance for smaller
sample size, while techniques that eliminate outliers before calculating z-
scores should be recommended.
The second Chapter discusses the role of EQA as a tool to assess harmo-
nization between methods. The role of EQA is described, together with the
pitfalls and current shortcomings for assessing harmonization. A major prob-
lem in assessing standardization between methods is the possible presence of
matrix effects in control samples, in which a method-specific bias may ap-
pear. Several explanations for matrix effects are mentioned and statistical
techniques are described that assist EQA organizers to split up the data in
homogeneous peer groups using multivariate statistics. The chapter also re-
views several techniques to be used in method comparison studies, and the
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preference for the use of orthogonal regression is expressed. In addition, an
example is given of a method-comparison study for Estradiol and Proges-
terone, with a novel technique of assessing standardization between various
methods, in the presence of matrix effects for a small number of samples.
The study also reveals that standardization between various methods is not
attained, and that the striving for standardization with standards of higher
order may not be satisfactory.
Chapter 3 introduces different evaluation techniques that combine informa-
tion from different samples or parameters: Variance and bias index scores,
Mean ranking scores, counts of z- and u-scores, and a long-term analytical
Coefficient of Variation. Also, a new and original method is introduced that
uses 3 steps to identify outliers in a first step, to find laboratories with ex-
ceeding variability in a second, and to identify laboratories with high bias in
a third step. Each of the techniques are evaluated and discussed by means
of a data set in which accidental outliers, high variability and high bias were
induced. In addition, the comparison between the different evaluation meth-
ods reveals that distinguishing between variability and bias is a tedious task,
and that some long-term analysis methods lack robustness against outliers.
Also, it is proven that evaluation techniques summarizing results of different
parameters may hide useful information. In addition, the 3-step method is
proposed as a method for discerning between errors produced in the pre- or
post-analytical phase, and errors that arise from the analytical phase.
Chapter 4 applies the 3-step method to data obtained from the Belgian EQA.
Data sets from alcohol, flow cytometry, lithium and semen analysis surveys
are examined. The method is extended for applicability to heteroscedastic,
i.e. unequal residual variability, regression models and demonstrates that
it is able to be used in a wide range of surveys. For each of the surveys
under consideration, a follow-up is made of the occurrence of accidental mis-
takes, and the evolution of within-laboratory variability and bias for selected
methods. It highlights several conclusions that show a striking similarity for
various EQA surveys: an improvement of laboratory performance has been
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attained over time. The major improvement was a reduction of accidental
mistakes. The analytical performance of selected methods, however, did not
show an improvement over time.
In Chapter 5, some graphical representations of EQA data are explored and
a graphical representation of the 3-step method is described. The histogram,
normal quantile plot and box plot are described in detail and suggested for
providing a quick visual overview of EQA data. Other graphical representa-
tions that respond to specific questions are given and discussed as well, like
Shewhart charts, Cusum charts and graphical representations to combine
variability and bias in one graph. In addition, the 3-step method is graph-
ically explored by means of three distinct graphs. The chapter finishes by
suggesting the use of interactive graphs for improving feedback from the EQA
organizers to the EQA participants by means of Scalable Vector Graphics.
The latter is illustrated with web-accessible examples of long-term evaluation
of z-scores and the results of the 3-step method for the data obtained in the
Belgian EQA for alcohol determination in blood.
In brief, this work describes in a critical and constructive way current sta-
tistical methods used in EQA and proposes novel statistical and graphical
techniques to help alleviating the future needs of External Quality Assess-
ment programmes.
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Résumé
La biologie clinique a connu au cours des dernières décennies une évolution
spectaculaire. Elle est devenue aujourd’hui une discipline incontournable
dans l’aide à la décision médicale. L’augmentation du volume d’analyses de
laboratoire n’est toutefois pas sans entraîner un risque accru d’erreurs de
mesure pouvant avoir des conséquences graves sur la vie même des patients.
Les programmes d’Evaluation Externe de la Qualité (EEQ), mis en place
depuis plusieurs années tout au niveau national qu’international, se sont fixés
pour objectifs d’aller au-delà des procédures de « contrôle de qualité interne »
de chaque laboratoire et de contribuer à l’amélioration globale de la qualité
par l’organisation d’enquêtes inter-laboratoires. Au cours de chaque enquête
EEQ, un (ou plusieurs) même échantillon contrôle est envoyé à l’ensemble des
laboratoires pour analyse. Une fois les dosages terminés, les résultats sont
renvoyés à l’organisme responsable EEQ. Ces résultats font ensuite l’objet
d’une analyse statistique, globale ou par technique de dosage (c’est-à-dire
par groupe de laboratoires utilisant le même principe analytique) et un rap-
port est adressé à chaque participant l’informant sur l’acceptabilité de ses
résultats (par rapport à des limites prédéfinies) et sur sa performance par
rapport à ses pairs.
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Ce mémoire, structuré en cinq chapitres, s’est intéressé à l’Evaluation Externe
de la Qualité des laboratoires de biologie clinique par une analyse critique des
méthodes existantes ainsi que par la mise au point de nouvelles approches
permettant d’améliorer les procédures actuellement en place.
Au Chapitre 1, l’accent est mis sur l’évolution du rôle des laboratoires de
biologie clinique et des programmes EEQ dans l’amélioration de la qualité.
Après la publication du rapport « To err is human: building a safer health
system », de nombreux chercheurs ont commencé à s’intéresser et étudier
en détail la fréquence, l’origine et l’impact des erreurs de laboratoire. Dans
ce contexte, le concept de « Total Testing Process (TTP) » est reconnu
comme le meilleur système pour traquer les erreurs de laboratoire. Les trois
phases du TTP, respectivement libellées pré-analytique, analytique et post-
analytique, sont détaillées en spécifiant pour chacune d’elles la nature et la
fréquence des erreurs. De plus, des améliorations potentielles sont décrites
à chaque fois, notamment grâce au rôle que peuvent jouer les programmes
EEQ dans cette problématique. Il faut reconnaître qu’à l’heure actuelle, ces
derniers se focalisent surtout sur l’évaluation et l’amélioration de la phase
analytique. Quelques propositions sont faites pour améliorer le rôle des pro-
grammes EEQ dans le suivi et le développement des phases pré-analytique
et post-analytique, en utilisant des échantillons contrôles de matériel spé-
cifique et en automatisant l’échange des données et des rapports entre les
participants et l’organisme EEQ. Le principe de la comparaison des résultats
d’un laboratoire avec ceux obtenus par les autres laboratoires est tradition-
nellement basé sur le calcul des « z-scores ». Une étude comparative des
méthodes de calcul des z-scores a été menée afin de mettre en évidence les
points forts et les points faibles de chacune d’elles. Il en ressort que les méth-
odes basées sur la statistique robuste sont peu fiables lorsque le nombre de
laboratoires est faible, tandis que celles basées sur l’élimination préalable des
valeurs aberrantes (« outliers ») avant le calcul des z-scores sont meilleures
et dès lors recommandées.
Le Chapitre 2 s’intéresse à l’intérêt des programmes EEQ en tant qu’outil
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d’évaluation de l’harmonisation des méthodes analytiques. Le rôle de l’EEQ,
les pièges et limitations actuelles de l’évaluation de l’harmonisation y sont
décrits. On évoque notamment la problématique de l’effet de matrice dans les
échantillons contrôles, qui peuvent causer un biais spécifique par méthode.
Ces effets de matrice trouvent des explications et peuvent être contournés
en formant des groupes homogènes de laboratoires en ayant recours à des
techniques de la statistique multivariée. Le chapitre 2 passe aussi en revue
plusieurs approches statistiques pour comparer différentes méthodes analy-
tiques; une préférence se dégage pour l’utilisation de la régression orthogo-
nale. En guise d’illustration, une étude comparative des méthodes de dosage
de l’estradiol et de la progestérone a été menée pour essayer de standardiser
plusieurs méthodes de dosage en présence d’effets de matrice pour certains
échantillons. L’étude montre que la standardisation n’est pas atteinte et que
le fait de rechercher une standardisation en se basant sur es standards d’ordre
plus élevé pourrait s’avérer insatisfaisant.
Le Chapitre 3 introduit diverses techniques d’évaluation de la qualité combi-
nant l’information de plusieurs échantillons ou paramètres, à savoir les scores
de variabilité et de biais, le score basé sur le classement des moyennes, les
scores Z et U, et le coefficient de variation (CV) à long-terme. On pro-
pose également une méthode nouvelle et originale en trois étapes (« 3-step
method ») basée sur le modèle de régression linéaire. La première étape con-
siste en la détection d’éventuels « outliers» pour chaque laboratoire ; dans
une deuxième étape, on identifie ensuite les laboratoires ayant une variabilité
excessive ; enfin dans une troisième étape, on repère les laboratoires avec un
biais important. Les méthodes existantes précitées et la nouvelle approche
en 3 étapes font ensuite l’objet d’une étude comparative par simulations sur
un échantillon de données dans lequel on a introduit des erreurs accidentelles,
une variabilité excessive et un biais élevé. Les simulations montrent qu’il n’est
pas facile de distinguer entre la variabilité et le biais, et que certaines méth-
odes d’analyse à long-terme ne sont pas robustes en présence d’« outliers ».
On a aussi montré que les techniques d’évaluation des différents paramètres
peuvent masquer des informations utiles. Le point saillant de l’étude est que
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la méthode en 3 étapes permet de distinguer les erreurs qui surviennent lors
des phases pré-analytique et post-analytique de celles provenant de la phase
analytique.
Au Chapitre 4, la méthode en 3 étapes est appliquée à des données du pro-
gramme Belge de l’Evaluation Externe de la Qualité : alcoolémie, cytométrie
de flux, lithium et analyse de sperme. La méthode est ensuite étendue pour
être applicable à des situations où les conditions d’homoscédasticité (ho-
mogénéité des variances) ne sont pas respectées, situation fréquente en EEQ.
On a effectué un suivi de l’occurrence d’erreurs accidentelles et de la variabil-
ité et du biais inter-laboratoires pour une méthode donnée des programmes
EEQ belges. Les conclusions montrent une similarité remarquable entre les
différentes périodes EEQ, à savoir une amélioration globale des prestations
des laboratoires dans le temps, due essentiellement à la réduction des erreurs
accidentelles. En effet, la performance analytique des méthodes de dosage
n’a pas réellement montré d’amélioration.
Le Chapitre 5 est consacré aux représentations graphiques des données EEQ,
en particulier pour la méthode en 3 étapes. L’histogramme, le graphe des
quantiles normaux et la boîte à moustaches sont fréquemment utilisés pour
une exploration visuelle des données EEQ. D’autres représentations graphiques,
davantage liées à des questions spécifiques, sont mentionnées comme la carte
de contrôle de Shewhart, celle des « cusums » et les représentations qui com-
binent la variabilité et le biais sur un seul graphique. La méthode en 3 étapes
est explorée graphiquement par trois graphes séparés. Le chapitre se termine
avec la présentation de graphes interactifs comme moyen d’améliorer le feed-
back des organisateurs EEQ aux participants, notamment en ayant recours
aux graphes vectoriels adaptables. Ceci est illustré par des exemples qui
peuvent être visualisés sur le web, notamment une évaluation à long-terme
des z-scores et les résultats de la méthode en 3 étapes pour les données EEQ
d’alcoolémie dans le sang.
En conclusion, ce travail revisite de façon critique et constructive les méth-
xiv
odes statistiques et graphiques utilisées actuellement en EEQ et propose de
nouvelles approches visant à répondre aux besoins futurs des programmes
d’Evaluation Externe de la Qualité.
xv
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Samenvatting
Laboratoriumgeneeskunde heeft de laatste decennia een spectaculaire evo-
lutie ondergaan en is tegenwoordig een onmisbare discipline geworden voor
de ondersteuning van diagnostische en therapeutische beslissingen. De forse
stijging van het aantal laboratoriumanalyses is samengegaan met een ver-
hoogd risico op meetfouten, die verreikende gevolgen, ook voor het leven van
de patiënten, kunnen hebben. Externe kwaliteitscontrole (EKE), een disci-
pline die al gedurende verschillende jaren in verschillende landen en op een
internationaal niveau wordt uitgevoerd, is één van de mechanismes om de
kwaliteit in het laboratorium te verbeteren, om een aanvulling te zijn op de
interne kwaliteitscontrole van elk laboratorium en om bij te dragen aan de
algemene verbetering van de kwaliteit door de organisatie van interlaborato-
riumproeven. Een EKE-ronde bestaat in het algemeen uit het versturen van
de aliquots van hetzelfde staal naar verschillende laboratoria, die bepaalde
testen erop uitvoeren. Na de analyse worden de resultaten teruggestuurd
naar de EKE-organisator. Daarna worden de resultaten statistisch geanaly-
seerd, globaal of per meettechniek (dwz per groep van laboratoria die dezelfde
meettechnologie gebruiken) en een rapport wordt verstuurd naar elke deelne-
mer dat informeert over de aanvaardbaarheid van zijn resultaten, tegenover
vooraf gestelde limieten en tegenover de andere laboratoria die eenzelfde
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meettechniek gebruiken.
Dit werk, in vijf hoofdstukken opgevat, gaat dieper in op de Externe Kwaliteit-
sevaluatie van de klinische laboratoria door een kritische analyse van de
bestaande evaluatiemethodes en ook door het opstellen van nieuwe benaderin-
gen die in staat zijn om de huidige evaluatietechnieken te verbeteren.
In het eerste hoofdstuk ligt de klemtoon op de evolutie van de rol van het klin-
isch laboratorium en EKE. Nadat het IOM rapport ’To Err is Human: Build-
ing a Safer Health System’ was verschenen, zijn wetenschappers begonnen de
frequentie, bron en impact van laboratoriumfouten in detail te onderzoeken.
Het totale testproces (TTP) wordt beschreven als het best referentiekader om
laboratoriumfouten te onderzoeken. De drie verschillende fases van het TTP
- respectievelijk pre-analytisch, analytisch en post-analytisch - worden in de-
tail beschreven en het karakter en de frequentie van fouten in elk proces wordt
uitgelegd. Voor iedere fase worden toekomstige verbeteringen beschreven en
de rol van EKE wordt hierin voorgesteld. Tegenwoordig bekommert de EKE
zich vooral om de evaluatie en de verbetering van de analytische fase. Er
worden enkele voorstellen gemaakt waarbij EKE programma’s ook het pre-
en post-analytisch deel kunnen opvolgen, door specifiek staalmateriaal te ge-
bruiken en door het rapporteringssyteem voor gegevens van de laboratoria
naar de EKE organisator te automatiseren. Het principe van de vergelijk-
ing van resultaten van een laboratorium met deze bekomen door de andere
laboratoria is traditioneel gebaseerd op de berekening van "z-scores". Een
studie die verschillende berekeningswijzes van z-scores vergelijkt is uitgevo-
erd teneinde de sterke en zwakke punten van elke wijze bloot te leggen. Deze
studie leidde tot de conclusie dat de methodes die op robuuste statistieken
gebaseerd zijn, minder betrouwbaar zijn wanneer het aantal laboratoria laag
is, terwijl zij die gebaseerd zijn op een voorafgaande stap die afwijkende
waardes ("outliers") elimineert betrouwbaardere z-scores opleveren en dus
aangeraden zijn.
Het tweede hoofdstuk beschrijft de rol van EKE als een middel om har-
xviii
monisering tussen methodes na te gaan. De rol van EKE wordt beschreven,
samen met de valkuilen en huidige tekortkomingen om harmonisering na te
gaan. Een groot probleem hierbij is het verschijnsel van matrixeffecten in
controlestalen, die een methode-specifieke bias kunnen veroorzaken. Ver-
schillende verklaringen voor matrixeffecten worden gegeven, en er wordt
een beschrijving gegeven van statistische technieken die EKE-organisatoren
informatie kunnen verschaffen of de te evalueren groepen homogeen zijn.
Oplossingen worden voorgesteld om de te evalueren groepen op te splitsen
aan de hand van multivariate statistiek. Het tweede hoofdstuk beschrijft ook
verschillende technieken die kunnen gebruikt worden in studies die methodes
met elkaar vergelijken, en een voorkeur voor orthogonale regressie wordt uit-
gelegd. Daarnaast wordt een voorbeeld gegeven van een studie die methodes
voor Estradiol en Progesterone vergelijkt met een nieuwe techniek om stan-
daardisering na te gaan tussen methodes in aanwezigheid van matrixeffecten
bij een klein deel van de stalen. De studie toont ook aan dat standaardisering
tussen verschillende methodes niet bereikt is, en het streven naar standaardis-
atie op basis van standaarden van hogere orde onvoldoende zou kunnen zijn.
Het derde hoodstuk introduceert verschillende evaluatietechnieken die infor-
matie combineren van verschillende stalen of parameters: variantie en bias
index scores, scores gebaseerd op de gemiddelde rangorde, tellingen van z-
en u-scores, en een langetermijns- analytische variatiecoëfficiënt. Er wordt
ook een nieuwe en originele methode voorgesteld die is gebaseerd op het
lineaire regressiemodel gebruikt en in 3 stappen ("3-step method") werkt.
De eerste stap spoort eventuele outliers op voor elk laboratorium apart, in
een tweede stap worden de laboratoria geïdentificeerd met een te grote vari-
abiliteit, en in een derde stap worden de laboratoria geïdentificeerd met een
grote bias. Dit model wordt in detail beschreven en zijn voor- en nadelen wor-
den gedetailleerd besproken. Elke zonet vermelde techniek wordt geëvalueerd
en besproken aan de hand van een dataset waarin toevallige fouten, hoge
variabiliteit en extreme bias werden gestoken. De vergelijking tussen deze
methodes toont aan dat het niet eenvoudig is om een onderscheid te maken
tussen variabiliteit en bias, en dat sommige methodes voor een analyse op
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lange termijn niet robuust zijn tegen de aanwezigheid van "outliers". Er wordt
ook aangetoond dat evaluatietechnieken die de resultaten van verschillende
parameters omvatten soms nuttige informatie verbergen. Ten slotte wordt de
3-stapsmethode voorgesteld als een methode om een onderscheid te maken
tussen de fouten die in de pre- en post-analytische fase worden gemaakt, en
fouten die ontstaan bij de analytische fase.
In het vierde Hoofdstuk wordt de 3-stapsmethode toegepast op gegevens die
bekomen werden in het Belgische systeem voor Externe Kwaliteitsevaluatie
voor alcohol, flow cytometrie, lithium en sperma-analyse. De methode wordt
uitgebreid om toegepast te worden voor heteroscedastische regressiemodellen
en er kan gezien worden dat ze toepasbaar is in een breed domein van EKE’s.
Voor elk van de EKE’s die in beschouwing worden genomen wordt een opvolg-
studie gemaakt van het voorkomen van toevallige fouten, en de evolutie van
de variabiliteit tussen de laboratoria en de bias voor enkele methodes. De
conclusies vertonen een opvallende gelijkenis voor verschillende EKE’s: een
verbetering van prestaties van laboratoria is bereikt over de tijd. De voor-
naamste verbetering was een reductie van het aantal toevallige fouten. De
prestatie van de analytische methodes vertoonde echter geen verbetering over
de tijd heen.
Het vijfde Hoofdstuk wijdt zich aan de grafische voorstelling van EKE-
gegevens en een beschrijving van een grafische voorstelling van de 3-staps
methode. Het histogram, de normale quantielplot en de box plot worden
vaak gebruikt voor een visuele verkenning van EKE gegevens. Andere grafis-
che voorstellingen, die eerder te maken hebben met specifieke vraagstellingen,
worden ook gegeven en besproken, zoals Shewhart grafieken, Cusum grafieken
en grafische voorstellingen die variabiliteit en bias in één grafiek combineren.
Daarnaast wordt de 3-staps methode grafisch verkend door middel van drie
aparte grafieken. Het hoofdstuk eindigt met de voorstelling van interactieve
grafieken als een middel om de terugkoppeling te verbeteren van EKE or-
ganisatoren naar de deelnemers door middel van Schaalbare Vectorgrafieken.
Dit wordt geïllustreerd met voorbeelden van een lange-termijn evaluatie van
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z-scores en de resultaten van de 3-stapsmethode voor de gegevens bekomen
in het Belgische EKE voor bepaling van alcohol in bloed en die via het web
kunnen worden bekeken.
Kortom, dit werk beschrijft op een kritische en constructieve manier de ver-
schillende statistische en grafische technieken die momenteel in EKE worden
gebruikt en beschrijft nieuwe benaderingen die een antwoord kunnen geven
op de toekomstige noden van programma’s voor Externe Kwaliteitsevaluatie.
xxi
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CHAPTER 1
External Quality Assessment for
Laboratory medicine
1.1 Introduction
Laboratory medicine, the specialty that deals with assaying biological spec-
imens from patients, is an integral part of the complex process of therapy
control and management of a patient’s disease [137, 146]. It is estimated
that laboratory test results have an impact on over 70 percent of medical
decisions [54, 15]. Clinical laboratories are high-output, high-quality enti-
ties, employing highly skilled and continuously trained staff [146, 46, 83].
They do not only deliver test results, they also act as knowledge service and
translate laboratory data into comprehensive information for the clinician
[84, 20]. During the last decade, clinical laboratories have undergone funda-
mental changes [16]. Their complexity and role in health care has evolved,
requiring a greater involvement of laboratory professionals in the diagnos-
tic process [46]. Remarkable developments in instrument technology and
computer science, laboratory automation, the expansion and improvement
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of testing procedures and controls, and compliance with systems of quality
management, have greatly enhanced the possibilities of the clinical labora-
tory. Nonetheless, technological advances in laboratory medicine have also
taken place in a context of drastic cost reductions. Two types of approaches
have been identified to reduce costs. The first approach focuses on advan-
tages of scale and encompasses consolidation of laboratory sections with the
creation of big central core laboratories, largely relying on automation and
scale savings. Secondly, an increased efficiency has been reached by improv-
ing the diagnostic performance, creating more effective diagnostic strategies
and effectively utilizing laboratory information for the diagnosis and treat-
ment of patients [119, 112, 145].
In spite of the changing needs and technologies, the basic process of the
clinical laboratory has remained the same and it can be precisely described
by the Total Testing Process (TTP), consisting of 11 steps divided into three
phases, first devoloped by Lundberg [88]. The pre-analytical phase, ranging
from taking the sample to preparing it for analysis; the analytical phase,
during which a test result is produced, and finally the post-analytical phase,
in which the result is verified, interpreted and a medical action is taken
(see Fig 1.1). Recently, it has been recognized that the pre-analytical phase
is preceded by a pre-pre-analytical phase and the post-analytical phase is
succeeded by a post-post-analytical phase. The “pre-pre-analytical” phase
includes the formulation of a clinical question and the selection of appropriate
laboratory tests. In the “post-post-analytical” phase, the clinician interprets
laboratory results to build a diagnosis and take subsequent therapeutic steps
[163].
Traditionally, clinical laboratories have been concerned with the quality of
the analytical aspect of their work. Unlike many other medical processes,
these activities are precisely defined and more controllable than a procedure
or treatment in other medical disciplines. In recent decades, standardization,
automation and technological advances have significantly improved the ana-
lytical reliability of laboratory results and decreased the error rates to a level
2
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Figure 1.1 The 11-step process of a clinical laboratory analysis.
which is far lower than seen in overall clinical health care areas, although it
doesn’t match up yet with industrial quality standards [185, 68, 123, 106].
In 1999, the Institute of Medicine (IOM) published its report ’To Err is
Human: Building a Safer Health System’ [71], investigating the level of mis-
takes in US clinical laboratories. It indicated that medical errors were the
eighth most important cause of death in the USA, more important than
breast cancer or AIDS-related deaths. It was the start of a debate and con-
cern about patient injuries in health care. Patient safety, an issue not well
understood or discussed in health care systems, became a major subject of
discussion and clinical laboratories started to investigate the nature, causes
and frequency of their errors. In this chapter, the role of External Quality
Assessment in improving quality and reducing laboratory errors will be dis-
cussed, with highlights on the current role of External Quality Assessment
(EQA) in the changing environment of laboratory medicine. The Total Test-
ing Process will be used as a framework for exploring sources and solutions
for mistakes. For each phase, the role of EQA will be exemplified and the
chapter ends with an in depth discussion of z-scores, which are one of the
most common statistical techniques to evaluate EQA data.
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1.2 Errors in laboratory medicine
1.2.1 Introduction
Investigating errors in laboratory medicine should start from a patient-center-
ed approach. Any direct or indirect negative consequence for the patient
related to a laboratory test must be considered [125, 127]. The Total Test-
ing Process is an excellent framework to start from. A mistake can occur
in each of the 11 steps in this process [15], starting from test request and
ending with the physician’s reaction to laboratory information. According to
this perspective, the definition of laboratory error is ‘‘a defect occurring at
any part of the laboratory cycle, from ordering tests to reporting results and
appropriately interpreting and reacting on these”. Investigating errors is nev-
ertheless a complicated subject, since the Total Testing Process is complex,
consisting of a series of interrelated processes [122, 13, 79, 128].
1.2.2 Identification of laboratory errors
Pre-analytical phase
The pre-analytical phase includes the phases from the test request to the
preparation of the sample for analysis [122]. Specifically, it starts from the
clinician’s request, including the selection of tests to be performed, prepa-
ration of the patient, collection of the primary sample, continuous with the
transportation of the sample to and within the laboratory and ends just be-
fore the analytical procedures begin. By far, sample misidentification is a
serious concern [81]. In addition, several patient-related and less controllable
variables may influence the in vivo concentration of several parameters in
the patient’s body fluids, for example the patient’s age, gender, ethnic back-
ground, diet, physical exercise or drug use. They need to be considered when
interpreting the final laboratory result and hence they have to be registered
correctly before sampling [25, 146, 80, 124]. The act of taking the sample
may also influence the laboratory results. Posture during blood sampling for
example, influences numerous parameters, and the use of a tourniquet may
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change the concentrations of various analytes. The transportation of the
sample from the sampling site to the laboratory has to ensure a timely de-
livery as well [146]. The type of container the blood is collected is a frequent
mistake as well [85]. In case of pre-analytical mistakes, the concentration
of the analyte in the sample does not reflect the true concentration in the
patient’s blood or other body fluids, although the sample may have been
analyzed correctly [146].
Analytical phase
The analytical phase starts when a sample is ready for analysis and lasts till
the approval of the test result. It consists of the sample preparation, the
determination of the test result, mostly by an automated analyzer, and the
final approval by the medical laboratory staff. The performance of analyti-
cal procedures is often described in terms of bias and variability, or trueness
and precision. Trueness is the proximity between the average value obtained
from a large series of test results and an accepted reference value [97]. For
method with high trueness, the average of several measurements made on
the same sample will be very close to the true value. For a precise method,
repeated measurements will be very close to each other. It should be noted
that, although different factors may influence trueness and precision in a dif-
ferent way, they both need to be under control to ensure the delivery of a
high quality test result.
Problems may arise before analysis when samples have to be diluted, for
example when the sample volume is insufficient or the dilution is inappro-
priate. Almost every analysis is preceded by a calibration and an internal
control check. Calibrators may be out of date or prepared in a wrong way
before analysis. One way to control the analytical process is internal quality
control. Adequate action should be undertaken whenever the internal quality
control indicates that the analysis process is out of specifications. In addi-
tion, every analytical method should give comparable results to any other
analytical method and in particular to a reference method. Although refer-
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ence methods with well-defined standards are available for many methods,
a problem persists for different antibody based assays. In this context, it is
important to use appropriate statistical techniques when performing method
comparisons. Often, manufacturers rely on Pearson correlation coefficients
and interpret them in conditions when they should not be used. Moreover, in-
terference with analytical procedures by endogenous or exogenous substances
may lead to false results [156]. Hemolysis, for example, is one of the factors
that may impact the final test results. Although debatable, we prefer to
classify hemolysis as an analytical event, since it is not always possible to
recognize it before analysis and because it interferes with the measurement
of several analytes [166]. The most important example from exogenous sub-
stances which may interfere with analytical test results are drugs and their
metabolites, and substances added to the blood to avoid coagulation [146].
Postanalytical phase
The postanalytical phase starts when the result has been verified and lasts
till the appropriate action has been taken by the medical staff. It includes
verification of laboratory results by qualified personnel, storing them into the
laboratory information system and reporting them to the clinical staff who
requested the tests. Often interpretative comments are given to guide the
clinical staff in their final diagnostic decision. It also involves an alert system
by passing urgent messages to the clinical staff whenever necessary. Report-
ing of results strongly affects the effective translation of results into clinical
information [70]. It also includes storage and disposal of samples when the
analyses have been completed [146, 120]. However, most post-analytical er-
rors derive from inappropriate interpretation and utilization of laboratory
results. A part of the post analytical procedures take place outside of the
laboratory and may be described by post-post analytical steps. They include
the receival, reading and interpretation of the results by the clinician, and
the final decision of the clinician based on the information provided to him.
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1.2.3 Frequency of laboratory mistakes
During the last decades, the laboratory error rate has been significantly re-
duced, in particular for analytical errors. The variability of analytical per-
formance is now less than 1/20th of what it was 40 years ago. Further, it has
been estimated that up to 75% of laboratory errors generate results without
endangering the patient results, and that 10-20 % are absurd results which
are detected before they result in inappropriate care. There is a rest of less
than 10% of errors which may have an impact on patient care [55, 126, 128].
Looking at the different phases of the TTP, it is generally accepted that the
pre-analytical phase is the most error-prone, with reported frequencies rang-
ing from 60 to more than 80% [126, 122, 55, 166, 21, 82]. Even more, the
frequency of error in this phase, which still consists of manually intensive
procedures, has increased in the last decade [79]. The error frequency of
the analytical phase is around 10%, and ranges in the postanalytical phase
between 20 and 50 %. It should be noted however that the exact number
of mistakes is difficult to assess, because there exists no widespread process
to follow them up systematically and there is a wide variety of definitions
and methods to measure them. Moreover, it has been shown that errors are
reported with higher frequency when studies look particularly for them than
when they are reported in the daily routine. Also, there may be a biased fo-
cus on mistakes that result in adverse events [15]. Overall, the reported error
rate in clinical laboratories ranges from less than 0.05% up to 10% [68, 21].
1.2.4 Reducing errors
The Institute of Medicine report “To Err Is Human” generated widespread
interest in medical errors and adverse events in health care, as well as strate-
gies for reducing them. The most obvious improvement in the latest decades
may have been the widespread implementation of quality management sys-
tems, encompassing processes for process and risk analysis, and focussing
on error prevention, detection and management [79, 124, 83]. Quality man-
agement systems should cover all the steps involved in the overall testing
and non-testing processes [133] and the implementation of a systematic error
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tracking system may be worked out in this framework. The International
Organization for Standardization (ISO) has released a norm, ISO 15189 [62],
focusing on quality management in the clinical laboratory. It encompasses
all the steps and processes within the TTP [120, 124, 21]. The following
paragraphs will explore the three main phases of the Total Testing Process
and describe in detail the different opportunities to improve quality in the
clinical laboratory which are not directly a consequence of a quality system
implementation.
Pre-analytical phase
Several issues have become important, such as involving the provision of
appropriate clinical history and laboratory specimens, and the satisfaction
of patients and professional staff about the collection process have become
important [55]. Automation has been described as one of the major recent
improvements to avoid errors in this phase. Bar-coded wrist bands, for exam-
ple, reduce patient identification errors, pre-analytical workstations perform-
ing sample preparation tasks are seen as a major improvement, and software
exists to reduce the number of mistakes during phlebotomy [128, 123, 85].
In addition, data loggers that register environmental parameters and three-
dimensional acceleration may inform about unwanted acceleration of auto-
matic transportation chain [37]. A recent study has shown, for example, that
sudden acceleration had a direct relation with increased hemolysis [162].
Analytical phase
The analytical phase has been for decades the phase that has attracted most
attention for improvement. In 1950, Levey and Jennings introduced the role
of control charts in clinical chemistry and clinical laboratories [76]. Later on,
Westgard et al developed a series of QC rules based on statistical process con-
trol to effectively apply internal control techniques [184, 183]. In addition to
good test performance and result calculation, attention is now also drawn to
adequate turnaround times and the electronic delivery of test result reports.
Engineering developments have helped to create automated analyzers, which
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are able to perform routine analyzes in a more standardized way [166]. Tra-
ditionally, External Quality Assessment (EQA) schemes have been designed
to control for errors in the analytical phase, providing participants a view of
their analytical performance with respect to other laboratories and providing
an overview of analytical performance of different types of analyzers.
Post-analytical phase
It has become essential for laboratory medicine to set high standards on the
way they communicate with clinicians, since laboratory tests serve as a basis
for many clinical decisions. Next to the test result, interpretation of results
should be given. Also, any information which may explain a deviating result
should be noted, like for a example a bias due to a high lipid or protein
concentration in the sample [156].
Information technology, in particular expert systems, may be applied to
screen and verify test results. They provide for example the means for a delta
check, which compares the current test result with previous results from the
patient. If the values are significantly different from historical values, the
result is flagged. It is important here to note that the choice of parameters
to perform delta checks should be made carefully and taking into account
the type of patient population [161]. In addition, electronic communication
and reporting offer significant opportunities to enhance the communication
between the laboratory and clinicians in the field and reduce diagnostic er-
rors [81, 55, 122, 123]. Care still has to be taken with keyboard entry errors,
and, as always, processes supported by advanced automatizing rely heavily
on a stable network infrastructure. The more processes rely on computeriza-
tion, the more vulnerable they are to network downtime or computer failures.
Attention should also be given to the interpretation of results by the clini-
cians. For example, a study [158] has shown that, even when specificity and
sensitivity of test are communicated, clinicians do not always know how to
interpret these values. Especially when the prevalence of a disease is low, di-
agnostic decisions may be impacted. To provide high quality interpretative
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comments, laboratory personnel should receive adequate training and also
here the need for quality assurance and audit is high [14, 123].
1.3 Quality for the clinical laboratory
Quality assurance has been defined as the whole spectrum of quality improv-
ing activities which ensure the usefulness of laboratory investigation. The
International Laboratory Accreditation Cooperation (ILAC) and the Inter-
national Organization for Standardization (ISO) have released standards re-
lating to this subject. The gold standard for most non-medical laboratories
has been ISO 17025 [61]. The International Organization for Standardization
has released a document particularly focusing on quality assurance in medical
laboratories, ISO 15189 [62]. It describes among others the organization and
management of the clinical laboratories, the set up of a quality management
system and management of nonconformities. It focuses on the three phases
of the Total Testing Process and describes in detail the actions to be under-
taken to maintain and assure quality. It also clearly requires that laboratories
participate in External Quality Assessment programmes [108, 153]. By par-
ticipating, a laboratory is able to to check whether its performance is within
the limits of its internal standards and to derive measures for continuously
improving the quality of its work [18]. Results from External Quality As-
sessment may be regarded as the single most relevant indicator of laboratory
quality [121].
1.4 External quality assessment
1.4.1 Background
External Quality Assessment is a widely used tool for assessing whether lab-
oratories perform tests competently. Its objective is to ascertain and assess
the ability of individuals and protocols to perform clinical assays satisfac-
torily, beyond the particular items or challenges presented. It may also
monitor the quality of commercial analytical systems, reagents and test kits
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[148, 169, 150]. It has its origin in the work of Belk and Sunderman [165],
who distributed samples from the same origin to a group of laboratories in
the Philadelphia area in 1947. They were originally used to identify a small
number of incompetent practitioners and may have been punitive towards
poor performers [108]. Nowadays External Quality Assessment is primarily
educational, providing valuable information to individual participants relat-
ing to their performance as well as facilitating method comparisons. Satis-
factory results in EQA schemes are an important evidence that analytical
procedures are under control, that technicians work in an appropriate way,
and that effective internal quality rules are in place [29, 43, 63, 154, 121, 42].
Two terms exist to describe this kind of activities, often used interchange-
ably: “proficiency testing” and “External Quality Assessment”. In general,
the former is more often used in North America and often related with regula-
tory, or legal, attributes. The latter is more often used within the European
area and is often seen as a broader activity, of which proficiency testing
makes up only a part, and usually regarded as educational and as a self-
assessment tool. In this work, we will stick to the term “External Quality
Assessment”. Currently, External Quality Assessment schemes operate in
the field of laboratory medicine in many countries and their aims, stages
of development, and design differ [169]. EQA programmes have shown in
the past their usefulness by helping to improve analytical performance and
hence diagnostic accuracy. The educational aspect of EQA programmes has
been mentioned several times as one of the key aspects helping to improve
the quality of clinical laboratories. This is likely due to a combination of
direct participant feedback and education through scientific meetings and
publications [53, 69, 132]. In addition, the follow-up of poor performance
in EQA programmes has helped laboratories in identifying analytical errors
and detecting their possible sources [14]. Also, the elimination of poor per-
formers has resulted in an overall improvement of test quality [69]. There
is however only indirect evidence that EQA has improved patient safety [108].
Since EQA programmes are the main tool enabling laboratories to monitor
the overall quality of their results, they must be aware of their own challenges
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and pitfalls. In particular, setting target values, preferably with traceability
towards reference methods, commutability of patient and EQA samples, and
providing comprehensive evaluation of the individual laboratory are corner-
stones of a well functioning EQA programme. Also, they should promote
the improvement of overall performances and support the management of
unsatisfactory performances [149, 121]. For this reason, it is important that
EQA organizers strive to use sample material which resembles real, single-
donor samples as much as possible, while achieving a stability which is strong
enough to cover the time delay by sending out the samples. Also, generat-
ing comprehensive information for laboratories, setting performance goals
and providing information about trends in analytical techniques and perfor-
mances are a continuous challenge [121].
A central and important aspect is the evaluation of the laboratories’ outcome
of measurements. Two main approaches exist to establish the performance
of laboratories. The first approach is the so-called peer group comparison
of each individual result with the results obtained by the other laborato-
ries. It assumes that the majority of the laboratories answer a result that
is equal or close to the correct result, and identifies laboratories who have
responded deviating values as poor performers. The procedure to determine
when a result deviates and to identify these laboratories will be explained
in larger detail later on in this work. The second approach is based on an-
alytical quality specifications or goals [67] which have been set by external
criteria. Setting analytical quality specifications has been a subject of debate
for many years and several strategies have been developed to calculate them.
In 1999, a conference sponsored by IUPAC, IFCC and WHO was held in
Stockholm on ‘‘Strategies to Set Global Analytical Quality Specifications in
Laboratory Medicine’’. It was a milestone in the discussion on setting ana-
lytical target. The hierarchy of strategies can be summarized as follows [117]:
1. Evaluation of the effect of analytical performance on clinical outcomes
in specific clinical situations. Sometimes a clear and unequivocal relation ex-
ists between levels of a certain single parameter and the onset of a particular
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pathology, for example in markers for cardial damage or in lead poisoning.
Performance limits may be derived from threshold values in these specific
settings.
2. Evaluation of the effect of analytical performance on clinical decisions
in general. Here, data based on components of biological variation or based
on the analysis of clinician’s opinion may be used.
3. Published professional recommendations from national and international
expert bodies or from expert local groups or individuals. For several param-
eters, like serum cholesterol for cardial failure risk assessment, or for serum
prostate-specific antigen (PSA), cut off values are determined by an interna-
tional expert group and may be used as a basis for calculating specification
limits.
4. Performance goals set by regulatory bodies or organizers of External
Quality Assessment schemes. The US national External Quality Assessment
organizer CLIA has established its own limits to evaluate its participants.
The procedures to develop these limits are not explicitly provided, they are
implicitly linked to the state-of-the-art laboratory practice as of 1988.
5. Goals based on the current state of the art, demonstrated by data from
EQA or as found in current publications about the applied methodology.
EQA organizers may use the data of their surveys to calculate limits beyond
which a normal value is very unlikely to fall. These limits however are purely
empirical and don’t have any link to clinical decision-making or biological
variability.
In 2010, the main actors in this consensus strategy have evaluated this pro-
cedure and concluded that the strategies developed then have shown to be
successful. They also recognized that work was still to be done, mainly in the
field of non-numerical evaluation scales, pre-analytical factors and matrix ef-
fects, point-of-care-testing, target values of control materials [116]. Recently,
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Haeckel has made an interesting proposal which could serve as an alterna-
tive to the second step in the hierarchy. It uses reference ranges, data from
analytical methods and takes into account the rate of false-positive rates [47]
and Krouwer has suggested to apply error grids [74].
1.4.2 Design of EQA schemes
An EQA scheme basically consists of preparing control samples, sending sam-
ples to the participants, and analyzing and reporting the participants’ results.
Initially, the EQA organizer selects an appropriate test material and deter-
mines which tests have to be determined by the participating laboratories.
Control material should be tested for its homogeneity and stability before
sending. Then, the EQA organizer sends the samples to the participating
laboratories, often under controlled conditions, to preserve the stability of the
parameters to be tested. Samples may be sent once a year and analyzed by
the laboratories on a regular basis. Samples may also be sent at distinct pe-
riods and the laboratory analyzes the samples upon arrival in the laboratory.
Samples are often shipped with an instruction form about their handling
upon arrival, and a list giving an overview of parameters to be determined.
Also, a description of the clinical case represented by the samples may be
given. The laboratories then analyze the samples according to their standard
routine procedures and return the results, preferably with interpretative com-
ments, to the EQA organizer [43]. The results may be written down on a
paper form or entered remotely in a web-based platform. After collection
of the data, the EQA organizer applies statistical and graphical techniques
to evaluate laboratories and the methods they applied. Usually, two reports
are made. An individual report, focusing on the individual performance of
the laboratory, is sent confidentially to each participating laboratory. Also,
a report describing the performance of the laboratory in global terms and
focusing on the performance of the analytical methods may be joined. Often,
results of several rounds are compiled in an additional report, overviewing
different clinical cases and describing a representative state of the art of
testing by the participating laboratories. Also here a report with individ-
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ual details for the laboratories may be provided confidentially. Laboratories
with unacceptable performances may receive a warning letter inviting them
to investigate their method and to undertake corrective measures.
1.4.3 Improvement of external quality assessment
Traditionally, External Quality Assessment has focused almost exclusively on
monitoring and improving the analytical phase. However, it has been shown
before that the analytical phase is the less error prone part of the Total Test-
ing Process. EQA schemes should attempt to focus on the pre- and post
analytical phases as well [107, 121]. Efforts have been made to build ques-
tionnaires about standard laboratory practices and questions about interpre-
tation of examination results [82]. The Norwegian EQA organizer NOKLUS
has developed Internet-based surveys to be sent to an extended group of
clinical practitioners. Examples are given in literature for the interpreta-
tion of urine albumin [1], glucose test results [155] and warfarin monitoring
[73]. In addition, the College of American Pathologists has organized a post-
analytical survey about interpretation of elevated calcium results [56], and
the IFCC Working Group Project “Laboratory Errors and Patient Safety”
has issued a list of quality indicators that can be used to measure and eval-
uate laboratory testing in the different phases of the TTP [147]. Surveys
investigating the interpretation of results tend to assess the post-post ana-
lytical phase instead of the post-analytical phase. Other enhancements are
possible for each of the three phases of the Total Testing Process, as discussed
in the following sections.
Assessing the pre-analytical process
Laboratories may be screened for behavior in case non-ideal samples or test
request lists arrive. EQA organizers may serve themselves of simulated spec-
imens, such as contaminated samples or samples with vague instructions
[121, 177, 82]. It should be noted that in this phase, risk evaluation is differ-
ent than the one commonly made. Errors appearing in this phase don’t have
a continuous character and may make the end result completely wrong [185].
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It is therefore important to evaluate in this phase the errors by frequency of
occurrence.
Assessing the analytical process
EQA has historically been considered as an important tool in controlling
analytical error, and also in this respect, improvements may be suggested.
The use of commutable control material, i.e. material behaving in a similar
way as native patient samples, is of interest to compare possible biasses
between analytical methods and should be stimulated. In addition, the use
of reference material is an added asset to inter-method comparison and the
use of target values established by reference methods would be an ideal goal
for all External Quality Assessment programmes. Also, when commutable
control material is used, the comparison of result interpretations can be made
without taking into account differences between methods. However, the mean
of a subset of methods or techniques is also often used, mainly in cases of test
specimens with so-called matrix effects, that do not affect patient specimens.
In this case, true bias may be masked [131, 182] and laboratories exhibiting
high precision should receive an optimal evaluation, disregarding the bias.
The next chapter will deal with this issue in further detail. Furthermore,
the use of an trueness-based rather than consensus-based evaluation creates
room for improvement for, for example, glucose assays [197]. Another aspect
which has not gained much attention yet is the monitoring of turnaround
times. EQA organizers may use inquiries to obtain information about this
issue [144].
Assessing the post-analytical process
The post-analytical process offers EQA organizers various opportunities of
action, of which only a part has been explored so far. Laboratories may
receive the description of a clinical case together with the samples they have
to analyze. For the risk assessment of Down’s syndrome for example, a risk
can be calculated based on a combination of various measurements on the
mother’s blood and other clinical data, such as the mother’s age, weight, and
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gestational age of the fetus. [177]. Another example is given by Sciacovelli
[149], who has asked laboratories to formulate interpretative comments. Key
phrases were identified in each comment according to the degree of abnor-
mality found in the samples. Subsequently these phrases were allocated into
key groups, and the consensus between laboratories in adding a brief inter-
pretative comment to the patients’ results was verified. Such a break down
of interpretations into key phrases enhances a computerized processing of the
data [78].
To mimic the Total Testing Process as much as possible, laboratories should
be enabled to report to the EQA organizer in a way that is as similar as
possible to their routine way of reporting. Nowadays many laboratories rely
heavily on their Laboratory Information System (LIS). A LIS is a comput-
erized platform enabling the capture of test results, storage and retrieval of
adequate data, and a communication with other information systems. The
international standard HL7 is a worldwide and generally accepted standard
supporting communication between medical centers. It uses structured mes-
sages to transfer information between different systems.
Laboratory test results may be reported according to the Logical Observa-
tion Identifier Names and Codes (LOINC) [91] conventions. EQA organizers
should include the possibility to communicate with their participants via
HL7 and use LOINC codes to describe the tests they want to be performed.
Using the power of LOINC, EQA organizers may also gain easily information
about the applied reference ranges and interpretation of test results. Even
more, laboratory reports can be made up based on HL7 messages and EQA
organizers should strive to receive the data in computer-readable HL7-format
and in human-readable laboratory test report format.
An automated way of reporting will not only enhance the communication
between laboratories and EQA organizers, it will also avoid clerical errors
while filling out web or paper forms, which are used nowadays. The latter
are specific for EQA and are not representative for the Total Testing Process.
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In this respect, it is interesting to read the comments on a question raised by
Woods in 2004 [193] about the way EQA organizers handle obvious mistakes,
such as a unit mistake or a wrongly placed decimal mark. Most responders
said not to change any reported value [92, 190, 77, 187]. Only a minority
mentioned unit mistakes as a reason why to change values [151, 129, 187].
In our opinion, values should never be changed without informing the labo-
ratory and we suggest a ’correction phase’ at the end of each EQA round. A
laboratory may be shown an intermediate report, with a temporary evalua-
tion of its results. z-scores (see sectio 1.5) and graphical representations (see
Chapter 5), as shown on the final report, may be used here. Subsequently,
laboratories may be invited to screen their results.
Data which are the result of an error are supposed to have high z-scores,
or to be shown as an outlying observation on the graphical representations,
and should attract the attention of the reader. It would then be advisable
to give the opportunity to the laboratories to comment on their own results.
Exceeding values may be flagged as an error, and specifications, such as pre-
analytical, analytical or post-analytical error may be specified. If possible,
the laboratory should have the possibility to respond the true analytical re-
sult of the test.
This approach will not only enable EQA organizers to use cleaner data in
calculating their measures of performance, it will also be more informative
to the laboratories. Moreover, summarizing statistics about the source of the
error reflect the laboratories’ performance in the light of pre-, middle- and
post-analytical error, and may be of interest to the participating laborato-
ries. Lastly, only corrected values should be used for any kind of calculations.
EQA organizers should not be blinded by the robustness of their methods.
Robust methods for estimating mean and variance are less sensitive to out-
lying results than standard methods, they are still sensitive to it.
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1.5 Statistical analysis of EQA data
1.5.1 The z-score concept
Ideally, every laboratory participating in an External Quality Assessment
programme should report a value which is close to the value which was ex-
pected to be reported. Every reported value which is ’too far away’ from
the expected value looks peculiar, and it is the principle of the evaluation
procedure to find those values which are too far from the expected value.
This logic forms the base of z-scores, which have become a way to assess the
quality of clinical laboratories by classifying them on a common continuous
scale and flagging those with unacceptable results. Besides, these scores can
be interpreted similarly to those of the internal quality procedures. They are
based on a measure of center and scale of the distribution of the results, in
which the difference from the center is expressed as a multiple of the measure
of scale:
z− score = x − µs
where x is the individual value for a laboratory, µ is the assigned value and
s is the standard deviation used to evaluate the laboratories.
There is a common agreement to flag z-scores with absolute values larger
than 3, requesting an action signal from the laboratory. Z-scores with abso-
lute values larger than 2 and smaller than 3 are regarded as a warning signal,
and those with absolute values smaller than 2 as within acceptable limits [2].
For a Normal distribution without any outliers, there is a chance of about 1
on 1000 to have an unacceptable z-score. Z-scores obtained for several sam-
ples may be combined and the frequency of exceeding a limit, 3 or lower, may
be used as a long-term evaluation tool. Therefore, z-scores convey a different
kind of information and are more flexible than outlier detection techniques,
which search only for discordant values.
The estimation of location and scale is of primary importance for obtain-
ing z-scores. In some cases, the estimates are known or fixed beforehand as
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derived by a reference method and/or a fit for purpose standard deviation
[3]. When mean (center) and standard deviation (scale) are calculated from
the sample values, however, they can be heavily influenced by outliers. For
example, when the sample size n<12, outlying results influence the estimates
in such a way, that z-scores are never larger than 3 [4]. Estimation of the
center and scale by avoiding the influence of outliers can be done by two
distinct types of approaches [3,5].
The outlier-based approaches first exclude outlying values, calculate the clas-
sical mean and standard deviation on the remaining data, and then compute
z-scores for all values, including those previously excluded. Other approaches
use robust statistics, which obtain measures of location and scale which are
less influenced by outliers. Healy introduced robust statistics in the field of
laboratory medicine [6] while Rocke described its use in EQA for the first
time in 1983 [7]. Today, robust statistics are popular in the domain of EQA,
as confirmed by the ISO recommendations for calculating z-scores [2]. In
EQA, standard deviations are not solely used for detecting laboratories that
reported "out-of-range" outlying values, but also serve as quality indicators
for analytical methods, in particular with respect to trueness and precision.
Here, the uncertainty and bias of variability estimators themselves are of im-
portance.
Finally, it is worth mentioning that the distribution of EQA data is often
assumed to be symmetric and possibly contaminated with few outlying re-
sults and most statistical tests in EQA programmes assume a contaminated
Normal distribution. Some authors [3,4], however, claim that the distribu-
tion, even in the absence of outliers, may be leptokurtic, i.e. exhibiting
heavier tails than the Normal distribution. Thus, comparing the two types
of estimating approaches for the specific classes of symmetric and unimodal
distributions, represented by a Normal and a Student’s t-distribution may
be of importance The purpose of this study [26] was to answer three simple
questions:
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(1) what is the false positive rate of z-scores estimation methods in non-
contaminated samples from the Normal and Student’s t distributions ?
(2) what is the true positive rate of z-score estimation methods in contami-
nated samples from the same distribution ?
(3) what is the accuracy and precision of the different variability estimators
of the Normal distribution ?
1.5.2 Estimating z-scores
Approach 1: Grubbs test
Although mainly used for sample sizes larger than 20, the Grubbs test [44]
may theoretically be used for smaller samples. It starts with calculating the
quantity G:
G =
max
1≤i≤n
|xi − x|
s
Now, if
G > n− 1√n
√√√√ Q2t (1− α2n ; n− 2)
n− 2 + Q2t (1− α2n ; n− 2)
where Qt(1− α2n ; n− 2) is the upper α/2n-quantile of the Student t-distrib-
ution on n-2 degrees of freedom, the most extreme value will be left out
of the data set and the Grubbs test will be applied again. This process is
repeated until the above inequality does no longer hold. Then, the average
and standard deviation are calculated on the reduced dataset and are used to
calculate z-scores for all the data, uncluding those excluded in the iterative
process. Another possibility exists of using a blocking procedure [139, 64].
However, this iterative procedure was preferred since the number of data in
this experiment, and hence, the number of possible outliers, are small.
Approach 2: Dixon test
This approach is based on an article published in 1950 by Dixon [30], who
developed several approaches to find outliers for sample sizes as small as n=3.
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The method is based on the calculation of ranges between lowest and highest
values of the samples, and subranges between the most extreme values from
the samples. It starts from an ordered sample x1≤ x2≤ ... ≤ xn-1 ≤ xn and
calculates the ranges depending on the sample size:
For sample sizes ranging from 3 to 7, the following ratio is calculated:
r = x2 − x1xn − x1 for outliers at the lower side
r = xn − xn−1xn − x1 for outliers at the upper side of the sample
For sample sizes ranging from 8 to 10, the ratio is slightly modified:
r = x2 − x1xn−1 − x1 for outliers at the lower side
r = xn − xn−1xn − x2 for outliers at the upper side of the sample
For sample sizes ranging from 11 to 13, we have:
r = x3 − x1xn−1 − x1 for outliers at the lower side
r = xn − xn−2xn − x2 for outliers at the upper side of the sample
For samples of larger size, the calculation of r becomes:
r = x3 − x1xn−2 − x1 for outliers at the lower side
r = xn − xn−2xn − x3 for outliers at the upper side of the sample
Dixon has described in 1951 [31] the distribution of r, which can be used
to build a hypothesis test around it. A low P-value of the hypothesis test
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then indicates that the sample contains an outlier. In this case, the most
extreme value is removed and the test is applied to the reminder of the data
till there is no significant proof of an outlier any more. The classical average
and standard deviation are calculated on the reminder of the data and are
applied to all the data, also the values earlier detected as outliers.
Approach 3: Tukey’s robust method
This approach is based on the assumption that the 25th percentile (P25) and
75th percentile (P75) are generally not influenced by outliers, so that the
standard deviation can be calculated by the following formula:
s = 0.7431× IQR
where IQR = P75 − P25 is the so-called interquartile range and the factor
0.7431 is the reciprocal of the difference between the 25th and 75th per-
centile of a standard Normal distribution.
Approach 4: Qn estimator
The Qn estimator [140] is given by sorting all pairwise absolute differences
of sample values, namely |xi − yj| (i<j; i=1,n-1; j=2,n) and taking the kth
order statistic from the ordered series. If we denote by {|xi − yi| ; i < j}(k)
this order statistic, then
Qn = D {|xi − yi| ; i < j}(k)
where D is a constant factor and equal to 1/
[√
2Φ−1
(
5
8
)]
, with Φ−1 the in-
verse cumulative distribution function of the standard Normal distribution,
and k=Ch2 ≈ C
n
2/4, where h=
n
2+1, is close to half the sample size.
Approach 5: ISO 13528
The ISO 13528 standard’s algorithm for calculating mean an standard devia-
tion is as a robust algorithm to be used in External Quality Assessment (see
Algorithm A in Appendix C of the standard). It makes use of the principle
of Winsorization and starts with the calculation of the median of the data:
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x∗ = median
followed by a first robust estimate of the standard deviation:
s∗ = 1.483 median of {|xi − x∗| ; i = 1, n}
Next, the quantity d is calculated
δ = 1.5s∗
and for every xi, an alternative value x∗i is attributed as follows (i=1,n):
x∗i =

x∗ − δ if xi < x∗ − δ
x∗ + δ if xi > x∗ − δ
xi otherwise
Then, new values for x∗ and s∗ are calculated by the equation
x∗ =
∑ x∗i
n
and
s∗ = 1.134
√√√√∑ni=1 (x∗i − x∗)2
n− 1
The new robust estimates of x∗ and s∗ are used to calculate new values of x∗i
and the iteration is continued till convergence.
1.5.3 Simulation study
A total of 1000 random samples was generated from a Normal distribution
with a population mean and standard deviation arbitrarily set at µ=10 and
sv=0.5. The data were generated for sample sizes from n=3 to 20. Subse-
quently, to obtain data from a leptokurtic distribution, a similar simulation
was performed using a Student’s t-distribution with 5 degrees of freedom.
Only samples for which all values were within the interval [µ-3sv,µ+3sv] were
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withheld. Next, the samples were contaminated by adding an outlier at
µ+3sv, at µ+5sv and at µ+7sv separately, resulting in a sample of size n+1.
Samples of size of n=3 without added outliers were not taken into account. z-
scores were calculated on each sample following the five different approaches.
The Grubbs and Dixon test were applied with an α of 0.05.
The ability of various approaches of flagging outliers when they exist and
of not flagging them when they don’t exist can as well be assessed in a way
similar to the evaluation of diagnostic tests: the first question addresses the
true positive rate and the second question addresses the true negative rate.
For this purpose, Negative Predictive Value (NPV) and Positive Predictive
Value (PPV) were calculated for each approach by modifying each algorithm
in letting a parameter vary that may be changed to increase or decrease
the number of z-scores above 3. For the Grubbs and Dixon tests-based ap-
proaches, the P-value for which outliers are excluded (a) was changed. For
the Qn approach, D was to be changed and for the Tukey approach, the fac-
tor that is multiplied with the IQR. Lower values of these two factors result
in lower standard deviations, higher z-scores and a higher z-citation rate.
For the ISO-13528 approach, d was chosen to be changed. NPV and PPV
for each of the different values of the varying parameter were recorded and
graphically displayed.
At last, for each simulated data series of samples generated from a Nor-
mal distribution, the variability estimator obtained by every approach was
recorded and its mean and standard error calculated.
1.5.4 Results
False outlier rates - The false outlier rates are visualized in Figure 1.2.
Among all approaches, the Tukey method showed the most distinctive be-
haviour; while all false outlier rates were below 15% for the Normal distri-
bution and below 30 % for the Student’s t-distribution, Tukey’s approach
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Figure 1.2 False flagging rates for the five different approaches, for
different sample sizes. Left graph shows results for the Normal
distribution, right graph those for the Student’s t distribution with
5 degrees of freedom. Results are based on a simulation with 1000
samples.
had for almost all sample sizes a rate above 20%. The Dixon and ISO ap-
proaches showed the lowest false outlier rates. In addition, it is seen that
for samples of size 6 or larger, false outlier rates didn’t change much for the
Normal distribution, except for the ISO approach. However, all increased
with increasing sample size for the Student’s t-distribution.
True outlier rate - The flagging rates when adding an outlier at varies
distances are shown in Figure 1.3. For all outlier distances, differences be-
tween the different approaches were similar for the Normal and Student’s
t-distribution. For outliers at µ+3sv, none of the approaches was able to flag
the outliers in more than half of the cases for all sample sizes. The Tukey
approach had the highest performance, reaching a flagging rate of nearly
50% as soon as the sample size was 6 or larger. The other approaches had
much weaker performance; the ISO approach had flagging rates below 10%
for very small samples. All other approaches exhibited outlier finding rates
of roughly 10-30%.
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For outliers at µ+5sv, a strong improvement of the Grubbs test-based algo-
rithm is obvious, outperforming the Tukey approach and reaching an outlier
finding rate near 100% for sample sizes of 10 or larger. Also here, the ISO ap-
proach has a very weak performance for very small sample sizes. The outlier
finding rate increases strongly with increasing sample size for all approaches.
The results point to a clear improvement of flagging rates for all approaches
with increasing sample size and outlier disance, with a probability of detec-
tion close to 100% for outliers at µ+7sv. The ISO and Dixon approaches,
however, still had a weak performance for very small sample sizes.
Negative and Positive Predictive Value - The results of the NPV and
PPV for sample size n=6 is shown in Figure 1.4 and for sample size n=8 in
Figure 1.5. The perfect approach, which would flag no z-scores larger than
3 in case they don’t exist (negative prediction) and would flag them all in
case they would exist (positive prediction), would show a curve made up by
a vertical line equal to the Y-axis and a horizontal line which intersects the
Y-axis at the value 1. The further the curve of an approach departs from the
perfect curve, the worse its performance.
For outliers at µ+3sv, curves were located far from the ideal line and NPV
and PPV for none of the approaches reached high levels: only a combination
of positive and negative predicted values of about 60% was feasible, and al-
though the Grubbs approach tended to perform better, there was not much
difference between the approaches. For increasing outlier distance, however,
it is seen that the curves tend to close the curve of the perfect approach. The
Qn approach consistently performed the worst. The outlier searching algo-
rithms showed a slightly better performance, mainly for outliers at moderate
distance from the center (µ+5sv). There was almost no difference between
the results of the data generated from the Normal or from the Student’s
t-distribution. A similar trend was seen for a sample size n=8. All algo-
rithms exhibited a weak performance for outliers at µ+3sv. For outliers at
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Figure 1.3 Flagging rates for the five different approaches with an
outlier at various distances from the center, for different sample
sizes. Upper graphs show results from the Normal distribution,
lower graphs those from the Student’s t distribution with 5 degrees
of freedom. Results are based on a simulation with 1000 samples.
µ+5sv, however, the Grubbs approach performed better than the other ap-
proaches. This difference became less clear for more distant outliers, where
all approaches showed almost perfect positive and negative predictive values.
Focussing on the Grubbs approach, the search for the optimal P-value for
excluding outliers (a) was made for different combinations of sample size
and outlier distance. The optimal a decreased when outliers became more
distant and with increasing sample size. For outliers at small distance from
the distribution, the most optimal a was 0.2 for all sample sizes. This value
decreased when the outliers was further away from the distribution (0.02-0.1
for outlier at µ+5sv, 0.007-0.06 for outlier at µ+7sv) (See Table 1.1).
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Figure 1.4 NPV and PPV for the five different approaches at differ-
ent outlier distances, sample size n=6. Upper graphs show results
from the Normal distribution, lower graphs those from the Stu-
dent’s t distribution with 5 degrees of freedom. Results are based
on a simulation with 1000 samples.
Variability and bias of standard deviation - The results are depicted in
Figure 1.6. In absence of outliers, Tukey and outlier search-based approaches
showed a higher distance between the estimated and actual population mean
of 0.5, consistently underestimating the standard error. The trueness and
precision of every estimator becomes worse when an outlier is present at
µ+3sv. Precision is more or less equal for all approaches. Trueness however
exhibits major differences between the approaches. The Tukey and Grubbs
approaches suffer the least from lack of trueness. Also here, trueness and
precision improve with increasing sample size.
Precision and trueness for outliers at µ+5sv show that the Qn and ISO es-
timator consistently overestimate the standard deviation. Only the Grubbs
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Figure 1.5 NPV and PPV for the five different approaches at differ-
ent outlier distances, sample size n=8. Upper graphs show results
from the Normal distribution, lower graphs those from the Stu-
dent’s t distribution with 5 degrees of freedom. Results are based
on a simulation with 1000 samples.
Table 1.1 Optimal values of α at which outliers should be searched
for, for having best combination of positive predictive value and
negative predictive value for the Grubbs approach to calculate z-
scores.
n Outlier
µ+3σv µ+5σv µ+7σv
5 0.20 0.10 0.06
6 0.20 0.08 0.04
7 0.20 0.08 0.04
8 0.20 0.06 0.02
9 0.20 0.04 0.02
10 0.20 0.04 0.02
11 0.20 0.04 0.009
12 0.20 0.04 0.007
20 0.20 0.02 0.007
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Figure 1.6 Trueness (upper graphs; expressed as s and compared
with true value of 0.5) and precision (lower graphs, expressed as
standard error of s) of estimates of standard deviation obtained by
the different approaches for the Normal distribution. A: no outliers
added; B: outlier at μ+3σv; B: outlier at μ+5σv. Results are based
on a simulation with 1000 samples.
and Tukey approaches are able to give estimates of the standard deviation
with high truness, the former starting from an sample size of 8, the latter
for all sample sizes. Also, the Grubbs approach outperforms the other ap-
proaches in terms of precision.
The difference between the approaches becomes even clearer when outliers
at µ+7sv are considered. The precision of the Grubbs approach outperforms
all the other approaches, also at small sample size. Regarding at the true-
ness, we can see that the outlier-search approaches, together with the Tukey
approach, have a higher trueness than the other approaches.
1.6 Conclusion
The world of the clinical laboratory has undergone major changes in the last
decades. Today it is considered as a knowledge center, not only for producing
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but also explaining analytical results to clinicians. It has become a prereq-
uisite for diagnostic and therapeutic decisions. Because of its crucial role,
and definitely after the release of the Institue of Medicine’s report ’To Err
is Human: building a Safer Health System’, laboratories must attein high
standards to avoid errors. For avoiding and discerning the possible causes of
errors, the implementation of a quality management system has become of
utmost importance.
External Quality Assessment is seen as a cornerstone of quality manage-
ment. It is the discipline in which results obtained for the same sample by
different laboratories are compared with each other. Historically, the an-
alytical phase has received most attention in EQA, in the sense that many
authors still try to explain deviating results in an EQA round by high bias or
variability, or a combination of both. EQA organizers, however, should not
solely use flaws in the analytical process as possible explanations of spurious
results. Errors may have taken place in the pre and/or post analytical phase
as well. In addition, EQA organizers should strive towards assessing pre- and
post-analytical phases, since investigations about errors have shown that the
pre- and post analytical phase are the most error-prone. Questionnaires are
a useful tool to assess both phases, and specific surveys can be set up, for
example by using specific sample material for assessing the pre-analytical
phase. EQA organizers could however assess the post-analytical aspect of
laboratory medicine by receiving the laboratory results and their interpreta-
tion in the same way as clinicians receive them. In fact, they should strive
towards closing the gap between the usual data flow in the routine labora-
tory and the typical data flow for an EQA survey. Technical solutions exist,
preferably under the form of HL7. In addition, EQA organizers have to be
aware of a small fraction of data that are heavily deviating. Enabling the
laboratories to rectify these data in a documented way, is one of the keys to
better statistical estimates of bias and variability.
There are various approaches for calculating mean and variabilty, and al-
though all of them perform well for larger sample sizes and outliers at a
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distance of several standard deviations from the mean, there are some dif-
ferences at smaller sample sizes. In general, the Tukey approach will indi-
cate more often z-scores above 3 than other approaches, whether outliers are
present are not, and hence overestimate the frequency of outliers. In compar-
ison with other approaches however, it yields, in the presence of an outlier
at small distance, the least biased estimate of variability. If this approach is
used, we want to recommend a minimal sample size of 6 since smaller sample
sizes have a combination of too high false outlier rates or too low true outlier
rates. The Qn and ISO approaches perform in a similar way, although the
latter has a very low true outlier finding rate at very small sample sizes. They
behave as good as unbiased estimates of the variability when no outliers are
present, but overestimate it heavily as soon as an outlier at small distance
is present. Even for sample sizes of 20, they overestimate the variability in
presence of outliers. We would not recommend to use these approaches for
sample sizes smaller than 10. The outlier-search approaches, in particular
the Grubbs approach, tend to perform better when considering true and false
outlier finding rates together. In addition, at least for sample sizes of 6 and
larger, the estimator of variability obtained by the Grubbs approach is more
stable and less biased than the other approaches in the presence of outliers at
far distance. For these reasons, we would recommend the Grubbs approach
for calculating z-scores. As a rule of thumb, we would propose to use an α of
0.05 for all sample sizes. If different values of α can be used, we would pro-
pose to let α be 0.1 for samples of size 10 and smaller, and 0.05 for samples
of larger size.
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CHAPTER 2
Matrix effects, EQA schemes and
standardization between methods
2.1 Introduction
One of the major problems in laboratory medicine today is the poor compara-
bility of results of patient samples that were obtained in different laboratories
using different analytical methods. Differences between results obtained for
the same patient may jeopardize correct clinical decisions [114, 22]. Patients
are frequently treated by a team of physicians rather than one, often ex-
tending across several health care disciplines and making use of information
from various laboratories. Comparability of laboratory results is also im-
portant for tests with regionally or nationally established decision limits, or
for tests used for monitoring patients over a long time period [164, 99, 114].
In addition, accurate results also allow laboratory data to be collected and
mined from different sources in order to identify public health needs or mon-
itor public health programmes [180, 181]. As a consequence, calibration and
harmonization of results from different analyzers, both between and within
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laboratories, and the continuity of such harmonization in time are of great
importance [8, 65].
The key to comparable results is standardization. Its goal is to assure that
results from measurements in patient samples are accurate, independent of
the measurement procedure used or the location and time of testing. In sta-
tistical terms, we speak about eradicating bias between methods. To achieve
standardization, the approach of traceability may be adopted from the field
of analytical chemistry. It is based on the reference measurement system,
in which, starting from reference material or standards that are nationally
or internationally recognized, a reliable transfer is provided towards routine
methods using metrological traceability [113, 39, 33]. The importance of
the metrological principles has been recognized by the International Orga-
nization for Standardization (ISO), which has written down rules to ensure
standardization in ISO 17511 [58] and 18153 [114, 59]. Later, the European
Commission has issued the Directive on In Vitro Diagnostic Medical Devices
(IVD) 98/79/EC [36]. It requires the clinical diagnostic industry to document
the metrologic traceability of in vitro diagnostic systems towards standards
supported by the international system SI [176, 8]. However, manufacturers
have prepared their own calibrators, which are not always available for other
manufacturers. Often, standards of higher order are stabilized, for exam-
ple by lyophilization, and lack similarity with human samples [136]. This
can lead to a disagreement between results from different commercial assays
[113, 115, 114]. Further, since the IVD directive doesn’t recognize interna-
tionally recognized reference materials, manufacturers have to select their
own reference systems, which may also cause disagreement between results
[6]. For this reason, the IVD directive also foresees a role for EQA schemes
in assessing agreement between routine methods, also known as post-market
vigilance [175]. In addition, a recenlty published roadmap for harmonization
between laboratories also underlines the role of EQA using commutable sam-
ples [103]. Although EQA programmes are by nature excellently placed for
this job, not every EQA survey can serve for post-market vigilance due to
the possible presence of matrix effects in the utilized sample material.
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2.2 Matrix effects
EQA organizers often use sample material specifically prepared to ease trans-
portation and storage, and that can be produced at a relatively low cost,
exhibits a low vial to vial variability and can be used to determine a wide
range of parameters on the same specimen [98, 52]. For this, samples are
prepared using a pool of human sera or plasma, are often lyophilized, and
stabilizers and other substances may have been added. Several analytes may
also have been added by spiking to obtain a wide range of values that can
be determined on one single sample. These preparation steps, however, may
have adverse effects on the physicochemical properties of the samples. For
example, lyophilization irreversibly denaturates lipoproteins, causes modifi-
cations in viscosity, and increases turbidity and alters the pH and surface
tension [39]. When the analyte is spiked using material of non-human origin,
complexes may be formed jeopardizing a correct measurement [40, 52]. Pro-
tein complexes may be modified during isolation from human sources and
can produce a different measurement signal than expected for native forms
of the analyte [99]. Analytical techniques based on immunological reactions,
such as immunoassays, are sensitive to factors influencing antigen-antibody
reactions, such as a specificity of antibodies after preparation [33, 41, 196].
As a consequence, samples may lack similarity with genuine samples analyzed
in the laboratory [175] and several methods may obtain different results for
a certain parameter, a characteristic commonly called “matrix effects” or
“non-commutability”.
The term “commutability” was first used to describe the ability of a ref-
erence or control material to exhibit properties comparable to the properties
of authentic clinical samples when analyzed by different analytical meth-
ods. This description is now more generally defined as the equivalence of
the analytical results of different measurement procedures for a reference
material and for representative samples from healthy and diseased individ-
uals. The ISO defines commutability as the degree to which a material
yields the same numerical relationships between results of measurements by
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a given set of measurement procedures. Some authors define it in a more
method-specific narrow way: it means that a reference or control material
will behave in the same way as a genuine human sample. This implies that
a sample may be commutable for one specific method, but not for another
[180, 99, 179, 98, 136, 130]. Matrix effects are defined as “a bias or difference
caused by a sample property other than the level of the substance or property
that is intended to be measured”. It includes physicochemical, mechanistic
and analytical interferences and substance isoforms [75].
In general, we can say that matrix effects in a processed material are caused
by an altered matrix which would not be expected to occur in typical au-
thentic clinical specimens and thus represents a difference between the EQA
sample material and authentic clinical specimens. In most cases, the pres-
ence and magnitude of a matrix bias is unknown [98]. Matrix effects are
somewhat unpredictable and their frequency may vary largely in the dif-
ferent experiments. For these reasons, Miller stated that prepared samples
are not suitable for field-based postmarketing assessments of standardization
[102, 100]. Moreover, recently, he stated that quality control samples should
not be used to verify the consistency of results for patient samples when a
new reagent lot is used [101].
2.3 Solutions for avoiding matrix effects
Two different approaches may be adopted to cope with matrix effects. First,
EQA organizers may attempt to produce commutable samples. Secondly,
when commutability cannot be assured, laboratories should be partitioned
into so-called peer groups. A peer group is a group of laboratories using the
same or similar analytical methodology for the determination of a certain
parameter, grouped in such a way that the group is free of matrix-dependent
bias.
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2.3.1 Improving sample quality
One approach to solving the non-commutability problem is to use authen-
tic clinical specimens or specimen pools for EQA. This approach has been
effective when adequate specimens can be obtained but has been limited
when multiple analytes, large quantities or long transportation distances are
required. A discussion paper from EQA working group B on target values
in EQA [172] recommended two different approaches for EQA. Fresh-frozen
native patient samples were recommended for method assessment using ref-
erence method target values. Non-commutable processed sera could be used
for participant assessment, in which case reference method values were infor-
mational only.
Careful preparation of a fresh-frozen off-the-clot serum pool, or other na-
tive clinical specimen, is critical to the validity of the assumption that the
material is commutable. A consensus guideline for preparation of a fresh-
frozen off-the-clot serum pool is CLSI document C37-A [24] which specifi-
cally addresses cholesterol but is applicable to most serum measurands [98].
Stöckl and Thienpont [176, 160] have proved that single individual dona-
tions can be used as EQA material; the only differences these samples show
with samples usually analyzed in routine labs are filtering and, possibly,
freezing. The main limitation for this kind of surveys is the volume of sam-
ple material to obtain. However, knowing that modern clinical analyzers
need only small volumes of sample, using aliquots of 0.5 mL, or even only
0.3 mL, about 600 samples could be used from one single donation [160].
A number of EQA programmes are run in several countries that use com-
mutable samples prepared from freshly collected and minimally processed
human samples. One of the oldest is the Glycohemoglobin Survey from the
College of American Pathologists in the USA. Hybrid approaches, in which
processed and authentic clinical specimens are used in the same EQA round,
represent a practical step forward to add value for individual participants and
for method manufacturers. Commutability provides a point of comparison
39
2. Matrix effects, EQA schemes and standardization between methods
for laboratories and manufactures with respect to the IVD directive for a cer-
tain set of parameters, and the prepared sample may be used for a screening
on a larger magnitude of parameters. [98].
2.3.2 Partitioning of results into peer groups
When matrix effects cannot be avoided, the most common procedure is to
group the participants according to their method into so-called “peer groups”.
The latter are formed per parameter and gather the laboratories that use the
same or similar methodology. It is for example common to group the lab-
oratories according to the manufacturer of the material used for analyzing
a certain parameter. They are likely to achieve the same analytical result
and their reported values should follow a unimodal distribution, eventually
contaminated by a low fraction of outliers. Z-scores may be calculated using
the algorithms described in Chapter 1. It should be clear here that the target
value, taken by the median or the mean after outliers are excluded, may be
different for each distinct peer group and hence the conclusions are less far-
reaching than those obtained by fresh samples. Peer group evaluation does
confirm that a laboratory is applying a technology correctly and does mea-
sure the uniformity of the manufacturer’s field method calibration process
among a group of users [100, 98]. It does however not bring any information
about a possible bias between methods for routine samples.
Homogeneity is a major prerequisite of peer groups. Lack of homogeneity
of the peer group inflates the standard deviation and decreases the flagging
rate by masking results which should be flagged. The creation of peer groups
is a compromise between reducing uncertainty about variability estimates by
taking peer groups as large as possible, and reducing inflated standard devia-
tions by taking peer groups as homogeneous as possible. These two objectives
become antagonistic when values obtained with slightly different methodol-
ogy is used and the question arises whether these values should be partitioned
in one or two peer groups. The increase of the standard deviation when two
heterogeneous groups are merged may be the key to the answer.
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If one heterogeneous group consists of two different homogeneous groups,
the mean and standard deviation will change and not reflect any more the
mean and standard deviation from the original groups. To calculate the ef-
fect of heterogeneity, we can start with a sample data of size n and mean
x¯1, in which a proportion p has shifted by a value δ to form a new subgroup
with mean x¯2 = x¯1 +δ. The mean of the heterogeneous distribution becomes
x¯ = x¯1+pδ. Assuming that the original standard deviation of the data series,
s1, remains the same for the two subgroups, the calculation of the standard
deviation of the heterogenous group then becomes
(n− 1)s2 =
n∑
i=1
(xi − x¯)2
=
(1−p)n∑
i=1
(xi − x¯1 − pδ)2 +
n∑
i=(1−p)n+1
(xi − x¯2 − (p− 1)δ)2
=
(1−p)n∑
i=1
(x − x¯1)2 −
(1−p)n∑
i=1
2pδ(xi − x¯1) +
(1−p)n∑
i=1
(pδ)2+
n∑
i=(1−p)n+1
(xi − x¯2)2 −
n∑
i=(1−p)n+1
2pδ(xi − x¯2) +
n∑
i=(1−p)n+1
[(p− 1)δ]2
=
[
(1− p)n− 1)s21 + (1− p)n(pδ)2 + (pn− 1)s21 + pn((p− 1)δ
]2
= (n− 2)s21 − p2nδ2 + pnδ2
Thus
s =
√
(n− 2)s21 + pnδ2 − p2nδ2
n− 1
The ratio n−2n−1 appears in the formula because the standard deviation is based
on the estimation of two different averages. For n large this ratio approaches
1 and then we have approximately
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s =
√
s21 + pδ2(1− p)
In case half of the data show an upwards shift of δ, p=0.5 and the formula
becomes:
s =
√
s21 + 0.25δ2
This formula is visualized in Figure 2.1.
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Figure 2.1 Behavior of standard deviation when a certain propor-
tion of the data exhibits a shift (δ). Lines are calculated based on
an sample of n=20.
It is clear that the standard deviation increases more than proportionally
with increasing shift. Also remark that the standard deviation increases
faster when the proportion of shifted data is larger.
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This model can be employed to investigate the influence of combining two
possibly heterogeneous groups into one peer group. Assume for example that
the original standard deviation of both groups is 1 and a shift in the standard
deviation of 5 % is allowed. The maximal standard deviation inflation would
be reached by a shift of 50 % of the data, and the maximum shift can then
be calculated as follows:
1.05 >
√
1 + 0.25δ2
or δ<0.64. In other words, as long as the bias between the two group means
is smaller than 0.64 and their standard deviation is 1, the shift in standard
deviation will be below the acceptable limit of 5 %.
Detecting heterogeneity in a peer group
It is interesting to know when, based on a number of samples used in EQA
rounds, the difference between two group means is smaller than the maxi-
mal allowable shift. A Multivariate Analysis of Variance (MANOVA) test
may be of interest. In classical analysis of variance, one checks whether one
or more groups differ with respect to a given variable. MANOVA does the
same, but checks whether one or more groups differ from each other for a
multivariate set of variables. In the case of EQA, responses obtained for a
series of samples for one particular parameter may serve as a multivariate
set, and two different methods may serve as the explanatory variable.
A MANOVA F-test, like many other hypothesis tests, yields clear results
when the null hypothesis is rejected: there is enough evidence to state that
there is a difference between the groups, and the chance of being mistaken
is very small. Remark that, when enough data is available, the P-value of
the test will be significant, even if the difference between the groups is small,
also when it is smaller than the maximum allowable difference. When, on the
other hand, the P-value is larger than a predefined threshold value a (often
taken 0.05), one has to decide that there is no evidence of a difference. Saying
that there is no difference would be wrong: the number of data may be too
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small or the variability is too large to detect a possible difference. In both
cases, it is useful to calculate the probability of rejecting the null hypothesis,
stating a predefined difference between the groups and error variance struc-
ture.
Power analysis for MANOVA can be applied and can be performed using
the Pillai-Bartlett’s trace. It starts from calculating a hypothetical between-
and within-group sum of squares matrix (see Appendix A5). The hypotheti-
cal between-group sum of squares matrix H˜1 is calculated as the crossproduct
M˜TM˜ of the following matrix:
M˜ =

µ11 µ21 ... µp1
µ11 µ21 ... µp1
.. ...
µ11 µ21 ... µp1
µ12 µ22 ... µp2
...
µ1r µ2r ... µpr
... ... ... ...
µ1r µ2r ... µpr

where µij is the mean of group j for sample i (i=1,...,p; j=1,...,r), p is the
number of samples and r is the number of groups. The hypothetical within-
group sum of squares, or matrix W˜1, is the crossproduct of the residual values
of the MANOVA model. If no correlation between measurements obtained
by the same laboratory can be assumed, the matrix is a diagonal matrix,
with the diagonal containing the expected variances of the parameter under
interest for the different samples. Finally, let T˜1=H˜1+W˜1.
Then, the theoretical Pillai-Bartlett (PB) test is given by
PB1 = tr(H˜1T˜−11 )
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Next, the noncentrality parameter (l) is given by [104, 109]
λ = PB1(s− PB1)/s(n− r + s− p)
with s = min(p,r−1). If Fcrit is the critical value of the F-distribution cor-
responding to the null hypothesis, for example the 95th percentile of the
F distribution with p(r−1) degrees of freedom in the numerator and and
s(n−r+s−p) numbers of degrees of freedom in the denominator , the power
of the test is obtained by
Power = P {F [p(r− 1), s(n− r + s− p), λ] > Fcrit}
Numerical example
Consider the determination of LDH in the Belgian EQA. There are 12 par-
ticipants using Tris/EDTA following the Scandinavian, Italian and Dutch
recommendations, of which 5 use a Beckman-Coulter kit and 7 use material
from Olympus. Taking into account a minimal sample size of 6 for calculat-
ing z-scores, joining the two groups may not only enable us to evaluate the
Beckman-Coulter users, but may also give more reliable estimates of analyt-
ical variability.
However, we only want to join the group if the results obtained by the two
methods are sufficiently homogeneous. The formulas describing the influence
of a shift on the standard deviation show that the standard deviation is in-
creased by 10 % if the group means differ by 16 U/L. The influence of shifts
of different size on the performance of z-score statistics and their ability to
flag exceeding values (|Z|>3) is laid down in Table 2.1. Z-scores were cal-
culated with the Grubbs’ test based-approach as described in Chapter 1 on
a simulation of 10000 normally distributed data of size 12, mean 400 and
standard deviation 15, of which 5 values showed a shift of different size (16,
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32 or 64). Afterwards one value was replaced by an outlier at µ2+3σ, µ2+5σ
and µ2+7σ. Assuming that we allow a maximal shift of 10 % in the standard
Table 2.1 Percentage of flags for z-scores beyond 3 when a part of the data
are shifted, in absence and presence of outliers at different distances.
Outlier Shift (U/L)
distance 16 32 64
µ2+0 1.60 % 0.50 % 0 %
µ2+3σ 13.8 % 4.60 % 0 %
µ2+5σ 74.2 % 48.6 % 2.20 %
µ2+7σ 99.1 % 93.5 % 29.4 %
deviation, how many samples would we need to reject the null hypothesis of
no shift if the shift is smaller than 16 and the standard deviation is expected
to be 15 U/L ? Let us work with 3 samples with a hypothetical mean of 400,
450 and 500 U/L. The hypothetical matrix of means then becomes:
M˜ =

400 450 500
400 450 500
400 450 500
400 450 500
400 450 500
400 450 500
400 450 500
415 465 515
415 465 515
415 465 515
415 465 515
415 465 515

and
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H˜1 =

1981125 2224875 2468625
2224875 2498625 2772375
2468625 2772375 3076125
.
Considering that there is no correlation between measurements obtained by
the same laboratory and that all samples are analyzed with a standard de-
viation of 15, the within group sums of squares matrix writes
W˜1 =

2700 0 0
0 2700 0
0 0 2700

Finally, the hypothetical Pillai-Bartlett trace is expected to be 1.0055 and l
becomes 18.20. The probability that the Pillai-Bartlett test yields a signifi-
cant F-value is then 0.78, which is acceptable. We selected data of 3 samples
that were sent out in the second half of 2010 and beginning of 2011 (C/9945,
C/9479 and C/10137). A Grubb’s test for outliers didn’t indicate any pres-
ence of outliers when the data were considered per method. The P-value
of the MANOVA test was 0.0008, which was strongly significant. Hence, we
conclude that there is a significant method-dependent bias between these two
methods and the two groups cannot be joined.
2.4 Method comparison studies
The statistical methods described so far in this chapter are of interest when
the presence of matrix effects is assumed or known. It may also be of interest
to assess commutability of sample material before it is used in EQA rounds
or for other assessments of standardization. The techniques used here are
based on the techniques to compare two analytical methods. The first part
of this section will first focus on the statistical approaches to compare the
bias between two analytical methods, and continue with a description of
the approaches described in the literature to assess commutability of sample
material.
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2.4.1 Assessing standardization of an analytical method
It is a common procedure to compare the bias between two methods using a
regression model. Data are collected from an experiment in which a relatively
large set of samples are split in two. One half of the aliquoted samples is
analyzed with one method, one half of the aliquoted is analyzed with another
method. Analyses are preferably performed in similar settings, i.e. in the
same laboratory at the same time under similar conditions. One may also as-
sess the comparability of results in an EQA setting, with a limited number of
samples and with numerous aliquots sent to several laboratories. Graphical
methods can be used to assess differences between samples [12, 4], but linear
regression methods are preferred [180]. One can depart from a least-squares
linear regression model (see Appendix A1), in which results obtained by one
method are considered as the independent, explanatory or X-variable, and
results obtained by the other method are considered as the dependent, or
Y-variable.
However, the linear regression analysis is subject to a series of assumptions
that should be met before its results can be interpreted.
• The residuals should be identically and independently distributed fol-
lowing a Normal distribution. This entails amongst others that the
variability of the points along the regression line should be the same
over the whole measurement range. Independence of points can be as-
sured by experimental set up, for example by measuring all the aliquots
in similar conditions, and excluding carryover effects from one sample
to the other sample. Normality of errors can be assessed by a normal
quantile plot. Heteroscedasticity, i.e. non-equality of residual variabil-
ity along the regression line, can be dealt with by introducing weighing
coefficients in the regression equation [152].
• The measurement of the independent variable is expected to be per-
formed without any variability, i.e. there should be absolute certainty
about the values obtained by the methods which values are set along
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the X-axis. This requirement can only be assumed in case of measure-
ments obtained by a reference method, and not when a routine method
is used. In the following sections we present a set of alternative ap-
proaches which can be used if one or more of the assumptions are not
met.
Orthogonal regression
Orthogonal regression can be applied whenever uncertainty exists about the
true value of the independent (X) variable. It yields parameter estimates of
the regression line that minimize the orthogonal distance between the ob-
served points and the regression line. The difference between least squares
and orthogonal regression is shown in Figure 2.2.
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Figure 2.2 Least Squares and Orthogonal linear regression. The
methods minimize a different distance between the observations and
the regression line: Least Squares regression (left graph) minimizes
the vertical distance, while orthogonal regression (right graph) min-
imizes the shortest distance.
There is no simple algebraic solution to the problem of orthogonal regression,
although some solutions may be given if assumptions are made. It is often
assumed that the variabilities of the independent variable and the dependent
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variable are known up to a fixed ratio. In the clinical chemistry field, this
solution is often called Deming regression. It assumes that the values of the
independent variable are normally distributed, and that the ratio of mea-
surement uncertainties, expressed as variances, is known. Often, this ratio
is set to 1, meaning that the analytical variability between the two methods
is assumed to be the same. In its original form, Deming regression assumes
that the measurement uncertainty is constant over the whole measurement
range. Since this assumption cannot always be made, one can also consider
general Deming regression [89].
Another approach is the standardized principal component [38]. It assumes
that the ratio of the analytical error variance to the total variance is equal
for the independent and dependent variabels.
Passing-Bablok regression
A method that doesn’t require any special assumptions regarding the distri-
bution of the data or the measurement errors of two methods was described
by Passing and Bablok [9, 10]. It gives estimates for the regression line us-
ing an algorithm that is based based on the calculation of the slopes of the
straight lines between any two points (See Appendix A3) . It also includes
the calculation of confidence intervals, although it should be noted that they
are usually wider than those obtained by classical linear regression [180, 9].
Stöckl [159] studied the question whether the statistical regression model
or the analytical input data have more influence on the validity of the regres-
sion estimates. He found that the quality of the analytical input data is more
crucial for the interpretation of the method comparison than the model used
and recommends, in case of poor estimates from linear regression, to investi-
gate the poor analytical performance rather than applying other regression
models. He confirms that the sample concentrations should be adequately
distributed over the whole measurement range and hence, the Deming, stan-
dardized principle components or Passing-Bablok regression are not always
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adequate for analyzing data obtained in EQA rounds, since mostly a limited
number of samples is analyzed multiple times in this context.
A method for multiple analysis of a limited number of samples
Assessing method performance with respect to bias and variability can be
done in an EQA setting by first determining a target value for a series of
samples followed by sending aliquots to the participating laboratories for
routine analysis. Since in this case only a limited number of samples are
analyzed multiple times, Passing-Bablok or Deming regression in its different
ways are not appropriate. We suggest a method based on the linear regression
model and accommodated for possible violations of its basic assumptions,
i.e. accommodating for a possible different measurement variability over
the measured range and for a possible lack of linearity. The latter is mostly
important in case some samples would exhibit matrix effects. The assumption
of linearity may be performed by a lack of fit test [105]. The test compares
a model where each group of measurements for a certain xi is considered as
a separate group, with a model where the different values xi are considered
to be continuous. For both models, the residual sums of squares (SSE) are
calculated and used to obtain an F-statistic. It is a powerful test and may
reject the null hypothesis solely based on statistical, and non clinical, reasons.
For this reason, one may adopt it by allowing a minimal deviation from
linearity for each sample. If we allow a deviation of δ % for each sample, we
may bootstrap [34] the sample under the conditions of the null distribution,
that allows a deviation of δ %, and proceed as follows:
(1) Obtain estimates of the weighted regression coefficients a and b
(2) Obtain the predicted values for the regression model ŷ
(3) Multiply each ŷ with a randomly selected number from the interval
[1 − δ/100;1 + δ/100] and add a randomly generated value from the
Normal distribution with 0 as mean and the residual standard error
as standard deviation; As such we obtain n x m sets of data (xij, y∗ij),
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i=1,...,n; j=1,...,m with n the number of samples and m the number of
laboratories
(4) Take a bootstrap sample from the n x m sets (xij, y∗ij)
(5) Calculate an F-statistic based on the bootstrapped sample
(6) Repeat “steps 2-4” 1000 times.
The distribution of 1000 F-values may serve as a sample of the null dis-
tribution while allowing a deviation of δ% for each sample. We conclude
non-linearity if F calculated on the original data is larger than the (1-a)th
quantile of the bootstrapped sample. Note that, in case of heteroscedasticity,
the formulas can be easily rewritten taking into account weighing factors.
2.4.2 Assessing commutability of EQA samples
Several protocols have been proposed to assess commutability of sample
material in quantitative terms. As for assessing standardization between
methods, mathematical assessments are preferred above visual inspections
via graphs. Vesper [180] has given an exhaustive overview of the applied
methodology. In gross, the applied statistical methodology is a biplot, where
samples can be visualized in clusters and where commutable material belongs
to the same cluster as human sera, or a linear regression model. Eckfeldt et
al. [33] used linear or polynomial regression to assess the commutability of
materials used in EQA schemes. In this approach, simple linear regression
analysis is performed to establish the relationship between results obtained
from authentic patient samples using two measurement procedures and the
two-tailed 95% prediction interval was calculated for the distribution of pa-
tient results. Measurement results obtained with a reference material (RM)
are then compared against the 95% prediction interval. Linearity of the rela-
tion is assessed by including a polynomial terms of second order. When the
latter reflects a non-significant effect, linearity is assumed. A power analysis
could be performed by considering the prediction interval for a new point
along the linear regression line [86].
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An alternative approach based on evaluation of the residuals from regres-
sion analysis was introduced by Franzini to evaluate commutability. In this
approach, a regression line is first calculated based on the two measurements
of the clinical samples. Subsequently, the residual value for each couple of
measurements of the RM with respect to the regression line of the clinical
samples is calculated. Then, the residuals are standardized by dividing them
by the residual standard error from the linear regression model of the clinical
samples. Commutability is assumed if the absolute value of the standardized
residuals is smaller than 3.
Another approach was suggested by Ricos et al. They used regression anal-
ysis with an evaluation approach based on expressing the residual as a per-
cent to identify non-commutable control materials for creatinine. They used
Passing-Bablok regression to determine the relationship between results for
native patient samples. For each control material, a residual was determined
as the difference from the value for that material predicted from the regres-
sion line for the native patient samples. The residual for the control material
was expressed as a percent of the value predicted from the regression rela-
tionship and called a bias (in percent). The bias (in percent) for each control
material was compared to three criteria to evaluate commutability [134, 135].
Baadenhuijsen et al. [8] described an alternative study design. The par-
ticipating laboratories were grouped in couples of two and fresh patient sera
were split into two portions, one portion from each sample was transported
the same day to the partner laboratory, which in turn proceeded in the same
way for its patient specimens. The interchanged fresh patient samples were
then analyzed (within 24 h of the initial analysis) in the same analytical
run with the reference materials, which were sent beforehand to each partic-
ipant on dry ice. Relations between measurements of routine methods were
assessed by a Passing-Bablok regression and results of sample material far
away from the regression line between two laboratories were considered as
non-commutable [8].
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2.5 Application: Oestradiol and Progesterone
In the last decades, immunoassays have replaced the time consuming ra-
dioimmunoassays for determining steroids. They are based on chemilumi-
nescence techniques and are executed on highly automated platforms, which
are now routinely used to measure steroids, such as estradiol (E2) and pro-
gesterone (P). The results of these methods, however, are not absolutely
reliable, as demonstrated by a high imprecision and indeterminate accuracy.
Boudou found for example that most of the immunoassays for progesterone
showed an underestimation at high levels and an overestimation at low levels
[17]. In addition, the kinetics of the antigen-antibody reaction and thus the
measurement data may be influenced by matrix effects. Results of steroid
immunoassays may also vary because of the procedure used to displace the
substance from its serumprotein binding. In direct assays, displacement by
competitive agents may be incomplete, whereas methods involving solvent
extraction may suffer from variable extraction efficiency.
A study was performed at the Institute of Public Health of Belgium in 2005
to assess bias and variability of the routine clinical methods for Estradiol
(E2) and progesterone [27]. In an attempt to exclude matrix effects as much
as possible, samples were off-the-clot serum and sent, without any addi-
tives or preservatives added, to the participants on dry ice. Five samples
were obtained from normally cycling women and three were from a pool of
donations by at least 10 different pregnant women. The sera from the nor-
mal cycling women were prepared with samples from one single donor; they
were rapidly isolated to avoid hemolysis and kept in sterile conditions. The
lipemia of the samples was evaluated by measuring the triglycerides on a Vit-
ros system (Ortho-Clinical Diagnostics, Raritan, NJ, USA). The presence of
other steroids was also analyzed: Estrone (Biosource Europe, Nivelles, Bel-
gium), Estriol (Gamma, Angleur, Belgium) and 17a-hydroxyprogesterone
(Biosource Europe). In order to control for possible bias caused by hu-
man anti-mouse antibodies (HAMA) in the two assays with the highest
bias, two samples (E2 concentrations of 1841 and 2026.4 pmol/L) were each
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measured in triplicate on Vitros and Vidas (Biomerieux, Marcy l’Etoile and
Paris, France) systems before and after incubation with Heterophilic Block-
ing Tubes from Scantibodies Laboratory Inc. (Santee, CA, USA). Samples
were stored at -70°C until the control samples were prepared for the trial.
Sterile aliquots of 500 µl were prepared and stored at -70°C until they were
distributed to the participating laboratories.
Determination of E2 and progesterone reference value was performed by pre-
viously described Isotope Dilution - Gas Chromatography / Mass Spectrom-
etry (ID–GC/MS) methods [173, 172, 174, 167]. The coefficient of variation
(CV) of the target value of E2, was estimated to be of the order <0.5% for
concentrations >220 pmol/L and 0.6% for concentrations <220 pmol/L. For
the extremely low concentrations (<18 pmol/L), the CV was about 2%. For
progesterone, the CV of the target value is estimated at <1%. An overview
of E2 and progesterone concentrations, obtained by ID-GC/MS, with their
clinical interpretation is given in Table 2.2.
The immunoassay systems taken into account were those most frequently
used in Belgium: Advia Centaur (using assay ACS Centaur E2 6)(Bayer, Tar-
rytown, NY, USA), Immulite (DPC, Los Angeles, CA, USA), Elecsys (Roche,
Basel, Switzerland), Access (Beckman-Coulter, Fullerton, CA, USA), Vitros
and Vidas.
First, outliers were excluded for further analysis. One value deviating by
more than 10000% from its true value, and the results of one laboratory of
which more than half the results deviated by more than 50%, were disre-
garded. As in a clinical setting, where results are interpreted according to
the patient’s physiological status at the time of sampling, CV and bias are
discussed per physiological condition with the emphasis on the highest CV or
bias. A weighted linear regression analysis and lack-of-fit test were performed
for each method separately to assess a linear relationship and the relation
between concentration and bias [152]. The null distribution of the lack-of-fit
test was developed by a 1000-fold bootstrap [34], which showed significance
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Table 2.2 Overview of individual sample hormone concentra-
tions as assessed by ID-GC/MS. These data are the target
values of E2 and progesterone, for comparison with the results
obtained in the different laboratories.
Phase E2(pmol/l)
Progesterone
(nmol/L)
Early 198.1 0.56
follicular 209.4 0.80
406.0 6.17
Perioovulatory or 598.1 22.53
mid-luteal 778.1 24.26
Pregnancy 1841 117.9
2026 41.48
3417 69.49
only if the means deviated by more than 10% from a linear relationship. To
achieve satisfactory power, only results from those immunoassay methods
that had at least seven users were considered in the study.
As a result, 140 laboratories were considered for E2 and 155 for proges-
terone. For the eight samples in the study, none of the laboratories reported
data below detection or quantification limit. Samples from different donors
of which the concentration was defined by ID-GC/MS allowed a regression
model to be used with the reference value as independent and the results
reported by the laboratories as the dependent variable.
Three parameters were considered from the regression analysis: (i) P-value
of a liberal lack-of-fit as a test for linear relationship: samples were omitted
until a linear relationship was found, allowing for a deviation of 10 % for
each sample; (ii) intercept of the weighted linear regression method with the
hypothesis test whether there is significant difference from 0; and (iii) slope
of the weighted linear regression method with the hypothesis test whether
there is significant difference from the 45°-line.
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Table 2.3 CV (%) per sample for E2 for the six automated immunoassay
analyzers most frequently used in Belgium in 2005.
Target value Advia DPC Elecsys Access Vitros Vidas
(pmol/L) Centaur Immulite
198.1 24 21 11 23 24 15
209.4 24 14 11 49 22 16
406 11 12 7 10 16 7
598.1 14 11 7 18 11 7
778.1 22 11 8 12 13 12
1841 21 12 5 18 8 11
2026 29 10 5 10 15 22
3417 8 9 4 7 7 10
Table 2.4 Relative bias (%) per sample for E2 for the six automated im-
munoassay analyzers most frequently used in Belgium in 2005.
Target value Advia DPC Elecsys Access Vitros Vidas
(pmol/L) Centaur Immulite
198.1 7 -5 5 30 15 9
209.4 -12 -4 15 22 18 20
406 -4 -8 7 17 -11 4
598.1 9 -17 7 36 -26 0
778.1 14 -3 22 16 -12 10
1841 -4 -6 18 -10 2 43
2026 -13 25 6 20 96 239
3417 -4 -11 9 -6 -15 21
Table 2.5 CVs (%) per sample for progesterone for the six automated im-
munoassay analyzers most frequently used in Belgium in 2005.
Target value Advia DPC Elecsys Access Vitros Vidas
(nmol/L) Centaur Immulite
0.56 107 59 52 202 88 102
0.80 58 43 23 84 33 74
6.17 16 11 6 33 9 10
22.53 8 10 7 18 9 12
24.26 8 8 7 11 7 9
41.48 16 8 11 15 9 10
69.49 8 7 7 10 7 10
117.9 14 14 8 45 10 6
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Table 2.6 Relative bias (%) per sample for progesterone for the six automated
immunoassay analyzers most frequently used in Belgium in 2005.
Target value Advia DPC Elecsys Access Vitros Vidas
(nmol/L) Centaur Immulite
0.56 618 224 475 643 841 327
0.80 17 54 49 203 103 145
6.17 64 22 -23 81 -10 21
22.53 35 15 12 63 30 47
24.26 40 7 12 40 15 52
41.48 145 9 67 20 73 75
69.49 28 -8 16 7 8 33
117.9 28 15 34 33 35 46
Variability
The results are shown in Table 2.3 for E2 and Table 2.5 for Progesterone.
Considering the lack of precision for E2 measurements of women in the early
follicular phase, Elecsys, Vidas and Immulite had the lowest variability (with
maximum values at, respectively, 11, 16 and 21%). Access had the highest
variability, with CV up to 49%. CVs for Advia Centaur and Vitros were in-
termediate (24%). For progesterone, CV values and bias for concentrations
<1 nmol/L were considered of no clinical importance and will not be dis-
cussed.
E2 measurements of samples from women in the periovulatory or luteal phase
demonstrated a similar trend. Elecsys, Immulite and Vidas had the lowest
variability (respectively, 8, 12 and 12%), while Advia Centaur was the least
precise (22%). Access and Vitros were intermediate with 18 and 16%, re-
spectively. Progesterone immunoassays (Table 2.5) demonstrated maximum
CVs <10% for Elecsys and Vitros (respectively, 7 and 9%). Access peaked
at 33%, while the other systems showed intermediate CVs (Advia Centaur:
16%; Immulite: 11%; Vidas: 12%).
For the samples that were mixtures of single blood draws from pregnant
women, Elecsys and Immulite had the lowest variability for E2 (5 and 12%),
while Vitros, Access and Vidas had, respectively, 15, 18 and 22%. Here,
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Advia Centaur had the highest variability ( 29%). For this category, CVs of
progesterone were below or near 10% for Elecsys, Vitros and Vidas (respec-
tively, 11, 10 and 10%). Notice that Access also has the highest CV (45%);
Advia Centaur and Immulite are intermediate (16 and 14%).
Bias
The relative bias for E2 for one sample (E2 concentration 2026.4 pmol/L) was
substantially higher than that seen for any other sample. For this sample,
four methods showed a bias of 20% or higher: Access (20%), Immulite (25%),
Vitros (96%) and Vidas (239%). Applying a theoretical correction for pos-
sible interfering substances (triglycerides, 2 mmol/L; estrone, 7013 pmol/L;
estriol, 18 pmol/L) did not reduce the bias of the measurements to within
acceptable limits (bias after correction by multiplying the cross reactivity
coefficient with the concentration of interfering substances: Immulite: 25%,
Access: 16%; Vitros: 78%; Vidas: 87%). Advia Centaur also showed high
bias for progesterone (145%). Results of this sample were not included in the
discussion of the bias. For E2 (Tables 2.3 and 2.4), Immulite has negative
bias for all other samples, while Elecsys and Vidas have overall positive bias.
Concerning magnitude, Immulite had distinctively lower bias for the samples
from women in early follicular phase (25%). Advia Centaur, Elecsys and Vit-
ros had slightly higher bias (respectively, up to 212, 15 and 18%). Access and
Vidas had up to 30 and 20%, respectively. For the samples from women in
the periovulatory or luteal phase, Vidas performed best (bias <10%). Bias
values for Advia Centaur and Immulite were slightly higher (respectively, 14
and -17%), while other systems have bias values >20% (Elecsys: 22%; Vitros:
-26%; Access: 36%). The picture for samples from pregnant women is differ-
ent: here, Vidas performed worst (43%). All other systems had intermediate
bias (between 10 and 20%), and there was no clear difference between meth-
ods.
Bias values for progesterone are generally positive (Tables 2.5 and 2.6). Advia
Centaur, Access and Vidas had overall positive bias. For all other methods
there was only one sample with negative bias. All systems showed bias values
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Table 2.7 Mean regression coefficients between reference values and values
reported by the laboratories. Results are expressed in pmol/L for estradiol
and nmol/L for progesterone.
Immunoassay Estradiol Progesterone
Intercept Slope Intercept Slope
Advia Centaur 17.82 0.96 2.37 ∗ 1.26 ∗
DPC Immulite -14.84 ∗ 0.92 ∗ 0.87 ∗ 1.07 ∗
Elecsys 24.57 ∗ 1.11 ∗ 0.19 ∗ 1.15 ∗
Access 104.0 ∗ 0.93 ∗ 3.56 ∗ 1.15 ∗
Vitros -13.67 0.92 ∗ 1.47 ∗ 1.10 ∗
Vidas -30.16 ∗ 1.31 ∗ 0.89 ∗ 1.41 ∗
∗Intercept significantly different from 0; slope significantly different from 1
for all phases of at least 15%. Values peaked at 81% (Access), 64% (Advia)
or 52% (Vidas).
The results of the linear regression are shown in Table 2.7. For E2, only
Advia Centaur and Elecsys had a linear relationship between reference and
reported values over the whole range (Figure 2.3). For the other systems, the
previously mentioned sample (concentration 2026.4 pmol/L) had significant
bias and had to be omitted from the regression analysis to obtain a linear
relationship.
Considering intercept and slope (Table 2.7), Immulite, Elecsys, Access and
Vidas had an intercept that significantly differed from 0, indicating a con-
centration-independent bias especially important for the low concentrations.
The slope differed significantly from 1 for all systems except the Advia Cen-
taur. Slopes ranged from 0.92 (Immulite and Vitros) to 1.31 (Vidas). Here
too, it should be noted that a non-significant difference for Advia Centaur
may have been caused by the high uncertainty of the method. For proges-
terone (Figure 2.4), one system did not seem to suffer from a lack of linear
relationship between RMV and reported values (Access). For the other sys-
tems, one (Advia Centaur, Elecsys, Vidas) or two (Immulite, Vitros) samples
had to be omitted to obtain a linear relationship. Intercepts were all signif-
icantly higher than 0, ranging from 0.19 (Elecsys) to 3.56 (Access). Slopes
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were all significantly higher than 1, yielding deviations from 7% (Immulite)
to 41% (Vidas).
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Figure 2.3 Weighted linear regression results for E2. Values indicated by crosses (+) are not
included for weighted linear regression, in order to obtain a linear relationship. All units are
in pmol/L.
To conclude, we can say that mean bias values of 0.20% occurred in 19% of
E2 and in 90% of progesterone measurements. This suggests that the IVD
directive from the European Union may not go far enough and that a more
suitable requirement may be to strive to compare every method with the
highest possible standard (in this case ID–GC/MS as reference method).
In addition, variation differed considerably between methods; it also dif-
fered considerably from reported intra-laboratory variance. Only for Elecsys
were the reported intra-lab CVs [195, 11]) for both E2 and progesterone com-
parable to the CVs in this study. This indicates that, for this system, the
inter-laboratory contribution of variance to the total was very small. For
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Figure 2.4 Weighted linear least-squares regression results for progesterone. Values indicated
by crosses (+) were not included for weighted linear regression, in order to obtain a linear
relationship. All units are in nmol/L.
other systems, the total inter-laboratory variability was clearly wider than
the reported intra-lab uncertainties [138, 192, 51, 5, 171, 168, 90], which
points to a significant difference between results for the same sample ob-
tained in different laboratories.
The bias of several methods for particular samples jeopardized a linear rela-
tionship between RMV and routine methods for E2 and progesterone. Vitros
systems reported almost twice, and Vidas more than three times the concen-
tration. Cross-reactivities reported by manufacturers were too low, however,
to explain the behavior of the sample by interferences from another substance.
Neither could lipemia or hemolysis be the reason, because the samples showed
no tendency to behave oddly. A test in which possible HAMA [23, 72] were
excluded before analysis did not help: Vidas still reported bias >200% and
Vitros still showed >90% bias. To date we can offer no explanation for the
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abnormal bias seen for this sample with some methods. However, the sample
consisted of a mixture of serum samples. Apart from the results recorded for
that particular sample, it should be noted that no single method had bias
values below 10% for all samples.
Considering progesterone, the results generally showed higher CVs and bias
values. All methods had overall positive bias values, ranging to 40%. In
conclusion, we can say that for E2 and progesterone measurements, a linear
relationship between the reference method values, determined by ID-GC/MS
and reported values was not assured for most methods in a range for E2 from
198.13 to 3417.3 pmol/L and for progesterone from 0.56 to 117.85 nmol/L.
Overall precision for progesterone was better than for E2 for all automated
analyzers except for Access.
2.6 Conclusion
In an era of increased patient mobility, comparison between laboratory re-
sults of different centers, often obtained by different analytical methods, is of
great importance and hence, standardization between methods should also be
a priority. Interlaboratory comparisons, as carried out by EQA, have become
essential to assess standardization between methods. There are however sev-
eral practical aspects involved that make these kind of studies a tedious task.
EQA sample material should be made on a large scale and be treated for
ensuring stability of parameters over time. Often, samples of different pa-
tients are merged and receive additives or other treatments to preserve them
over a long time. These manipulations may induce matrix effects, i.e. the
difference between analytical results obtained by different measurement pro-
cedures do not reflect the differences observed for routine clinical samples. As
a consequence, samples may lack similarity with genuine samples routinely
analyzed in the laboratory - an effect also called lack of commutabilty. Often
a trade off has to be made between long-term stability of sample material
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and commutability.
For some parameters, commutable material exists, but unfortunatley, to-
day, the only way to obtain material that is commutable for a large set of
parameters is fresh, single-donation material. Freezing or pooling material
from different patients may induce bias between methods. However, finding
fresh serum single-donation samples is not easy, definitely when the EQA
organizer wants to send samples that reflect a particular pathology or physi-
ological stage. In addition, the intake of particular drugs may induce matrix
effects as well. For this reason, EQA organizers should be aware of the de-
gree of commutability of their sample material and undertake the necessary
actions whenever commutability is not attained and laboratories should be
partitioned into so-called peer groups. A peer group is a group of laboratories
using the same or similar analytical methodology for the determination of a
certain parameter, grouped in such a way that the group is free of matrix-
dependent bias.
The homogeneity of the peer group with respect to matrix effects is a basic
and necessary assumption that has to be assessed before any evaluation can
be carried out, since a heterogeneity inflates the standard deviation of the
peer group and may mask deviating results. Whenever details about the ap-
plied methodology are available and the EQA organizer can use results from
previous surveys a multivariate model can be built that can detect hetero-
geneity with sufficient power. Before application of the model, the user has
to set up a tolerance limit towards inflation of standard deviation. From this,
a maximal bias between methods can be derived. The latter is subject to a
power analysis, that yields the required number of samples used in the mul-
tivariate analysis to obtain with satisfactory probability the certainty that a
peer group is homogeneous.
Another option to avoid matrix effects is a deliberate choice of sample mate-
rial. We could think of a preferred hierarchy of sample material. The top of
the hiearchy is best fitted for standardization studies: fresh samples sent out
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immediately after collection from the patient. Care has to be taken however
that the patient is free of HAMA and is not taking any drugs that may cause
interference with one or more analytical methods. Next are single-donation
samples which have undergone freezing, followed by fresh pools of samples
and freshly frozen pools of samples. At the bottom of the hierarchy are
the samples which have been stabilized by additives and/or have undergone
freeze-drying.
Matrix effects, however, are not the only obstruction in the quest for stan-
dardization between methods. In this context, it is also important that
method comparison studies, outside of the EQA setting, are analysed with
the right statistical techniques. Ordinary least squares regression suffers from
different flaws and is not always the most appropriate technique. Orthogonal
regression should be used, while the basic assumptions should be assessed as
well. The statistical techniques used for analyzing EQA data can be divided
in two groups: evaluations performed for each sample separately and evalua-
tions taking into account different samples for which a target value has been
set.
Whenever an analysis is desired taking into account the values reported for
different samples, for which an assigned value has been calculated using a
reference method, a linear regression analysis can be applied in order to as-
sess the bias of a particular method over a concentration range. The nature
of EQA data is structured to perform a lack of fit test, which could indicate
absence of linearity for one or more samples and hence, the presence of ma-
trix effects. Care should be taken however with the power of the test, since a
statistically significant lack of fit may appear even when the difference of the
mean reported values of a certain sample does not exceed limits of clinical
relevance. For this reason, the null distribution of the lack of fit test should
be set up using predefined limits of acceptability, where the bootstrap is a
useful help. The application of this technique to a survey for oestradiol and
progesterone has shown that pooled samples of pregnant women that were
fresh frozen showed matrix effects. It was also evidenced that traceability
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towards a standard of higher order is not a satisfactory criterion for ensuring
standardization between methods. Because of the considerable bias differ-
ences between methods, a clinical follow-up of a patient should always be per-
formed using the same, fit-for-purpose and well-validated assay. Considering
the large bias of some methods, it is recommended to use method-specific
reference intervals for the different physiopathological conditions.
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CHAPTER 3
Combined evaluation of different
EQA surveys or samples
3.1 Introduction
Scientific articles reporting results from EQA have been focusing mainly on
the evolution of the total variability between laboratories. Little attention
has been paid to the individual follow-up of laboratories over a longer time
period, or over a series of parameters. A literature search for scientific arti-
cles published in 2010 and in the first half of 2011 reporting findings of EQA
surveys for at least one quantitative parameter for different samples resulted
in 16 articles. Less than half (only 7 from the 16) mentioned an evaluation
and follow up of the individual results of the laboratories, mainly by count-
ing the number of laboratories reporting unacceptable results. All articles
focussed in some or another way at the inter-laboratory variability. Although
the latter is an important indicator of measurement uncertainty expressed
on an inter-laboratory level, analyzing data over different surveys sheds light
on the individual performance of the laboratories. A survey with one sample
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may inform the laboratory about its performance with respect to its peer
group or to analytical performance goals. When an interpretation is made
over several samples together, information can be generalized and a better
understanding of the laboratory performance in terms of bias, variability and
total error can be obtained, helping laboratories deciding where efforts for
improvement should be made [35]. Only few approaches have been proposed
in the literature to calculate performance statistics by combining data from
different samples, surveys and/or laboratory test parameters. They will be
presented, exemplified and commented in the next sections, with a focus on
their robustness against outliers, and their ability to describe elevated bias
and/or variability.
3.2 An artificial data set to compare the ap-
proaches
To evaluate the performance of the different approaches for finding poorly
performing laboratories, they were applied to the same artificial data set.
This data set represents simulated data from 224 laboratories, which have
reported results for 10 parameters determined on one sample for 40 artificial
surveys. It has been created to simulate the effect of outliers, variability and
bias. For this purpose, a full factorial design was set up with the following
factors and their levels:
(1) Outlier frequency: none (0%), low (5%) and high (10%)
(2) Bias: none, small (all data shifted 1 SD upwards), high (all data shifted
10 SDs upwards)
(3) Variability: none (SD=1), slightly increased (SD=2), highly increased
(SD=5)
The data set contains results of 120 excellently performing laboratories, with-
out outliers or bias and a standard deviation of 1. For each of the other com-
binations of the factor levels, 4 laboratories were simulated. Outliers, bias or
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variability were each time simulated for only one of the 10 parameters. This
led to a data set of 224 laboratories, of which 120 performed excellently and
104 exhibited outliers, increased variability and/or higher bias for 1 parame-
ter. Mean values of samples were arbitrarily set at a value between 10 and 70,
yielding CVs between 1.4% and 45%. Note that about half of the laboratories
exhibited a deviation from the ideal performance, i.e. their results contained
outliers or reflected an increase in bias and/or variability. Although in reality
a smaller fraction of the laboratories is expected to exhibit deviating results,
this set up is preferred here to give a clear idea of the performance of the
different evaluation methods with respect to weakly performing laboratories
as explained by presence of spurious results, high variability or bias.
3.3 Variance and Bias index scores
3.3.1 Introduction
The principle of calculating a performance index on the basis of survey results
has been adopted in the United Kingdom since several decades [188, 19] and
is still a popular tool for expressing laboratory performance [118, 66, 170].
The cornerstone of the calculation is a comparison with a Chosen Coefficient
of Variation (CCV; expressed as a percentage), in casu a mean Coefficient of
Variation obtained for a certain parameter at a certain survey in the past.
A “bias index score” (BIS) and a “variance index score” (VIS) is calculated
by taking the difference between each participant’s reported value (x) and a
designated value (DV) and to express it as a fraction of the CCV, expressed
as a percentage:
Bias Index Score (BIS) = (x −DV)DV
10000
CCV
Variance Index Score (VIS) = |BIS|
The DV is calculated as a trimmed mean, whereas the BIS and VIS represent
in fact the ratio, expressed as a percentage, of the relative distance between
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an individual result and its target value, with a coefficient of variation from
the past. For excluding the effect of outliers, BIS values higher than 400 or
lower than -400 are set at 400 and -400, respectively. Similarly, VIS values
higher than 400 are set at 400.
Performance scoring is made using the VIS, which can be combined over
surveys or analytes. Combining over surveys, the UK NEQAS defines a
mean running VIS (MRVIS), which is the mean VIS value of the last 10 or
12 values. Consequently, a mean running BIS (MRBIS) is given as the mean
BIS of the last 10 or 12 values. In addition, an overall overall mean running
VIS (OMRVIS) is given as the last 40 (or 30) VIS values for all analytes
assayed by the laboratory. Values of MRVIS or OMRVIS are categorized as
shown in Table 3.1.
3.3.2 Example
The results of the MRVIS and OMRVIS are used to classify laboratories. In
contrary with the UK NEQAS, the median is used as the DV, since this facil-
itates comparisons with other methods. As CCV value, the double of the CV
of the population of non-contaminated result was proposed. Knowing that
the expected mean of the absolute value of a standard normally distributed
value is 0.80, the expected value of the MRVIS is then 40. The MRVIS and
OMRVIS values were calculated for four distinct periods: the artificial survey
1-10, 11-20, 21-30 and 31-40. Subsequently they were classified according to
Table 3.1 and the percentage of laboratories belonging to each class for the
four different periods are shown in Table 3.2. Note that the distribution of
Table 3.1 Classification of laboratory performances ac-
cording to their MRVIS or OMRVIS value.
Range of MRVIS, OMRVIS Category
≤50 Ideal
50 - 100 Good
100 - 200 Adequate
>200 Poor
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the number of laboratories over the different classes depends on the CCV
value: a lower CCV value would have caused more laboratories belonging to
the worse performance classes. In this case, it is more important to look at
the relative shifts between the performance classes in presence of a combina-
tion of outliers, bias or increased variability, instead of the actual distribution
between ideal, good, adequate or poor for a given shift, standard deviation
and outlier frequency.
The presence of outliers causes a shift towards the weaker performance classes,
mainly when the bias and standard deviation are small. However, the most
determining effects on the classification are the bias and standard deviation,
clearly exhibiting a shift towards the weaker classes with increasing bias and
variability. It should be noted that a small increase in standard deviation,
from 1 to 2, shows a larger effect than a small increase of the bias, from 0 to
1. A combined effect of bias and standard deviation shows a shift towards
the worse performing classes that is larger than the shift when only bias or
increased standard deviation exist. A larger bias or increased standard devi-
ation results in 100% poorly performing laboratories.
Remark that a weaker performance of 1 of the 10 parameters doesn’t in-
fluence the OMRVIS profoundly: outliers, bias or increased variability only
influences the distribution between the ideally and well performing labora-
tories.
3.3.3 Comments
One of the major advantages of the variance index scoring system is a simple
indication of laboratory performance, which can be merged over a variable
number of surveys and parameters. Its use of a chosen coefficient of variation
reflects the idea that, compared to the past, a good performing laboratory
should respond closer to the designated value. In this way, the system fa-
vors laboratories performing better over time. Nevertheless, the evaluation
strongly depends on the representativeness of the CCV. Since CCV values
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Table 3.2 MRVIS and OMRVIS classifications for the example data set. MRVIS
was calculated based on the parameter for which outlier frequency, variability and
bias was induced, OMRVIS was calculated based on all the parameters. Results
based on 224 simulated laboratories, having reported values for 10 parameters
during 40 surveys.
MRVIS OMRVIS
Bias SD Outliers Ideal Good Adequate Poor Ideal Good Adequate/
(%) Poor
0 1 0 72.5 26.9 0.63 0.00 94.2 5.83 0.00
0 1 5 50.0 31.3 18.8 0.00 81.3 18.8 0.00
0 1 10 37.5 31.3 25 6.25 68.8 31.3 0.00
0 2 0 25.0 56.3 18.8 0.00 81.3 18.8 0.00
0 2 5 18.8 31.3 50 0.00 75 25.0 0.00
0 2 10 12.5 43.8 43.8 0.00 75 25.0 0.00
0 5 0 0.00 6.25 62.5 31.3 31.3 68.8 0.00
0 5 5 0.00 0.00 43.8 56.3 25 75.0 0.00
0 5 10 12.5 6.25 31.3 50 25 75.0 0.00
1 1 0 56.3 37.5 6.25 0.00 100 0.00 0.00
1 1 5 25.0 56.3 12.5 6.25 62.5 37.5 0.00
1 1 10 37.5 56.3 6.25 0.00 81.3 18.8 0.00
1 2 0 12.5 68.8 18.8 0.00 87.5 12.5 0.00
1 2 5 6.25 62.5 31.3 0.00 81.3 18.8 0.00
1 2 10 12.5 37.5 50.0 0.00 75.0 25.0 0.00
1 5 0 6.25 0.00 50.0 43.8 37.5 62.5 0.00
1 5 5 0.00 12.5 43.8 43.8 25.0 75.0 0.00
1 5 10 6.25 0.00 62.5 31.3 25.0 75.0 0.00
10 1 0 0.00 0.00 0.00 100 0.00 100 0.00
10 1 5 0.00 0.00 0.00 100 0.00 100 0.00
10 1 10 0.00 0.00 0.00 100 0.00 100 0.00
10 2 0 0.00 0.00 0.00 100 0.00 100 0.00
10 2 5 0.00 0.00 0.00 100 0.00 100 0.00
10 2 10 0.00 0.00 0.00 100 0.00 100 0.00
10 5 0 0.00 0.00 0.00 100 0.00 100 0.00
10 5 5 0.00 0.00 0.00 100 0.00 100 0.00
10 5 10 0.00 0.00 0.00 100 0.00 100 0.00
are a measure of the past, performance indicators denote only a reference to
a previously attained analytical performance level.
Although only the VIS indicator is used to assess a laboratory’s performance,
the BIS and its derived variables are also given to the laboratory. It should
be noted here that, although a combination of BIS with high absolute value
and a low VIS reflects a bias for a certain parameter or laboratory, a high
VIS value not solely means an increased variability. Disregarding outliers,
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the VIS and its derived parameters are a measure of the sum of bias and
variability, i.e. total error. Hence, the term VARIANCE index score may
be misleading. A laboratory experiencing an increased VIS should also look
ad the evolution of the BIS values. An increased analytical variability can
only be considered if the BIS doesn’t increase. All other possibilities, i.e. an
increased bias or a combination of increased bias and variability, cannot be
distinguished. Although the method does an effort to make the VIS robust
against outliers by ceiling individual VIS scores at 400, the method is still
influenced by outliers and an observed increase in VIS or BIS may be due to
an increased error rate in the laboratory as well. At last, pooling VIS values
for different parameters together may mask laboratory mistakes in one single
parameter, as seen by the high occurrence of ideal and good values of the
OMRVIS. The latter demonstrates the necessity of an evaluation for each
parameter separately.
3.4 Mean ranking scores
3.4.1 Introduction
Ehrmeyer and Laessig [35] abandoned the traditional approach to derive the
criterion for acceptable results from a measure of variability based on the
participant’s results or obtained via analytical performance goals and devel-
oped a method that is related with non-parametric statistics. The basis of
the test is the difference between an individual value and the “target” mean
value of a parameter determined for each peer group:
error = individual value − target value
For each sample, laboratories are sorted from the smallest to the largest
absolute value of the error and for each individual result, the proportion
of results with equal or smaller absolute value of the error are recorded. As
such, a cumulative distribution function is obtained and every reported value
can be linked with its own percentile value, i.e. the percent of laboratories
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performing equal or worse with respect to the analysis of a certain param-
eter for a certain sample. Subsequently, median percentile values obtained
for a certain laboratory for different samples are taken and a score on a scale
from 0 to 100 is obtained. Lower values indicate good performance, higher
values point to weak performance. By taking the percentile function result
of a maximal allowable absolute error, comparison with analytical targets
can easily be introduced into the algorithm and in this way, the approach
is able to evaluate laboratories with respect to peer-group comparisons and
to analytical target performance as well. Furthermore, averaging the errors
may help laboratories differentiating between random and systematic bias:
an average of the errors strongly deviating from zero indicates systematic
bias, while a strongly deviating average of absolute values points to a com-
bination of random error and/or systematic bias. Ehrmeyer has applied the
method to EQA surveys for blood-gas and confirmed that the method can
be applied to other data as well.
3.4.2 Example
The mean ranking approach has been applied to the example data set. Per-
centile functions were calculated for the reported values of the first parameter
and median values were taken over 4 distinct groups of 10 surveys (surveys
1-10, 11-20, 21-30 and 31-40). Average ranking values of laboratories for each
group of 10 surveys are given in Table 3.3. The effect of added outliers is
almost not visible in the mean ranking. Only for the laboratories not having
any bias or increased variability, a slight increase of the mean ranking can
be observed when outlier frequencies rise. Further, ranking clearly increases
with increasing bias or variability. In contrary to the performance index scor-
ing system, a combined effect of bias and variability doesn’t make the mean
ranking to rise higher than their separate effects. For example, when outliers
are not present, mean ranking of laboratories having a bias of one standard
deviation and a standard deviation of 5 (mean ranking=60.9) is lower than
when bias is absent (mean ranking=66.2). Furthermore, a high bias yields
74
3.4 Mean ranking scores
Table 3.3 Mean ranking of laboratories exhibiting different devi-
ations from the ideal process for the example data set, containing
results of 224 simulated laboratories, having reported values for
10 parameters during 40 surveys, with induced bias, increased
variability and outliers.
Standard Outliers Mean
Bias deviation (%) ranking
0 1 0 33.4
0 1 5 36.0
0 1 10 44.6
0 2 0 40.5
0 2 5 49.3
0 2 10 50.0
0 5 0 66.2
0 5 5 73.8
0 5 10 63.3
1 1 0 37.9
1 1 5 39.1
1 1 10 37.5
1 2 0 47.2
1 2 5 51.0
1 2 10 49.8
1 5 0 60.9
1 5 5 67.3
1 5 10 74.3
10 1 0 90.1
10 1 5 90.7
10 1 10 91.0
10 2 0 88.8
10 2 5 90.9
10 2 10 89.8
10 5 0 88.5
10 5 5 85.5
10 5 10 88.8
mean ranking values of around 90%, without distinction between variability
levels or outlier frequencies.
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3.4.3 Comments
A major advantage of the approach is its flexibility of use: it can be applied
without the need to calculate any standard deviation or using an analytical
performance goal. Even more, if analytical performance goals are available,
they can be easily integrated. In addition, it is quite robust to outliers
and hence, it defines weakly performing laboratories mainly on their perfor-
mance in the analytical step of the total error process: an increase of the
mean ranking value points to an increased bias and/or analytical variability.
Laboratories having problems in their pre- or post-analytical phase, as may
be expressed by a high frequency of outliers in EQA results, may escape no-
tice by this test.The interpretation of the mean error values, before and after
removing the sign, is very similar to the interpretation differences between
BIS and VIS values from the performance scoring system and, as noted there,
cannot always help in distinguishing between bias and variability.
3.5 Z-and u-scores count
3.5.1 Introduction
The Belgian EQAs for chemistry, immunoassays, therapeutic drug monitor-
ing, alcohol, hematology and coagulation use a long-term evaluation tech-
nique based on the frequency of flags for z- and u-scores, as described by
Albert [2]. They are calculated as shown in Table 3.4.
Table 3.4 Calculation and flagging of z- and u-scores.
Calculation Flagging
Z-score individual result − group mediangroup standard deviation |z-score|>3
U-score individual result − group mediangroup median |u-score|>u
∗
u∗= analytical threshold, generally based on biological variability
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Z-scores reflect the performance of a laboratory with respect to its peer
group. Assuming that the majority of the laboratories reports a reliable
result, a laboratory reporting a result that deviates more than 3 standard
deviations away from the center of its peer group is flagged for a high z-score.
The percentage of flagged u-scores reflects the performance of a laboratory
with respect to a parameter-specific analytical quality specification limit, de-
rived according to the Stockholm consensus and often based on biological
variability (see Chapter 1).
Frequencies of flagged z- and u-scores (Pz and Pu) can be merged over the re-
sults reported by a laboratory for a certain domain, or over the results found
with a certain method. Disregarding outliers, interpreting z- and u-scores
together informs the laboratory about the quality of the applied method-
ology and about the quality of the use of the methodology, as outlined in
Table 3.5. A combination of low z- and u-scores is optimal and points to the
proper use of a proper methodology. When u-scores increase while z-scores
are low, the laboratory is able to perform similar to other members of its peer
group, so it uses its methodology in a proper way. The increasing u-scores
indicate however an increasing failure to meet analytical targets, unveiling a
weak method performance. When z-scores increase while u-scores are low,
the laboratory is still able to meet analytical targets, but its results deviate
from what other laboratories obtain, indicating a weak method use.
Table 3.5 Proper and improper use of methodology, ans explained by z- and u-scores.
High u-scores Low u-scores
High z-scores Laboratory uses Laboratory uses
methodology improperly proper methodology improperly
Low z-scores Laboratory uses Laboratory uses
improper methodology properly proper methodology properly
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3.5.2 Example
The results are shown in Table 3.6. Z-scores were based on an average and
standard deviation calculated after a removing outliers using Grubbs test
(α = 0.05), as described in Chapter 1. They were first calculated based on
the parameter for which outliers, bias and variability were introduced and
subsequently based on all the data. U-scores were evaluated using a maximal
allowable deviation of 15 %. The percentage of z- flags and of an u-flags were
averaged over each of the four groups of consecutive surveys (surveys 1-10,
11-20, 21-30 and 31-40). The percentage of flaggings is clearly subject to
presence of outliers, as illustrated by an overall increasing percentage of cita-
tions when the frequency of outliers increases. The percentage of z-citations
appears to be insensitive to laboratories experiencing increasing bias. On the
other hand, laboratories experiencing an increase in their standard deviation
clearly have a higher chance of being flagged for their z-scores.
The percentage of u-flags, however, clearly increases with increasing bias and
variability and accumulates to higher percentages when bias and variability
occur together. The difference between z- and u-flags for one parameter on
the one hand and all the parameters on the other hand clearly demonstrates
that the effect of outliers, bias or increased variability for one parameter
becomes attenuated when more parameters are evaluated together.
3.5.3 Comments
The summary of percentage of z- and u-flags is an easy to understand and
flexible approach to score laboratories. It can be merged over different sam-
ples, surveys, laboratories or methods and as such, it gives a good idea of the
state of the art of the performance of a certain laboratory or method, the
latter mainly with respect to the frequency of u-flags. They may indicated
whether large deviations are due to a weak method, or a weak application of
a good method. The statistics are however influenced by presence of outliers
and cannot discriminate between bias or variability. The statistic can be
used as a tool by EQA organizers to monitor the laboratories and to detect
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Table 3.6 Percentage of z- and u-flags for the example data set, containing results of 224
simulated laboratories, having reported values for 10 parameters during 40 surveys, with
induced bias, increased variability and outliers.
One parameter All parameters
Bias SD Outliers (%) Z-flags (%) U-flags (%) Z-flags (%) U-flags (%)
0 1 0 0 1.08 0.25 0.200
0 1 5 7.50 7.50 0.75 0.813
0 1 10 10.6 11.0 1.1 1.06
0 2 0 0 5.00 0.43 0.563
0 2 5 6.25 12.5 1.00 1.38
0 2 10 6.88 17.5 0.75 1.75
0 5 0 0.625 36.3 0.18 3.63
0 5 5 5.63 41.3 0.75 4.13
0 5 10 13.1 43.8 1.8 4.44
1 1 0 0 1.25 0.19 0.188
1 1 5 6.87 8.13 0.81 0.813
1 1 10 7.50 9.38 0.94 1.00
1 2 0 0 6.25 0.44 0.625
1 2 5 3.75 13.8 0.63 1.38
1 2 10 11.9 16.9 1.50 1.88
1 5 0 3.13 39.4 0.44 3.94
1 5 5 6.88 41.3 0.88 4.19
1 5 10 11.3 45 1.3 4.56
10 1 0 1.25 99.4 0.44 10.1
10 1 5 8.13 99.4 1.2 10.1
10 1 10 13.1 100 1.6 10.2
10 2 0 2.50 95.0 0.63 9.69
10 2 5 11.2 96.9 1.4 9.69
10 2 10 11.2 98.8 1.3 9.93
10 5 0 26.4 81.3 2.8 8.18
10 5 5 18.4 86.3 1.9 8.769
10 5 10 24.4 85.0 2.6 8.56
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laboratories suffering lack of performance and also here, evaluation per pa-
rameter is advised, since bad performance of one parameter may be masked
when statistics are calculated over a whole range of parameters.
3.6 Long-term Analytical Coefficient of Vari-
ation
3.6.1 Introduction
A first evaluation technique based on a regression model was introduced by
Meijer [93] in 2002 to evaluate the long-term performance of laboratories par-
ticipating in the European Concerted Action on Thrombosis (ECAT) EQA
programme. The model was initially applied to the test results for plasma
antithrombin activity and later applied to the determination of activitity and
antigen of protein C and S and the von Willebrand factor. [94, 95, 96]. The
evaluation is done by fitting a linear regression model using consensus values
obtained for a certain parameter for different samples as the independent
variable (x) and reported values of the same laboratory as the dependent
variable (y). See Appendix A1 for a detailed description of linear regression
models. The slope (b) and the residual standard deviation (s) of each regres-
sion line were calculated, together with the mean values for x (x) and y (y)
as well as the standard deviation of x (sx). The number of laboratory results
included for a certain laboratory is expressed by ni.
First, the long-term total error (TE) for a laboratory i (i=1,...,N) is cal-
culated taking into account all its reported values as follows:
TEi =
√∑ni
j=1(yij − xj)2
ni
where yij is a reported value by laboratory i for consensus value xj(j=1,..,ni).
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The total bias (B) and the random analytical error can be derived as fol-
lows:
∑ni
j=1 (yij − xj)2
ni
= 1ni
(bi − 1)2 ni∑
j=1
(xj − x)2 + ni(yi − x)2 +
ni∑
j=1
(yij − yˆij)2

= (bi − 1)2.ni − 1ni s
2
x + (yi − x)2 +
ni − 2
ni
s2i
where x¯ and sx are respectively the mean and the standard deviation of the
consensus values for the different samples, si the variability of the regression
line, ŷij is the value of the dependent variable of laboratory i for consensus
value xj as predicted by the regression model and bi is the slope for the
regression line. The formula contains three terms, of which only the last
one is dependent on the variability of the points around the regression line.
The two first terms make up the bias, while the latter term is an indicator
of the within-laboratory variability. The factors (ni − 1)ni and
(ni − 2)
ni
in
the formulas are attributable to the difference in corrections for degrees of
freedom in the definition of TE, s and sx. They approach 1 when n becomes
larger and then the total error may be approximated by the following formula:
TEi =
√
s2i + (bi − 1)2s2x + (yi − x)2
The part of the total error attributable to the bias is:
Bi =
√
ni − 1
ni
(b− 1)2s2x + (yi − x)2
The bias consists of a constant and a proportional, or concentration-dependent
part. Constant (CB) and Proportional Bias (PrB) can then be written as:
CBi =
√
(yi − x)2
PrBi =
√
ni − 1
ni
(bi − 1)2s2x
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The Long-Term Analytical CV (LCVa) is based on si and the mean value of all
consensus values (x). To allow comparison of the LCVa among laboratories,
it should be calculated after adjustment for the bias. Therefore, the LCVa
for a particular laboratory is now calculated using the formula:
LCVa =
si
bi
x .100%
At last, the Analytical Critical Difference (ACD) reflects the minimum an-
alytical capability of a laboratory to significantly distinguish between two
different test results with a significance level of 95%. It is calculated as
follows:
ACDi =
si
b
√
2Qt(0.975; n− 2)
where Qt(0.975; n− 2) is the 97.5th percentile of the Student’s t-distribution
on n−2 degrees of freedom.
3.6.2 Example
Results of LCVa, total, proportional and constant bias, total error and ACD
are shown in Table 3.7. They were calculated and averaged over the four dis-
tinct consecutive survey periods as the other long term evaluation techniques
(surveys 1-10, 11-20, 21-30, 31-40). The most striking results are the nega-
tive values for LCVa and ACD, caused by a negative slope of the regression
line. A reason for a negative slope is visualized in Figure 3.1. The data set
consists of 10 points, of which 9 follow a line close to the 45°-line. One point
of the 10 is an extreme outlier, it is 10 times its true value. It influences
the regression variability and the slope from the regression line considerably,
making the residual standard error to increase and the regression coefficient
to be negative.
Due to the heavy influence of outliers on the regression model, it is preferred
to interpret LCVa and ACD only for the cases where no outliers were added.
As LCVa is more a measure of variability, it is clearly influenced by the
82
3.6 Long-term Analytical Coefficient of Variation
22 24 26 28 30
25
35
45
Target value
R
ep
or
te
d 
va
lu
e
A
22 24 26 28 30
22
24
26
28
30
Target value
R
ep
or
te
d 
va
lu
e
B
Figure 3.1 Regression line between target values and responded
values, in the presence and absence of an outlier. Laboratory (A)
has an outlier and an LCVa of 88.3%, laboratory (B) has reported
the same values except the outlier, and has an LCVa of 3.1%.
analytical variability of the laboratory rather than the bias. We see how-
ever, certainly for laboratories having high analytical variability, the LCVa
increasing with increasing bias. In terms of bias, a clear increase of bias is
visible for increasing shifts. Remark that the constant bias follows the shifts
well and that the proportional bias also increases with increasing analytical
variability. The total error follows clearly the changes in bias and standard
deviation and approaches to the square root of the sums of the squared shift
and standard deviation. The ACD is heavily influenced by an increasing
variability, but almost not at all by an increasing bias.
3.6.3 Comments
In comparison with the three previous approaches, this approach is able to
estimate individual, within-laboratory bias and variability and doesn’t take
into account the values of other laboratories. The approach could even be
used in small-scale surveys, because the performance indicators are calcu-
lated with respect to the reference values and not the values reported by
other laboratories. To monitor the performance of a laboratory, one may
interpret the values of total error (TE), bias, LCVa and ACD with results
previously obtained by the laboratory, results obtained by other laboratories
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Table 3.7 Total Error (TE), Constant (CB) and Proportional Bias (PrB), LCVa and ACD
for the example data set, containing results of 224 simulated laboratories, having reported
values for 10 parameters during 40 surveys, with induced bias, increased variability and
outliers.
Bias SD Outliers (%) LCVa CB PrB TB TE ACD
0 1 0 3.70 0.503 0.25 0.601 1.09 3.35
0 1 5 -2.33 2.24 1.56 2.96 6.1 0.250
0 1 10 1.28 2.96 2.46 4.05 8.53 19.3
0 2 0 7.04 0.592 0.41 0.792 1.84 7.18
0 2 5 -11.5 1.94 2.28 3.10 5.85 -28.5
0 2 10 13.3 1.94 1.6 2.68 6.92 54.6
0 5 0 13.5 0.998 1.16 1.69 4.43 19.0
0 5 5 38.7 2.69 1.78 3.58 7.47 78.3
0 5 10 99.3 3.48 2.15 4.43 10.6 322
1 1 0 3.84 0.53 0.29 0.644 1.09 3.31
1 1 5 -30.7 2.54 1.77 3.21 6.58 -172
1 1 10 10.9 2.74 1.56 3.29 7.05 46.5
1 2 0 7.66 0.663 0.48 0.887 2.07 7.92
1 2 5 48.9 1.99 1.37 2.49 4.58 96.7
1 2 10 34.3 4.13 1.92 4.68 9.14 152
1 5 0 15.7 1.65 1.37 2.39 5.15 16.1
1 5 5 35.5 3.14 1.59 3.80 8.09 105
1 5 10 -42.0 3.18 3.42 4.99 10.1 -70
10 1 0 3.66 9.71 0.29 9.72 9.76 3.42
10 1 5 16.4 11.2 0.98 11.3 12.1 31.9
10 1 10 20.1 12.2 1.78 12.4 13.6 59.1
10 2 0 8.14 9.50 0.55 9.52 9.69 8.1
10 2 5 57.3 11.1 1.5 11.2 12.1 131
10 2 10 14.8 11.2 1.04 11.3 12.1 35.9
10 5 0 -20.3 9.99 1.24 10.1 11.1 -48.1
10 5 5 10.9 10.2 1.86 10.5 11.9 22.8
10 5 10 1.18 11.1 1.31 11.3 12.8 35.6
or by performance goals.
Foremost among the properties of the LCVa and ACD is the high depen-
dence of absence of outliers before a worthwile interpretation can be made.
Outliers influence the estimates of the residual error and the regression line
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coefficients of a simple linear regression line heavily. Besides, a slight bias
may influence the LCVa and ACD in a non-intuitive way. The regression line
of the results from a laboratory having a slight positive bias for the higher
values and a slight negative bias for the lower values for example, will have
a higher slope and hence a lower LCVa than a laboratory having no bias but
a comparable residual error.
Bias has been introduced in the data set as a constant bias and this is nicely
reflected by the constant bias measurement of the method. However, estima-
tions of proportional or constant bias are disturbed by high a high residual
error, as is seen by an increasing total, proportional and constant bias with
increasing variability. LCVa on its turn is, disregarding outliers, a good indi-
cator of increased variability. Bias doesn’t influence LCVa much. Although
the technique easily allows combining information from different samples and
surveys together, it lacks flexibility on the level of combining information ob-
tained for different parameters together and hence, cannot be applied for
a global evaluation of a series of parameters. It does however enable EQA
organizers to monitor laboratory performance over a long period.
3.7 A novel three-step method
3.7.1 Introduction
The methods discussed so far show one or more of the shortcomings listed
below.
Robustness against outliers
Most of the performance indicators suffer from lack of robustness against
outliers. The LCVa is the most prominent example of how a single deviating
point may make a performance indicator unreliable. In addition, the perfor-
mance score indexes and the z-and u-scores counts score laboratories worse
when outliers occur.
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Distinguishing between outliers, bias and variability
Because of the pedagogic aspect of several EQA prgrammes, they should
strive to help weakly performing laboratories to understand the nature of
their mistakes. In this sense, a classification between different types of mis-
takes is preferred. Westgard [185] has pointed to the different character of
mistakes in the pre- and post-analytical phase on the one hand and the ana-
lytical phase on the other hand. The first can more easily be represented by
outliers occurring at a low frequency, while mistakes in the analytical phase
can more easily be represented by increased bias and/or variability. Evalua-
tion methods should strive towards a distinction between these three types
of estimates.
Estimating within-laboratory variability
In EQA programmes, a measure of variability is often taken over a series of
reported results for a certain sample, yielding a measure of total variability
measure. The use and interpretation of this variability has two main draw-
backs. First of all, the terminology may be misleading, since this measure of
total variability is often called inter-laboratory variability. Following the rule
of combined standard deviation as explained in the Guide to the expression
of uncertainty in measurement (GUM) [194], the total variability found in
data reported in EQA studies can be seen as a variability which is composed
of an intra-laboratory and an inter-laboratory part. Confusion of the latter
with the total variability should be avoided.
Secondly, the total measure of variability doesn’t inform the individual lab-
oratory about its proper analytical variability. A measure of variability re-
flecting the individual analytical variability, the intra-laboratory component,
is needed. The latter may be calculated in two different ways. First, an EQA
organizer may send two or more vials with the same content but a different
label to the participants. After removal of outliers, a linear mixed model may
be applied to the data, with the laboratories modeled as a random factor.
Estimators of intra- and inter-laboratory variance can be obtained and their
sum gives an estimate of total variance, which is a better estimator of the
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total variability than a variance of the reported values. Secondly, the EQA
organizer may send different samples to the participants and determine a
target value for each sample. A regression line can be calculated for each in-
dividual laboratory between the target values and the reported values. The
residual error of the regression line is a measure of the analytical variability
of the laboratory.
3.7.2 Pitfalls of using a linear regression line
In a first instance, a linear regression model made up between the target
values of a series of samples and the data reported by a particular laboratory
can be considered as a valuable model to estimate analytical variability and
bias of a certain laboratory. Fig 3.2 demonstrates the model. The spread
of the points around the regression line is measured by the residual error
and reflects the analytical variability of the laboratory. The position of the
regression line, indicated by its intercept and slope, with respect to the stan-
dard 45°-line, reflects the bias of the regression line. Bias is then expressed
as the deviation between the intercept and slope of the individual regression
line and the intercept and slope of the reference regression line, such as the
mean regression line of a group of laboratories, or the 45°-line.
Remark that the linear regression model doesn’t take into account the mea-
surement uncertainty around the target values. As a consequence, target
values should be determined with the highest accuracy. They can be set by
a reference laboratory or be calculated using the reported values. We refer
to Duewer [32] for an exhaustive overview of statistical estimators of target
values in an EQA setting. To our experience, the median is a good estimator
of central location and will be used in the examples given in this work. In ad-
dition, the regression model is only valid when matrix effects can be excluded
and hence a linear relation between the target value and the responded values
can be attained. For a detailed discussion about matrix effects, see Chapter 2.
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Figure 3.2 Example of a linear regression model. The independent
variable is made up by the “Target values” of different samples, the
dependent variable is set up by the “Reported values” of a partic-
ular laboratory. The solid line is the least-squares linear regression
line through the points, the dashed line is the 45°-line.
The regression model is, as already illustrated by the LCVa, strongly influ-
enced by outlying points. Figure 3.3 shows the relation between target and
reported values for two different laboratories for the same group of surveys,
as found in the example data set. The regression lines represented by the
full lines in both graphs are drawn through all the points in the graph. They
have the same residual error and regression coefficients. There is however a
difference: while the majority of the points in graph A lie closely around a
regression line (the dashed line) and only one point deviates strongly (the
point indicated by the arrow), the majority of the points in graph B deviate
strongly from the regression line. Recalculating the regression line in graph
A without the exceeding point makes the residual error to drop from 42 to 2.
The point indicated by the arrow in graph A is called an outlier, since it is a
non-representative point, influencing the regression’s coefficients and residual
error. Because outliers around a regression line may exist, they should first
be excluded before interpreting the regression line.
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Figure 3.3 Effect of an outlying point on a least-squares linear regression
line. The full lines are drawn through all the points, the dashed line in
graph A is drawn without the exceeding point. The regression residual
variability and position of the regression line for laboratory A and B are
equal.
Two different types of solutions exist to deal with outlying observations when
calculating a regression line. The first option calculates robust estimates of
the regression line and its residual error, the second option searches for out-
liers and removes them before calculating a simple linear regression line.
Atkinson [7] has shown that the second option is preferred, since robust es-
timates show a low estimation efficiency. Therefore, before any variability of
bias is calculated by means of a least squares regression line, outliers against
the individual regression lines have to be removed.
Once a regression line has been obtained after regression outliers have been
excluded, one may interpret its residual error as a measure of analytical,
within-laboratory variability and the intercept and slope as a measure of
bias. Remark that there is a high uncertainty about the regression lines with
89
3. Combined evaluation of different EQA surveys or samples
high analytical variability, as depicted in Figure 3.4. Both regression lines
have the same position, as indicated by their intercept and slope, but the
certainty about the position of the latter is very low, i.e. there is a high
probability that its position may be strongly different if results from other
samples would have been used to draw it. For this reason, variability should
be interpreted before interpreting any bias and an algorithm consisting of
three steps can be built: first, outliers are found with respect to the individ-
ual regression line of each laboratory, followed by a step to find regression
lines with excessive variability and finally regression lines with high bias are
identified.
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Figure 3.4 Regression lines with equal regression coefficients but different
residual error. The position of the regression line in the left graph is more
certain than in the right graph.
3.7.3 Description of the algorithm
The 3-step procedure [28] is based on a linear regression model. Let N denote
the number of laboratories participating in the EQA programme and ni the
number of EQA samples assayed by laboratory i (i=1,...,N). For each labo-
ratory, the relationship between the reported values and the target values of
a given parameter can be described by the linear model
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yij = ai + bixj + eij
where yij is the value reported by laboratory i (i = 1, ..., N) for sample
j (j =1, ..., ni), ai and bi the intercept and slope of the regression line for
laboratory i, xj the target value for sample j and eij the residual or error term.
It is assumed to be normally and independently distributed with a mean of 0
and variance s2i . The latter is a measure of the analytical variability for lab-
oratory i, while the parameters ai and bi indicate the laboratory’s bias from
the 45°-line, or from the mean regression line estimated from all laboratories.
Step 1. Finding outliers against the individual regression lines
The first step considers the regression line of each laboratory individually
and searches for points that are exceedingly far from the regression line and
can be considered as outliers. They are seen as measurements that are not
representative for the analytical process of the laboratory. To exclude po-
tential outliers, we propose to use a least trimmed squares (LTS) regression
[141, 143] to obtain a rough estimate of the regression line, which holds for
the majority of the data points. This is followed by use of the outlier search
algorithm described by Atkinson [7]. LTS-regression minimizes the sum of
the squared residuals of a predefined fraction of the data, usually a pro-
portion slightly above 50%. The latter can be parametrized in software for
calculating LTS regression. However, default values do not always yield an
optimal curve and it is advisably to increase the fraction for which the sum
of the squared residuals is minimized, trying to configure the proportion high
enough for an optimal curve, but not too high in order to exclude outliers
with high probability. One may proceed as follows:
(1) Define Q as the largest integer smaller than 60% of the number of
couples (xi,yi) used to calculate the regression line.
(2) calculate an LTS-regression that minimizes the sum of the squared
residuals of Q data points. Define s2Q as the sum its squared residuals.
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(3) Calculate an LTS-regression that minimizes the sum of the squared
residuals of Q+1 data points. Define s2Q+1 as the sum its squared resid-
uals. Repeat the same for an LTS-regression that minimizes the sum
of the squared residuals of Q+2 and Q+3 data points. Define s2Q+2 and
s2Q+3 as their respective sum of squared residuals.
(4) If
s2Q+1
s2Q
>10,
s2Q+1
s2Q+2
>10 or
s2Q+1
s2Q+3
>10, choose the regression line that cor-
responds with the lowest value of s2Q, s2Q+2 and s2Q+3.
Next, the mi (mi ≤ ni) points
Next, the mi (mi ≤ ni) points satisfying the following inequalit∣∣∣∣∣eijs∗i
∣∣∣∣∣ ≤ Qt(1− α1; ni − 2)
were subject to an ordinary least-squares (OLS) linear regression. In the
above inequality, Qt(1− α1; ni − 2) is the upper α1-quantile of the Student
t-distribution with (ni–2) degrees of freedom,
s∗i = 1.4826
(
1 + 5ni − 2
)√
median e2ij
and α1 is a predefined significance level. Let rij be the residuals of the OLS
regression and si its residual error. Then, outliers were defined as values for
which
rij
si
√
1− hij
> t∗ for the points included in the OLS regression
rij
si
√
1 + hij
> t∗ for the points not included in the OLS regression
The critical value t∗ is the upper-α2 percentile from the Student t-distribution
with (mi−2) degrees of freedom and hij is the corresponding diagonal element
of the hat matrix from the LTS-regression. The hij-values are the so-called
leverages, which measure the influence of the individual point on the position
of the regression line.
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It should be noted here that this test does not include any inter-laboratory
comparison. Outliers are identified per laboratory by comparing its reported
results with each other and with the target values.
Step 2: Finding laboratories with high analytical variability
The differences between the different residual variances should be taken into
account when assessing bias with the peer group’s mean regression line.
When outliers are excluded in the first step, a regression line is calculated
for each laboratory separately and an estimate of the residual variance s2i is
obtained for each laboratory. The second step of the procedure is to identify
laboratories with excessive s2i values. The method used has been described
earlier [3, 49]. It is based on the assumptions that both the theoretical
residual variance s2i and the estimated residual variance s2i are log-normally
distributed. The following formula can be derived:
log σ2α3 = log M− 0.5log
[
1 + V−2kM2/(2k+1)M
]
+Qz(1− α3)
√
V− 2kM2/(2k + 1)
where k=∑Ni=1(mi − 1)−1/N, M=Mean s2i , V=Var s2i and Qz(1− α3) is the
upper α3-percentile of the standard Normal distribution. Mean s2i and Var s2i
are the mean and variance of the residual variances from the regression lines
obtained in the first step. The value σ2α3will be used as the critical thresh-
old above which a residual variance s2i will be considered to be exceedingly
large. Since some of the N estimates s2i may themselves be outliers, a trim-
ming procedure is performed before calculation by disregarding an arbitrary
proportion of the lowest and highest variance values.
Step 3: Finding laboratories with exceeding bias
As before, let ai and bi be the estimated intercept and slope of the corre-
sponding regression lines once outliers are excluded in the two previous steps.
The literature on regression explains how the joint distribution of intercept
and slope can be considered as bivariate Normal [152], with mean (a, b),
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Figure 3.5 Example of a scatter plot of slope versus intercept, with a
99.9 % robust confidence ellipse.
standard deviations (SD) (sa, sb) and correlation r. When plotted on a two-
dimensional graph, the points will be positioned in a cloud around which an
ellipse-shaped confidence region can be drawn, as in Figure 3.2.
The center of the ellipse is the intercept and slope of the mean regression
line and the shape is characterized by their SDs (sa, sb) and correlation r. A
point outside the ellipse corresponds to a laboratory with significant outlying
bias. The minimum covariance determinant (MCD) estimator [142, 189] is
proposed as a robust measure of means, SDs and correlation of the bivariate
distribution. Mahalanobis distances based on the MCD estimator are used
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as a measure of individual outliers and are calculated for all regression lines,
also the lines excluded because of exceeding variability. Regression lines for
which the Mahalanobis distance is larger than the upper α4-percentile of a
χ2-distribution with two degrees of freedom correspond to laboratories ex-
hibiting unacceptable bias.
3.7.4 Example
An analysis was performed on the example data set by grouping the surveys
in four groups of 10 surveys (surveys 1-10, 11-20, 21-30 and 31-40). For each
group of surveys, outliers were identified against the individual regression
line for each laboratory as described in the first step of the algorithm. Fol-
lowing, the residual error was calculated by taking the square root of the
mean residual variances of each regression line. The residual variances were
subject to the second step of the algorithm. Finally, regression lines not
exhibiting exceeding residual variance were subject to the third step. The
average intercept and slope of the regression lines used in the third step was
calculated. All regression lines were evaluated for bias and the percentage of
bias outliers was counted. The first step was performed with α1=0.001 and
α2 = 0.01,the second step was performed with α3 = 0.01 and a trimming of
5% and the last step was performed with α4=0.001.
Next, the analyzes was repeated without leaving out any regression outlier in
the calculations of the second step and without any regression line with ex-
ceeding variability in the third step. The outliers against the regression line
are found with very high probability, while the method protects well against
erroneously indicating non-outliers as outliers: the negative predictive value
is at least 97.3%, while the positive predictive value is at least 90.9 %. The
residual error reflects very well the standard deviation of the original data:
rounded to an integer, they are all equal to the original standard deviation
of the data and no interference of outliers is detected.
The algorithm indicating exceeding variabilities as outliers however, lacks
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Figure 3.6 Scatter plot of slope versus intercept with a robust confidence
ellipse for a selection of laboratories and surveys, for the hypothetical
example, with induced bias and increased variability. Results based on
152 simulated laboratories.
some sensitivity: laboratories with a standard deviation of 2 are almost not
detected as having exceeding variability; laboratories with a standard devi-
ation of 5 on the contrary are well indicated as having exceeding variability.
The estimation of the regression coefficients follows the bias of the data very
well: the slope should be one and the average intercept should approach the
induced bias. Only for the cases with high induced variability, the estima-
tion is weaker. All laboratories having a bias of 10 were flagged for exceeding
bias, but they were not the only ones: as soon as the variability of the data
increases, the chance of being flagged for outlying bias increases as well. A
scatter plot of intercept and slope values of the laboratories for which no re-
gression outliers were induced is given in Figure 3.6. As can be seen here, all
regression lines with high induced bias are outside of the confidence ellipse,
as is the case for only a part of the regression lines with low induced bias.
It is interesting to know what the performance indicators would be if no val-
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Table 3.8 Performance statistics of the example data set for outlier rates in the first step,
residual error in the second step and bias in the third step. NPV stands for Negative Predictive
Value, i.e. the percentage of correctly identified non-outlying points and PPV for Positive
Predictive Value, i.e. correctly identified outlying points. Results based on 224 simulated
laboratories, having reported values for 10 parameters during 40 surveys, with induced bias,
increased variability and outliers.
Regression Mean Variability Average Average Bias
Bias SD Outliers Outliers residual outliers intercept slope outliers
(%) NPV (%) PPV (%) error (%) (%)
0 1 0 99.6 (.) 0.99 0 -0.50 1.0 0
0 1 5 97.3 100 0.82 0 0.49 0.96 0
0 1 10 99.3 100 0.91 0 -0.22 0.99 0
0 2 0 100 (.) 1.9 0 2.7 0.91 0
0 2 5 99.3 100 1.9 12.5 0.17 0.98 0
0 2 10 98.1 100 1.8 0 -0.1 1.0 6.30
0 5 0 99.4 (.) 4.6 93.8 6.8 0.73 43.8
0 5 5 100 100 5.2 93.8 4.3 0.89 68.8
0 5 10 100 100 4.8 93.8 2.6 0.90 43.8
1 1 0 99.4 (.) 0.98 0 0.78 1.0 0
1 1 5 99.3 100 1.1 0 2.5 0.92 0
1 1 10 99.3 100 0.95 0 -1.0 1.0 0
1 2 0 98.1 (.) 1.9 0 -0.79 1.0 6.30
1 2 5 100 100 2.2 12.5 2.0 0.97 18.5
1 2 10 100 100 2.0 6.25 0.14 1.0 12.5
1 5 0 98.1 (.) 4.9 81.25 -2.4 1.0 62.5
1 5 5 100 100 4.7 93.8 2.7 0.92 56.3
1 5 10 100 100 5.2 87.5 -7.4 1.2 62.5
10 1 0 99.4 (.) 0.97 0 10 0.98 100
10 1 5 99.3 100 0.98 0 11 0.97 100
10 1 10 100 100 1.0 0 12 0.96 100
10 2 0 99.4 (.) 2.0 6.25 13 0.92 100
10 2 5 99.3 100 2.0 6.25 8.8 1.0 100
10 2 10 100 100 1.8 0 11 0.97 100
10 5 0 99.4 (.) 4.9 93.8 6.1 1.1 100
10 5 5 100 100 4.7 93.8 11 1.0 100
10 5 10 100 90.9 4.9 87.5 15. 0.80 100
ues would have been left out in the first or second step. The results are listed
in Table 3.9. Not excluding outliers against the regression line has an adverse
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effect on the estimators of the regression line and flagging rates for outliers
or bias. Even with a modest outlier frequency rate of 5 %, almost half of the
laboratories are flagged for exceeding variability and more than one third for
exceeding bias. In addition, the residual error is overestimated as soon as
outliers appear. The estimated mean residual error in presence of outliers
is higher than the estimated mean residual error of the data simulated with
the highest standard deviation and without outliers. Even more, because of
the presence of regression lines of the data simulated with the highest stan-
dard deviation and without outliers is flagged for exceeding variability. In
addition, outliers cause an increase of proportion of falsely flagged regression
lines for bias.
3.7.5 Comments
The technique displayed here uses limits based on statistical analysis of the
performance attained and is different from evaluation procedures that use
limits based on experience or biological variability, although the possibility
exists to introduce the latter in the second and third step of the procedure.
By combining data from different samples, the method helps laboratories to
understand their results in a better way and unveils more information than
a parameter performance characteristic based on such as total error, such as
the performance index scoring system or the mean rankings. The method’s
capability for searching outliers of different types is, as far as we know, a
new and definitely useful method for addressing the different types of er-
rors seen in EQA programmes. The first step excellently identifies outliers
against the laboratory’s individual regression line with high sensitivity and
specificity, yielding two major benefits. First of all, outliers cannot be used
as reliable indicators for long-term performance of the analytical phase of the
Total Testing Process, but may be informative for the laboratories and sup-
port their strategies to improve the pre- or post analytical phases. Secondly,
excluding outliers before estimating the regression line gives a pure estimate
of the precision and trueness of each individual laboratory’s analytical pro-
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Table 3.9 Mean variability, intercept, slop of regression lines and mean flagging
rate for variability and bias outliers if all data would have been taken into
account for the hypothetical example, with induced bias, increased variability
and outliers. Results based on 224 simulated laboratories.
Mean resi- Variability Average Average Bias
Bias SD Outliers dual standard outliers intercept slope outliers
(%) error (%) (%)
0 1 0 1.00 0 -0.5 1.00 0
0 1 5 7.91 43.8 8.0 0.88 37.5
0 1 10 9.25 62.5 -15.0 1.50 50.0
0 2 0 1.86 0 2.7 0.90 6.30
0 2 5 6.72 37.5 -0.5 0.95 43.8
0 2 10 8.03 50 3.9 0.99 56.3
0 5 0 4.74 0 6.3 0.74 43.8
0 5 5 7.93 31.3 4.7 0.90 62.5
0 5 10 11.0 81.3 3.6 0.95 93.8
1 1 0 0.99 0 0.6 1.00 0
1 1 5 7.65 56.3 -2.9 1.20 50.0
1 1 10 8.39 68.8 10.0 0.72 68.8
1 2 0 2.12 0 -2.3 1.10 6.3
1 2 5 5.49 25 0.2 1.10 37.5
1 2 10 9.88 68.8 9.0 0.96 68.8
1 5 0 5.16 0 -0.3 0.93 56.3
1 5 5 8.43 43.8 1.0 0.72 68.8
1 5 10 10.04 81.3 -10.0 1.40 81.3
10 1 0 0.99 0 10.0 0.99 100
10 1 5 5.38 12.5 2.8 1.30 100
10 1 10 6.74 31.3 1.4 1.30 100
10 2 0 2.09 0 12.7 0.93 100
10 2 5 5.08 6.3 23.0 0.72 100
10 2 10 5.51 25 12.0 1.02 100
10 5 0 5.01 0 5.5 1.07 100
10 5 5 6.35 31.3 20.0 0.81 100
10 5 10 6.57 18.8 19.0 0.71 100
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cess. Outlying regression lines in the second and third steps encompass a
global evaluation of the analytical phase and values exceeding the limits of
acceptability that are found in these steps indicate poor laboratory analyti-
cal performance. Regression lines flagged for high variability point towards
possibilities for increasing their reprodbility. Regression lines flagged for high
bias point towards measurements that are constantly too high or too low for
a certain range of concentrations. Care should be taken however when a
laboratory finds its regression flagged for exceeding bias and variability. The
high variability may yield an uncertain estimation of the regression line, that
bias has become difficult to interpret. In this case, laboratories would better
put efforts first in increasing their reproducibility.
3.8 Conclusion
A combined analysis of different samples or parameters informs the labora-
tories better about their flaws rather than a report of just one sample and it
allows monitoring laboratory performance over time as well. Various meth-
ods performing this kind of analysis are available. Some of them, such as
the MRVIS, mean ranking scoring, Z/U scores, all have in common to count
the number of times a laboratory reports a result beyond some limits. For
the MRVIS, these limits are calculated using previous results, for perfor-
mance scoring and z-scores, they are defined in comparison with the results
reported by the other laboratories and for the u-scores count, they are de-
fined with respect to analytical performance goals. Other approaches, such
as the LCVa-ACD and the newly introduced 3-step method, build a regres-
sion model and derive estimates of bias and within-laboratory variability. If
assigned values can be obtained with high precision, several of the methods,
such as the MRVIS, Pu, LCVa-ACD and the 3-step method can be applied
for surveys with a small number of participants.
The comparison of the different approaches using the same data set is to
our knowledge new. We have tried to compare them in a data set in which
some specific errors were induced. Using data from real EQA rounds has the
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advantage that their relevance is shown for the data they have been designed,
but the disadvantage is that no deliberate deviations were introduced in the
data. Artificial data sets, on the other hand, give the advantage to induce
specific errors and their relevance depends on how well they approach real
EQA data.
The use of the artificial data set has shown that several methods do not
always clearly measure what they indicate. Various techniques, such as the
MRVIS or mean ranking scores, for example, were not completely able to
distinguish between bias and variability. In addition, a particular flaw of the
LCVa-ACD technique was observed for laboratories with a slightly positive
bias: the LCVa decreases, indicating better performance, while, in fact, the
analytical quality of the result decreases because of a bias. Furthermore,
EQA organizers using methods that combine results from a series of different
parameters should be warned that a good performance for the overall test
may hide bad performance for a particular test. As a consequence, these
types of tests should be utilized together with a detailed analysis for each
parameter separately. Moreover, some of the methods lack any robustness.
A laboratory performing well in comparison with the other laboratories and
with respect to analytical goals may be flagged as soon as it reports one
strongly deviating value, that does reflect any deviation in the analytical
process. In addition, it should be born in mind that the nature of mistakes
in the laboratory are different from phase to phase. As seen in Chapter 1,
mistakes in the pre- and post analytical phase produce usually extremely
deviating results, that are best described with frequency of occurrence than
the size of the deviation. Errors in the analytical phase are better explained
by high bias or variability.
While several methods deal with strongly deviating results by filtering them
out using robust or non-parametric techniques, so far, the 3-step method is
the only method that pays attention to these errors and interprets them as
mistakes due to the pre- or post analytical phase. The method is also superior
to the other methods for distinguishing between bias and variability. How-
101
3. Combined evaluation of different EQA surveys or samples
ever, the method is not always applicable and is built on some assumptions
that should be met before it is interpreted. It relies heavily on the correct
calculation of target values. When the latter are wrongly set, the frequency
of outliers in the first step may increase and the variability estimate may
be underestimated. In addition, it assumes a linear relation between target
and reported values. Whenever a laboratory finds that its outliers against te
regression model are concentrated around a particular concentration range,
mostly near lower or higher concentrations, it should focus rather on the
linearity of its results - so more on the analytical phase - than searching
for reducing errors in the pre- or post-analytical phase. Also, EQA organiz-
ers that find a high occurence of regression outliers for a particular sample
should consider that the sample may suffer from unforeseen matrix effects
and redraw it for analysis.
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Applications of the 3-step method
4.1 Introduction
The 3-step procedure described in Chapter 3 can be used under various con-
ditions. It can be applied to any EQA data set obtained for a series of
samples where a target value for one or more parameters can be set. A
major prerequisite is the absence of matrix effects and the assumption of
a linear relation between target values and reported values. The approach
may reveal information about the frequency of accidental mistakes, within-
laboratory variability and bias.
When data are obtained over a longer period of time, the variability and
bias can be considered as a long-term analytical variability and bias. This
information is useful in addition to the information obtained during the val-
idation protocol of an analytical process, since it is usually recorded over a
much longer time range than is the phase for a validation process. More-
over, the time range can be subdivided into different distinct periods and a
comparison between periods may reveal information about the evolution of
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quality in the clinical laboratory.
When data are obtained from different samples sent in the same survey,
the method reveals information about the within-laboratory standard devi-
ation and bias for the particular day of analysis and the results should be
comparable with those of the method validation. For the EQA organizer,
the method may add useful information when the performance of labora-
tories and/or methodologies is assessed over time and or between methods.
Individual laboratory performance may be monitored and a method assess-
ment can be made over time by comparing the performance over different
sub-periods. In this chapter, several data sets are analyzed with the 3-step
procedure. The method was applied to data obtained in four different surveys
that were organized by the Belgian EQA scheme.
4.2 Applying the 3-step method
The analysis proceeds each time according to the structure described below.
For each laboeratory a regression line is calculated and outliers against it are
identified. Then the regression residual variabilities of all regression lines are
compared with each other and afterwards the bias, reflected by the position
of the regression lines, is evaluated.
4.2.1 Identification of outliers
Data were grouped per laboratory. When different methodologies were used
within the laboratories or when different parameters were analyzed, the
grouping was made per laboratory, applied methodology and parameter.
When different periods were involved in the analysis, one regression line was
constructed spanning over all time periods.
The outliers against each regression line were identified with α1 set at 0.001
and α2 at 0.01 and their frequency was analyzed per laboratory, per method-
ology, per parameter, per period, or any combination of these. Frequencies
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between periods or methodologies were compared with a Chi-square statistic
or, in case few data are available, with the Fisher’s exact test and/or visual-
ized by a histogram. A generalized linear model (GLM) approach to assess
differences in outlier frequencies between methodologies or periods was ap-
plied as well.
Since regression outlier calculation encompasses a comparison within each
individual laboratory’s results, all results were interpreted, also the results
obtained by methods used by one or a few laboratories. The only inclusion
criterion that was applied was a minimal number of data for each regression
line.
4.2.2 Identification of exceeding variability
For each regression line, the method allows to assess whether the regression
line’s variability exceeds a certain limit; the parameter α3 was set at 0.01
and a trimming of 10% was applied. If applicable, the frequency of regres-
sion lines with exceeding variability was compared between methodologies
and/or periods with the Fisher’s exact test. In addition, the residual stan-
dard error of the regression lines, calculated without taking into account the
exceeding residual standard error, was considered as a representative statistic
for the state of the art analytical variability of a certain parameter, method
and/or period.
The results of methods that were applied by at least 4 (or, in one study,
6) laboratories throughout the study period were compared between time
periods and methods with a general linear mixed model (GLMM), in which
the methods and periods were considered as fixed factors and laboratories as
a random factor. When no interaction between periods and methods were
significant, a comparison was made between periods after averaging results
over all methods and between methods after averaging results over all peri-
ods. In case of a significant interaction, periods were compared per method
and methods per period. Comparisons were each time adjusted for simulta-
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neous hypothesis testing according to Tukey or Sidak.
4.2.3 Identification of exceeding bias
Similarly to the evaluation of regression lines with exceeding variability, re-
gression lines with exceeding bias may be identified as well and the frequency
of regression lines with exceeding bias can be compared between methods
and/or periods via the Fisher’s exact test. To identify regression lines with
exceeding bias, the parameter α4 was set at 0.001.
In addition, the difference between a regression line and the 45°-line may
be calculated by taking the maximum distance between the 45°-line and the
regression line within the measurement range of the data under considera-
tion. This distance may be expressed as a maximum bias, (absolute value
of maximal distance between the regression line and the 45°-line), or as rel-
ative bias (maximal distance divided by corresponding target value). Both
absolute and relative biases are continuous and, as well as residual standard
errors, may be compared between periods and/or methods via a GLMM and
subsequent multiple comparisons between groups. The results of some meth-
ods may show a high absolute bias and a low relative bias, or vice versa. The
first case means that the regression lines deviate from the 45°-line for higher
target values, the later means that the regression lines deviate from the 45°-
line for the lower target values. Analogous to the comparison of residual
standard error, regression lines with exceeding variability and bias should be
excluded for calculation.
4.3 Belgian EQA for ethanol determination
4.3.1 Introduction
Assay of ethanol in blood is a widely applied technique for toxicological and
forensic purposes. The first application is often used in the emergency labora-
tory for diagnosing acute intoxication; it is performed under strict conditions
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and serves among others to deliver evidence for legal cases. Thus, labo-
ratories often have two methods at their disposal: one method for routine
intoxication measurement and one routine for medico-legal purposes. The
latter, in particular, needs to be an accurate, precise and selective procedure
for determining blood alcohol. Chromatographic methods are best suited
here and, in Belgium, required for medico-legal reasons. They enable a reli-
able, fast, precise and sensitive analysis. Other methods are often based on
the alcohol-dehydrogenase-facilitated production of NADH+ with ethanol as
substrate and subsequent colorization of a dye via diaphorase. Subsequently,
the colored dye is spectrophotometrically measured. This reaction is not
entirely selective for blood ethanol. There is a high interference with other
alcohols, such as methanol or isopropanol. Also, endogenous dehydrogenases
and substrates other than alcohols, such as lactate, may interfere with NADH
production, leading to falsely elevated ethanol measurements. Often, labo-
ratories use both a chromatographic and ADH-based method.
The Belgian EQA for blood or serum ethanol has been running since 2002.
The sample material is generally prepared from fresh serum samples, spiked
with ethanol and stored deep-frozen till send-out. Participants are requested
to keep the vials cooled till analysis. Data were reported in an electronic
form starting from 2003 and laboratories were able to register measurements
with an enzymatic-based and a chromatographic method together.
A selection was made to obtain samples solely spiked with ethanol with
a minimal concentration of 0.1 g/L for a long-term follow up. Only exact
results were taken into account, i.e. any censored result reported like ’<x’
or ’>x’ was discarded. To evaluate performance over time, the time range
was arbitrarily divided into three distinct periods: 2003-2005, 2006-2008 and
2009-2011.
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4.3.2 Results
The study entails 15791 reported results of 79 samples by 218 laboratories
over a time span of 9 years. The number of data, samples and laboratories
are listed in Table 4.1. A total of 158 laboratories has reported results over
the whole study period, of which 123 (78 %) laboratories have been using
the same methodology for the whole period.
Table 4.1 Number of data for long-term alcohol study of the results of the Belgian
EQA for blood alcohol testing.
Period No. of observations No. of samples No. of laboratories
2003-2005 3241 28 193
2006-2008 3206 26 195
2009-2011 3174 25 184
Outliers against the regression line
Outliers against the laboratories’ individual regression lines were first counted
per period and laboratory and their frequency was displayed by histograms
(Fig 4.1). There was a tendency towards less outliers per laboratory for the
period 2008-2011. A generalized linear mixed model showed that there was
a significant drop in the outlier frequency between this and the two former
periods.
The outlier frequency counted per method and period is shown in Table
4.2. The total number of outliers decreased significantly from the first two
towards the last period. When counted per method, this drop was signifi-
cant for the ADH-methods of Vitros, Roche and Dade (Emit) and for the
headspace chromatographic method.
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Figure 4.1 Histograms of percentage of regression outliers per laboratory,
for the three time periods in the long-term alcohol study of the results of
the Belgian EQA for blood alcohol testing. Period 1: 2003-2005, Period
2: 2006-2008, Period 3: 2009-2011.
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Table 4.2 Outliers against the individual regression line for a certain method applied by the
laboratories individually for the long-term alcohol study of the results of the Belgian EQA for
blood alcohol testing. The percentages of outliers are shown followed by the total number of
results for the corresponding method and period. N stands for the total number of results for a
certain period and method. Period 1: 2003-2005, Period 2: 2006-2008, Period 3: 2009-2011.
Period 1 Period 2 Period 3
Method N Outliers (%) N Outliers (%) N Outliers (%)
ADH- Abbott AxSym 46 0 46 50 4.00
ADH- Abbott TDx/ADx 33 3.03 30 20.0 14 0
ADH- Beckman 38 5.26 52 17.3 52 5.77
ADH - Dade Dimension 56 14.3 52 3.85 46 6.52
ADH- Dade (Emit) 168 9.52 148 8.11 155 0.65 ∗
ADH- Roche 1903 8.57 1860 6.29 1880 3.35 ∗
ADH- Vitros 580 12.8 564 17.7 541 2.96 ∗
Direct Gas Chromatography
(capillary-column) 84 23.8 96 3.12 104 3.85
∗
Direct Gas Chromatography
(packed-column) 149 5.37 155 9.03 150 3.32
Headspace Chromatography
(capillary-column) 184 11.4 203 8.37 182 3.85
∗
Total 3241 9.66 3206 8.73 3174 3.28 ∗
∗A significantly lower frequency was observed in period 3
Variability around the linear regression lines
The frequency of regression lines with exceeding bias, counted per method
and period and the regression residual standard error are shown in Table 4.3.
The total number of regression outliers per period didn’t differ significantly
from each other, neither was there any method for which a significant evolu-
tion in residual variability outlier rate was detected. Averaged over the whole
study period, 6.4 % of the laboratories were flagged for exceeding variability.
For a comparison between methods, the methods used by at least 4 for all the
periods laboratories were considered. For none of the methods, a significant
evolution over time was recorded, nor an interaction between the time and
method factor. There was however a significant difference between the mean
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residual standard error values for the methods: the Direct Gas Chromatog-
raphy had a significantly lower variability than the other methods, except
for the Headspace chromatography. The latter itself had an intermediate
variability, which was not different from the Direct Gas chromatography nor
from the enzymatic methods.
Table 4.3 Frequency of variability outliers (in percentage) and regression residual standard
error for the most popular methods over the whole time period in the long-term alcohol
study of the results of the Belgian EQA for blood alcohol testing. Period 1: 2003-2005,
Period 2: 2006-2008, Period 3: 2008-2011.
Method N Regression lines with Regression residual
exceeding variability (%) standard error
Period Period
1 2 3 1 2 3
ADH- Abbott AxSym 2 100 0 50
ADH- Abbott TDx/ADx 1 100 100 100
ADH- Beckman 2 50 0 0
ADH - Dade Dimension 2 0 0 50
ADH- Dade (Emit) 6 0 0 16.7 0.024 0.028 0.03
ADH- Roche 72 2.78 8.33 1.39 0.025 0.022 0.022
ADH- Vitros 22 4.55 18.2 4.55 0.024 0.028 0.018
Direct Gas Chromatography
(capillary-column) 3 0 0 0
Direct Gas Chromatography
(packed-column) 6 0 0 0 0.014 0.016 0.017
∗
Headspace Chromatography
(capillary-column) 7 0 0 0 0.022 0.023 0.02
Total 123 5.69 8.94 4.88
∗Method with significantly lower regression residual standard error, except when compared to Headspace
Chromatography (capillary-column)
Bias of the regression line
The frequency of regression lines that were flagged for exceeding bias, calcu-
lated using the laboratories that have used the same methodology throughout
the study period, together with the maximal absolute and relative bias, are
given in Table 4.4. The frequency of bias outliers is remarkably lower than
the frequency of variability outliers, the totals for each period are not sig-
nificantly different. Further, there was no significant evolution observable
over time and the low frequency did not allow a reliable comparison between
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methods. Averaged over all periods, 1.1 % of the laboratories are flagged for
exceeding bias.
There was neither a significant interaction nor a significant difference in ab-
solute or relative bias between the time periods. The absolute bias, however,
was higher for the ADH-method with Vitros than for other methods. The
bias of this method is visualized in Figure 4.2. All the regression lines are
close to the 45°-line for small values. For larger values, however, the lines
tend towards values under the 45°-line. This means that, on average, results
obtained with this method are slightly underestimated for larger concen-
trations. The bias is however so small that not any laboratory using this
methodology was flagged for exceeding bias.
Table 4.4 Percentage of laboratories flagged for exceeding bias and absolute and relative bias
for the most popular methods in the long-term alcohol study of the results of the Belgian EQA
for blood alcohol testing. Period 1: 2003-2005, Period 2: 2006-2008, Period 3: 2008-2011.
Method N Bias outliers (%) Absolute bias Relative bias
Period Period Period
1 2 3 1 2 3 1 2 3
ADH- Abbott AxSym 2 0 0 0
ADH- Abbott TDx/ADx 1 0 0 100
ADH- Beckman 2 0 0 0
ADH - Dade Dimension 2 0 0 0
ADH- Dade (Emit) 6 0 16.7 0 0.05 0.14 0.03 9.2 8.1 8.0
ADH- Roche 72 1.39 0 0 0.05 0.10 0.06 13 18 12
ADH- Vitros 22 0 0 0 ∗ 0.17 0.19 0.09 9.8 8.8 12
Direct Gas Chromatography
(capillary-column) 3 33.3 0 0
Direct Gas Chromatography
(packed-column) 6 0 0 0 0.04 0.05 0.02 8.8 4.4 8.6
Headspace Chromatography
(capillary-column) 7 0 0 0 0.07 0.07 0.04 12 11 9.6
Total 123 1.62 0.813 0.813
∗ADH-Vitros had a significantly higher absolute bias than the other methods
4.3.3 Discussion
The average variability and bias of the reported results has remained stable
over time. A slight difference between methods is visible, with mainly the
Vitros method showing a slight negative bias with increasing alcohol con-
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centration. In addition, the frequency of laboratories found to underperform
with respect to bias or variability remained stable over time and the main
problem is caused by exceeding variability.
In contrast to a stable variability and bias, a clear drop in accidental mis-
takes has been recorded since 2009. An explanation may lay in the fact that
from 2010 on, a post-analytical control step was introduced to verify and
eventually correct for largely exceeding values. This result points rather to a
decrease in post-analytical error, partially due to the complexity of reporting
results to the EQA organizer.
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Figure 4.2 Regression lines for the results obtained for
the Vitros method in the long-term alcohol study of the
results of the Belgian EQA for blood alcohol testing, all
periods together. The thick grey line is the 45°-line.
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4.4 EQA survey for lymphocyte subset count-
ing
4.4.1 Introduction
Flow cytometry is a widely used laboratory method for the identification and
quantification of lymphocyte subsets. It is particularly helpful in the diag-
nosis and monitoring of cellular immunodeficiency diseases, leukaemia and
lymphomas. Lymphocyte subset count by flow cytometry has been subject
to external quality control procedures for more than 20 years.
The Belgian EQA scheme for lymphocyte subset counting has been running
since 2000. For each send-out, fresh human peripheral blood was obtained
by voluntary donation after consent from the individual donors. Aliquots of
3 ml were prepared, packaged and sent on the day of collection to the par-
ticipating laboratories by overnight mail. All laboratories were encouraged
to perform sample testing as soon as possible and to process the samples
according to their usual procedures. Three surveys take place every year,
each incorporating three samples. To avoid sample deterioration effect, only
results from assays carried out within two days after collection were taken
into account.
Several lymphocyte subset counts were requested, of which the percentages
and absolute counts of CD3+, CD4+, CD8+, CD19+ and NK lymphocytes
have been asked for almost the whole period. Since the applied methodol-
ogy is rather diverse, the data were analyzed without taking into account
differences between methodology.
4.4.2 Results
A summary of the number of data involved for each period is given in Table
4.5. For a follow-up between the distinct periods, only results of laboratories
that have reported results over the whole period were taken into account.
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Table 4.5 Number of data, samples and laboratories for the long-term lymphocyte subset
counting follow-up. Period 1: mid 2000-beginning 2004, Period 2: mid 2004-end 2007, Period
3: beginning 2008-mid 2011.
Parameter No. labo-
ratories,
Period 1 Period 2 Period 3
all periods N Samples Laboratories N Samples Laboratories N Samples Laboratories
CD3 % 43 1419 32 56 1613 33 58 1458 33 50
CD3 43 1284 32 54 1552 33 58 1381 30 50
CD4 % 43 1424 32 56 1613 33 58 1458 33 50
CD4 43 1309 32 54 1553 33 58 1282 30 50
CD8 % 43 1424 32 56 1613 33 58 1452 33 50
CD8 43 1289 32 54 1553 33 58 1381 30 50
CD19 % 43 1408 32 56 1604 33 57 1429 33 50
CD19 43 1270 32 54 1544 33 57 1355 30 50
NK % 38 512 12 45 1556 33 56 1418 33 49
NK 38 488 12 45 1502 33 56 1348 30 49
Outliers against the regression line
The percentage of outliers per laboratory, registered for all parameters to-
gether, is shown in Figure 4.3. The frequency of outliers was significantly
lower in period 2 with respect to the two other periods, with a median num-
ber of regression outliers was 3 percent in the former and 5 % in the latter.
All except one laboratory had at least one regression outlier for at least one
parameter.
The same data, grouped for all laboratories together and split per parameter
and period, are shown in Table 4.6. The outlier rate merged over all param-
eters dropped from the first to the second and increased again in the third
period. Considered per parameter, the outlier rate was highest in the first
period and dropped significantly for percentages of CD3, CD4 and CD8 and
absolute counts of CD3 and CD8, while the rate from 2008 to 2011 had an
intermediate value. The outlier rate rose significantly between period 2 and
3 for percentages and absolute counts of CD19.
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Figure 4.3 Distribution of outliers against the individual
regression lines for the lymphocyte subset counting follow-
up, considered over all parameters, for the three distinct
periods. Period 1: mid 2000-beginning 2004, Period 2:
mid 2004-end 2007, Period 3: beginning 2008-mid 2011.
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Table 4.6 Regression outliers against the regression model, merged over all laboratories
and displayed per year and parameter for the lymphocyte subset counting EQA follow-
up, for the three distinct periods. Period 1: mid 2000-beginning 2004, Period 2: mid
2004-end 2007, Period 3: beginning 2008-mid 2011
Period 1 Period 2 Period 3
Parameter N Outliers (%) N Outliers(%) N Outliers(%)
CD3 % 1058 6.90 1236 3.56 1159 4.75 (a)
CD3 961 6.04 1157 2.68 1061 3.58 (a)
CD4 % 1060 7.36 1236 3.56 1159 5.61 (a)
CD4 995 5.23 1191 3.02 1091 5.04
CD8 % 1060 7.45 1236 3.32 1155 4.24 (c)
CD8 975 6.15 1191 2.44 1091 4.77 (a)
CD19 % 1056 4.92 1269 3.63 1182 6.94 (b)
CD19 960 5.00 1188 4.04 1091 7.79 (b)
NK % 228 0.877 621 4.03 578 6.23
NK 168 2.98 450 5.11 405 6.17
Total 8521 5.95 10775 3.41 9972 5.44
(a) Periods 1 and 2 differed significantly; (b) periods 2 and 3 differed significantly; (c) period 2 significantly
different from periods 1 and 3
Variability around the linear regression lines
The percentage of regression lines with exceeding bias and their residual
standard error are shown in Table 4.7. Except for NK, absolute counts show
a higher rate of exceeding values for regression variability (P<0.001). There
was no evolution over time visible for any of the parameters.
Considering the number of regression lines with exceeding variability for each
laboratory, more than 80 percent of the laboratories were not flagged for ex-
ceeding variability for any parameter, 34 in period 1, 32 in period 2 and 33 in
period 3. The worst performers showed in period 1 50 %, in period 2 37.5 %
and in period 1 40 % regression lines with exceeding variability. Considering
the number of regression lines with exceeding bias for each laboratory, more
than 60 percent of the laboratories were not flagged for exceeding variability
for any parameter, 24 in period 1, 25 in period 2 and period 3. The worst
performers showed a frequency of regression lines with exceeding variability
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of 87.5 % in period 1 and 50 % in periods 2 and 3.
Per parameter, the mean values for the three periods are very similar and for
none of the parameters, a significant difference between the periods exists.
Table 4.7 Frequency of regression lines with exceeding variability and mean
regression residual standard error for the three distinct periods, calculated
per parameter for the lymphocyte subset counting EQA follow-up, for the
three distinct periods. Period 1: mid 2000-beginning 2004, Period 2: mid
2004-end 2007, Period 3: beginning 2008-mid 2011.
Parameter N Lines with exceeding variability Regression residual standard error
Period Period
1 2 3 1 2 3
CD3 % 38 7.90 2.63 2.63 1.8 1.7 1.7
CD3 37 10.8 10.8 13.5 0.086 0.087 0.084
CD4 % 38 2.63 5.26 10.5 1.7 1.70 1.6
CD4 38 13.2 21.1 18.4 0.061 0.057 0.061
CD8 % 38 10.5 5.26 10.5 1.4 1.3 1.3
CD8 38 15.8 7.90 10.5 0.040 0.037 0.04
CD19 % 39 7.69 7.69 12.8 0.80 0.77 0.81
CD19 38 15.8 7.90 18.4 0.018 0.018 0.02
NK % 19 5.26 10.5 10.5 1.1 0.96 0.83
NK 14 0 7.14 7.14 0.025 0.024 0.024
Bias of the regression line
The number of lines identified with exceeding bias have been counted for
each parameter and are shown per period in Table 4.8. The numbers were
very low and there was no significant evolution over time.
Remark that slightly higher numbers for exceeding bias were found for the
percentages than for the absolute counts. Only 2 laboratories were flagged
for exceeding bias for four or more parameters. Both of them were flagged
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Table 4.8 Count of lines with exceeding bias, per parameter
and period for the lymphocyte subset counting EQA follow-up,
for the three distinct periods. Period 1: mid 2000-beginning
2004, Period 2: mid 2004-end 2007, Period 3: beginning 2008-
mid 2011.
Parameter No of Number of bias outliers
laboratories Period 1 Period 2 Period 3
CD3 % 37 1 1 1
CD3 37 0 0 0
CD4 % 37 1 0 2
CD4 38 0 0 0
CD8 % 35 3 2 3
CD8 37 1 0 0
CD19 % 38 1 2 4
CD19 35 3 1 0
NK % 18 1 1 0
NK 14 0 1 0
Total 326 11 8 10
for exceeding variability as well. The mean absolute and relative bias were
calculated for each parameter per period and are displayed in 4.9.
For the percentage counts, relative bias was lower for CD3 % and CD4 %
and absolute bias was significantly higher for only CD3 %.
For the absolute counts, all absolute bias measures differed significantly from
each other, except for NK, that had an intermediate value CD8 and CD19.
Also the relative bias values differed significantly from each other, except for
CD4, that had an intermediate value between CD3 and CD8.
No evolution in mean absolute or relative bias was observed over time.
4.4.3 Discussion
By far, the largest deviations from the ideal behavior is found by the identifi-
cation of outliers against the individual regression line of each laboratory, for
each parameter. Discarding outliers, variability and bias remained markedly
stable over time. A large majority of laboratories was not flagged for re-
gression variability or bias, while a few poor performers were identified with
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Table 4.9 Relative and absolute bias, calculated per param-
eter for each period separately in the lymphocyte subset
counting EQA follow-up. Period 1: mid 2000-beginning
2004, Period 2: mid 2004-end 2007, Period 3: beginning
2008-mid 2011.
Parameter Absolute bias Relative bias
Period Period
1 2 3 1 2 3
CD3 % 1.5 1.60 1.46 0.021 0.021 0.019
CD4 % 1.1 1.49 1.43 0.026 0.031 0.032
CD8 % 1.6 1.52 1.52 0.064 0.079 0.054
CD19 % 1.0 1.16 1.13 0.087 0.10 0.087
NK % 1.0 1.26 0.96 0.12 0.17 0.17
CD3 0.11 0.076 0.086 0.067 0.056 0.060
CD4 0.068 0.063 0.072 0.07 0.066 0.090
CD8 0.040 0.049 0.055 0.10 0.11 0.087
CD19 0.026 0.031 0.031 0.15 0.15 0.11
NK 0.031 0.033 0.032 0.17 0.193 0.19
up to 50 % of their regression lines with exceeding bias and/or variability.
These findings are in line with those published by Levering, who also found
a modest improvement in laboratory performance.
Further, this study shows that the evolution of performance was not a con-
stantly improving process. For different parameters, a worsening was ob-
served between the second and third period. This shows that EQA organizers
should remain alert for changing performance and never cease to trust that
once a quality level has been reached, performance will never drop again.
Even more, the method, although used here in a static way, with distinct
time periods and a strict selection of data, may be applied dynamically as
well, with moving time windows of variable length. When used by the indi-
vidual laboratories, they may help in quickly identifying deviating behavior
and characterizing the source of errors.
We have tried to identify the cause of the problems of bias of several labo-
ratories by presenting several cases to the EQA’s expert committee for lym-
phocyte subset counting. The bias of one laboratory for CD3+, CD4+ and
CD8+ cells could probably be attributed to the extreme susceptibility of
the Cell-Dyn Sapphire haematology analyser for sample ageing. For another
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laboratory, the negative bias found for the determination of CD19+ lympho-
cytes could be attributed to an inadequate setting of the light-scatter gate
leading to the presence of too much nonlymphocyte contaminants causing an
underestimation of the true percentage of CD19+ cells.
4.5 EQA survey for Lithium
4.5.1 Introduction
Lithium (Li+) is a monovalent cation with antipsychotic activity and is used
in the prophylaxis and the treatment of manic-depressive illnesses. Blood
levels need to be closely monitored, since it has a narrow therapeutic index.
The Belgian EQA for Therapeutic Drug Monitoring assessed the performance
of lithium assays in Belgium and organized in 2010 a survey involving nine
fresh serum samples, with lithium concentrations ranging from 0 to 3.975
mmol/L. Some laboratories used the reference method (Flame photometry -
with internal standard) and the median values of their reported values were
taken as target value.
The data were obtained in one single survey and as a consequence, the
performance assessment of laboratories and methods is a snapshot of the
performance on the day of analysis and not a long-term evaluation. The
residual standard error is more linked to a within-day repeatability in this
case. One sample was discarded for the application of the 3-step procedure
since it didn’t contain any lithium.
The regression outlier detection step was slightly modified for analyzing this
data set. A residual dot plot of several regression lines obtained in this study
indicated that the regression models were heteroscedastic, with a higher vari-
ability for samples with a higher concentration of Li+. For this reason, the
following modifications were applied:
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A variability measure for each sample was calculated by selecting the methods
used by 6 laboratories or more. For each sample, the variance was calculated
for each method after excluding outliers according to the sequential Grubbs
method with an alpha of 0.05, as described in Chapter 1. The variance values
obtained for the different methods were pooled per sample using the following
formula:
s2pooled =
∑k
i=1(ni − 1)s2i
N− k
with k the number of methods, N the total number of data obtained for
all the methods together and ni and s2i the number of data and variance
for a particular method. Next, the robust regression model was applied as
usual and spurious points were identified. The last part of the regression
outlier finding step, where every individual point is evaluated with respect
to a simple linear regression model built without the suspect points, was
built using the inverse variances for each sample as weights. Further, due
to the low number of data available for each regression line and hence a low
certainty about the variability and bias estimates of the regression lies, we
opted in this case to compare regression lines used by at least 6 laboratories.
4.5.2 Results
The 8 samples were analyzed by 114 laboratories. The distribution of the
analytical methods is shown in Table 4.10.
Outliers against the regression line
In total, the vast majority of the laboratories (108; 95%) did not produce any
spurious result at all. Four laboratories had one regression outlier (one used
Flame photometry with internal standard and one used Spectrophotometry-
Abbott Architect/Aeroset) and 2 laboratories had 2 regression outliers (one
used Atomic absorption photometry and one used Roche-Integra)
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Table 4.10 Number of laboratories for each applied methodology
in the 2010 Belgian EQA survey for Lithium.
Method No. of laboratories
Atomic absorption photometry 6
Colorimetric reflectometry - OCD 22
Direct potentiometry - ISE - AVL 1
Direct potentiometry - ISE - Instr. Laboratory 2
Direct potentiometry - ISE - Menarini Spotlyte 2
Direct potentiometry - ISE - Roche - Integra 13
Enzymatic method- Spectrophotometry - Diazyme 1
Flame photometry - with internal standard 8
Flame photometry - without internal standard 2
Inductively Coupled Plasma-Mass Spectrometry 1
Spectrophotometry - Abbott - Architect / Aeroset 4
Spectrophotometry - Roche - cobas c 501 31
Spectrophotometry - Siemens - Advia 3
Spectrophotometry - Siemens Dimension 7
Spectrophotometry - Thermo electron corporation 11
Total 114
Variability around the regression line
The distribution of the regression lines with exceeding bias for the different
methods and the residual standard error for the methods used by at least 4
laboratories is shown in Table 4.11. For 3 methods (Direct potentiometry-
ISE, AVL and Instrument Laboratory and Enzymatic method - Spectropho-
tometry - Diazyme), all participating laboratories were flagged for exceeding
variability.
Other laboratories flagged in this step applied Atomic absorption photom-
etry, colorimetric reflectometry - OCD or Spectrophotometry, Siemens Di-
mension or Thermo electron corporation. The low numbers however didn’t
allow to give any statistical significance to the data. The P-value for the
Fisher’s exact test for difference in outlier rate per method was 0.073.
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Concerning residual standard error, a significant difference between meth-
ods was found. The two methods with the lowest variability were Direct
potentiometry from Roche/Integra and the Flame photometry with inter-
nal standard. Their residual standard error was significantly lower than the
method with highest mean residual standard error, the colorimetric reflec-
tometry from OCD. Other methods didn’t differ significantly.
Table 4.11 Overview of regression lines with exceeding variability, for meth-
ods used by at least 6 laboratories in the 2010 Belgian EQA survey for
Lithium.
Method N Outliers (%) Residual
standard
error
Atomic absorption photometry 6 16.7 0.01
Colorimetric reflectometry - OCD 22 9.09 0.015
Direct potentiometry - ISE - AVL 1 100
Direct potentiometry - ISE - Instr. Laboratory 2 100
Direct potentiometry - ISE - Menarini Spotlyte 2 0
Direct potentiometry - ISE - Roche - Integra 13 0 0.01
Enzymatic method- Spectrophotometry - Diazyme 1 100
Flame photometry - with internal standard 8 0 0.009
Flame photometry - without internal standard 2 0
Inductively Coupled Plasma-Mass Spectrometry 1 0
Spectrophotometry - Abbott - Architect - Aeroset 4 0
Spectrophotometry - Roche - Cobas c 501 31 0 0.012
Spectrophotometry - Siemens- Advia 3 0
Spectrophotometry - Siemens - Dimension 7 14.3 0.013
Spectrophotometry - Thermo electron corporation 11 18.2 0.014
Total 114 8.77
Note: the residual standard error of Colorimetric reflectometry - OCD was signif-
icantly higher in comparison with Direct potentiometry - ISE - Roche and Integra
and Flame photometry - with internal standard
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Bias of the regression line
The distribution of the frequency of regression lines with exceeding bias, to-
gether with the absolute and relative bias for the most popular methods, is
shown in Table 4.11. Five laboratories were flagged for exceeding variability;
they used atomic absorption photometry, direct potentiometry from AVL,
spectrophotometry from Diazyme or Roche/Cobas c501, flame photometry
with internal standard. A Fisher’s exact test between the most popular
methods didn’t reveal any significant difference in outlier rate between the
methods.
The method with the highest absolute bias was the spectrophotometric meth-
od from Thermo electron. It had an absolute bias that was significantly
higher than all the other methods, except the Atomic absorption photome-
try. Relative bias was not significantly different between the methods.
Figure 4.4 explains why the Thermo electron method had a significantly
higher absolute bias, but no significantly higher relative bias. All regression
lines followed the 45°-line very well for lower concentrations, meaning that
their intercept was close to zero. For increasing concentrations, however, the
regression lines deviated from the 45°-line, meaning that they all had slopes
lower than 1.
4.5.3 Discussion
A large series of different methods are used in Belgium for assaying lithium.
The low frequency of outliers against the regression line indicate that labo-
ratories deliver results which are in accordance with their own results. When
the results of different laboratories are compared with each other, we can
see that a relatively large amount of laboratories (8.8 %) have an analytical
variability that can be considered as exceedingly large and a smaller amount
of laboratories (4.4 %) show an exceeding bias. For the methods that were
reported by a sufficiently large number of laboratories, a comparison of re-
gression residual standard error and bias indicated that some methods have
a significantly higher variability than others and one method has a signifi-
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Table 4.12 Frequency of regression lines with exceeding bias in the 2010 Belgian EQA survey
for Lithium, counted per method.
Method N Outliers (%) Absolute bias Relative bias
Atomic absorption photometry 6 16.7 0.2143 0.1156
Colorimetric reflectometry - OCD 22 0 0.2060 0.1404
Direct potentiometry - ISE - AVL 1 100
Direct potentiometry - ISE - Instr. Laboratory 2 0
Direct potentiometry - ISE - Menarini Spotlyte 2 0
Direct potentiometry - ISE - Roche - Integra 13 0 0.1703 0.0839
Enzymatic method- Spectrophotometry - Diazyme 1 100
Flame photometry - with internal standard 8 12.5 0.0754 0.0777
Flame photometry - without internal standard 2 0
Inductively Coupled Plasma-Mass Spectrometry 1 0
Spectrophotometry - Abbott - Architect / Aeroset 4 0
Spectrophotometry - Roche - cobas c 501 31 3.23 0.2065 0.1226
Spectrophotometry - Siemens- Advia 3 0
Spectrophotometry - Siemens - Dimension 7 0 0.1440 0.1723
Spectrophotometry - Thermo electron corporation 11 0 0.5399 * 0.1576
Total 114 4.39
∗Absolute bias of Spectrophotometry - Thermo electron corporation was significantly higher than
the bias of other methods, except for Atomic absorption photometry
cantly higher bias. The reference method has excellent performances in terms
of variability and bias. From the other methods, only Direct potentiometry
- ISE - Roche - Integra showed a comparable performance.
4.6 Belgian EQA for semen analysis
4.6.1 Introduction
Semen analysis is a routine analysis for assessing male fertility. Several fac-
tors of the sperm are assessed, of which the concentration of sperm cells is
one. It is performed by counting the number of cells in a counting chamber
under controlled conditions. It is a manual process and has suffered from
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Figure 4.4 Regression lines of the “Thermo electron”
method, used by 11 laboratories in the 2010 Belgian EQA
survey for Lithium. The thick grey line is the 45° line.
major variability in the past. For this reason, the Belgian EQA for semen
analysis has aimed at contributing standardization and quality assessment.
The programme started in 2004 and data have been registered in a uniform
way since then end of 2005. The 3-step method has been applied to the data
obtained since then. In total, 172 different laboratories have participated in
the study period, of which 105 have participated during the whole period.
Count data have a tendency to be asymmetrically distributed, as illustrated
in Fig 4.5. For this reason, target and reported values have been log-
transformed before analysis. The analysis was subsequently performed in
the same way as the other analyzes in this chapter. The first period ranged
from 2005 to 2007, the second period from 2008 to 2011.
4.6.2 Results
In total, 1633 results obtained for 14 samples were reported from 2005 to
2007 and 1931 results obtained for 16 samples were reported from 2008 to
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Figure 4.5 Typical histogram of reported values for sperm
cell counts (sample SP/1101-1 of survey 2011/1) for labo-
ratories using the same method (Improved Neubauer with
positive displacement).
2011. The applied methods in the first and second part of the study period
are listed in Table 4.13.
The Improved Neubauer method with a positive displacement has become
much more popular over time. It is nowadays used by more than 60% of the
laboratories. Some other methods have undergone a decline in use, such as
the Bürker and Improved Neubauer without positive displacement.
Outliers against the regression line
In the first period, 5.8 % outliers were found, while in the second period,
only 2.7 % outliers were recorded (see Table 4.14). The same also holds for
the laboratories that have not changed method during the study period: 5.7
with respect to 2.5 The distribution of number of regression outliers per lab-
oratory, for all laboratories, is shown in Figure 4.6.
The evolution was assessed for laboratories that used the same method
throughout the study period. The total frequency, merged over all methods,
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Table 4.13 Distribution of number of laboratories for each applied
methodology in the two study periods for the semen analysis EQA
follow-up study, together with the number of laboratories that have
applied the same methodology during the two periods. Period 1:
2005-2007, Period 2: 2008-2011.
Method Period 1 Period 2 Continuously
Disposable chamber 7 14 1
Bürker 22 10 8
Fuchs-Rosenthal (reusable) 8 4 4
Improved Neubauer 26 4 0
Improved Neubauer, Positive disp. 46 84 34
Makler 8 7 4
Microscope slide 3 2 2
Thoma 9 7 3
Total 129 132 56
Table 4.14 Frequency of outliers from the linear regression line for the semen
analysis EQA follow-up study. Period 1: 2005-2007, Period 2: 2008-2011.
Period 1 Period 2
Method Total Outliers (%) Total Outliers (%)
Disposable chamber 14 0 16 0
Bürker 109 6.42 126 3.97
Fuchs-Rosenthal 56 8.93 64 7.81
Improved Neubauer, Positive disp. 500 4.60 574 1.74 *
Makler 56 14.3 64 1.56 *
Microscope slide 14 7.13 16 0
Thoma 42 2.38 48 4.17
Total 791 5.69 908 2.53 *
∗Outlier rates significantly different between period 1 and period 2
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Figure 4.6 Number of outliers against the linear regression
model per laboratory for the two distinct periods for the
semen analysis EQA follow-up study. Period 1: 2005-
2007, Period 2: 2008-2011.
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dropped significantly in the second period. It is most clear for the Improved
Neubauer with positive displacement and Makler chambers, for which the
drop in outlier frequencies was significant.
Variability around the regression line
The results are shown in Table 4.15. A Fisher’s exact test for assessing dif-
ference in variability outliers between the first and the second period led to
a P-value of 0.16, meaning that the observed drop in variability outliers was
not significant.
Remark that also a few laboratories that used the reference method, Im-
proved Neubauer with positive displacement, were flagged for exceeding vari-
ability.
There was no significant interaction between the period and applied method-
ology for the regression residual standard error. Neither was there a signifi-
cant difference between the periods.
For the method on the contrary, a significant difference was found: the resid-
ual standard error for the Fuchs-Rosenthal method was significantly higher
than for the Bürker and Improved Neubauer with positive displacement.
Bias of the regression line
The number of laboratories flagged for exceeding bias was very low and didn’t
evolve significantly over time. The Fisher exact test for the difference be-
tween the frequency of bias outliers, for all methods together, was 0.2431.
For the absolute bias, there was no interaction between the periods and
methods and no significant difference between the periods. For the meth-
ods, however, a significant difference was found: the Fuchs-Rosenthal and
Makler methods showed a higher absolute bias than the Improved Neubauer
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Table 4.15 Count of regression lines with exceeding variability and regression residual
standard error for the most popular methods in the semen analysis EQA follow-up study.
Period 1: 2005-2007, Period 2: 2008-2011.
Method No. of Variability outliers (%) Residual
Labora- standard error
tories Period 1 Period 2 Period 1 Period 2
Disposable chamber 1 0 0
Bürker 7 0 0 0.129 0.112
Fuchs-Rosenthal 4 33.3 0 0.183 0.181
Improved Neubauer, Positive disp. 36 5.56 2.78 0.138 0.118
Makler 4 75 25 0.204 0.162
Microscope slide 1 100 0
Thoma 3 0 0
Total 55 12.7 3.63
Note: Fuchs-Rosenthal exhibits a residual standard error that is signifantly higher than the residual
standard error from the other methods, except for Makler
Table 4.16 Count of regression lines with exceeding bias and absolute and relative bias for
the data obtained for semen analysis EQA follow-up study. Period 1: 2005-2007, Period 2:
2008-2011.
Method No. of Lines with Absolute Relative
labora- exceeding bias bias
tories bias (%)
Period Period Period
1 2 1 2 1 2
Disposable chamber 1 0 0
Bürker 7 0 0 0.175 0.127 0.069 0.043
Fuchs-Rosenthal 3 0 0 0.304 0.195 0.122 0.086
Improved Neubauer, Positive
disp.
36 0 0 0.097 0.129 0.034 0.052
Makler 4 0 50 0.168 0.054 0.068 0.024
Microscope slide 1 0 100
Thoma 3 0 0
Total 55 0 5.45
Note: absolute bias of Improved Neubauer, Positive disp. is significantly lower than the absolute bias of
the other methods, except for Bürker
with positive displacement. The relative bias showed a significant interac-
tion effect between the time and methods. In the first period, the difference
between the methods were similar to the differences for absolute bias. For
the second period, no significant differences between methods were found.
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4.6.3 Discussion
An evolution in accidental mistakes, identified as outliers against the regres-
sion line, has taken place over time. Nowadays there are less accidental
mistakes and this is the only evolution seen over time.
The results show that the choice for the Improved Neubauer technique with
positive displacement as the reference method was optimal: the method has
the lowest variability. From the other methods, the Bürker method had the
best performance.
4.7 Conclusion
The examples that illustrate the application of the 3-step method have shown
that the method is easily applicable to various types of surveys and that it
can be easily adapted to specific characteristics of a particular survey, for
example in case the regression model suffers from heteroscedasticity. In ad-
dition, the link between poor performance according to the 3-step method
and mistakes in the analytical process has been investigated and confirmed
for two examples for lymphocyte subset counting.
In addition, the method has shown its usefulness for one survey incorporat-
ing a relatively large amount of samples and for a historical series of surveys
with a small number of samples. Of course, the obtained variability estimate
is different: in the first case, the variability estimate is linked with repeata-
bility, while in the second case it is more linked to reproducibility.
Long-term performance of laboratories can be applied in different ways. It
may be performed for a cohort of laboratories continuously using the same
analytical method over a long period and, as such, yield information about
the performance evolution of a certain method. If however the group of lab-
oratories using the same method changes, there is a risk that the evolution
of performance over time is biased. Moreover, an improvement over time of
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accidental mistake rate may reflect a different approach of the EQA orga-
nizer, as has been the case for the alcohol surveys. This finding proofs that
post-analytical aspects are also in EQA surveys an often overlooked aspect.
The largest prerequisite for application of the method is the setting of reliable
target values. Preferably, a reference method, like for alcohol, semen analysis
or lithium, is preferred. In absence of a reference method, however, just as
for lymphocyte subset counting, the median value can easily be taken as the
target value as well. Care has to be taken however and it is adviseable, as
done for this particular survey, to verify the technique of the median value
with the results of a group of expert laboratories.
Finally, some general remarks can be made that apply to all data anal-
ysed in this chapter. An evolution over time was mainly due to a change
in frequency of outliers against the linear regression lines and no evolution
over time for variability and/or bias was detected for laboratories using the
same method over the whole period. These observations may lead to an
important conclusion: the evolution of laboratory performance over time is
mainly attributable by the decrease of spurious results. The results also
show that method performance is a stable factor over time. Hence, wherever
EQA organizers observe an evolution of laboratory variability and/or bias
over time, a distinction should be between changes in accidental mistakes
and pure bias and variability. For the latter, a further distinction needs to
be made between an increased use of better performing methods and an in-
creased performance of individual methods. The EQA for sperm analysis,
for example, has shown that the best performing method has become more
popular in the latest years. In this case, a possible increase in performance in
the Belgian laboratories would be due to an increased popularity of the best
performing method, rather than to an increased performance of the latter.
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CHAPTER 5
Graphical representations of EQA
data
5.1 Introduction
The first chapter of this work mentioned the educational role of EQA pro-
grammes, in which a non-punitive evaluation is given to each individual par-
ticipant. Comparing the result of a laboratory with the results obtained by
other participants, or by performance goals defined by the EQA organizer,
is an important evaluation technique and is greatly supported by the use of
graphical representations. Even more, two international standards require
the use of graphical representations. The IUPAC protocol for Proficiency
Testing [178] for example, clearly stipulates that the EQA organizer should
provide to each participant a report with the evaluation of its performance.
The report should show the distribution of the results from all laboratories
together with the individual score of the laboratory under interest. The re-
sults of all laboratories should be provided in graphical form and the IUPAC
guide clearly suggests histograms or other distribution plots. Also the ISO
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13528 standard [60] requires that EQA participants dispose of tools to in-
terpret their results graphically and describes in detail several options for
a graphical representation of the EQA results, mainly under the form of z-
scores. In analogy with the IUPAC protocol, it requires that participants
dispose of tools to evaluate their results graphically.
Graphical representations should attempt to summarize data by giving as
much information as possible, with as few lines, shapes or colors. For repre-
senting EQA data, we can add some specific requirements: the quality of the
representations should not be influenced by extremely small or large sample
sizes and be robust against the presence of a small fraction of strongly devi-
ating data.
This chapter deals with an in depth discussion of several techniques to rep-
resent EQA data in participant’s reports and looks for further perspectives
to make reports more informative for laboratories.
5.2 Graphics for one-dimensional data
5.2.1 Normal quantile plot
Although called Normal probability plots, the Normal quantile plots for dis-
playing univariate series of data are promoted by the ISO 13528 standard.
They are constructed by using the quantile function as a link between the
original data set and the standard Normal distribution. First, the inverse
quantile function is applied to each value of a data series and the result is
used to calculate the corresponding quantile of a Normal distribution. Sub-
sequently, the original values are plotted along the Y-axis against the values
obtained from the standard Normal distribution along the X-axis.
Normal quantile plots yield information about the shape of the distribu-
tion, as well as identification of exceeding points. In the ideal case, when
the data are normally distributed and no exceeding points exist, the points
136
5.2 Graphics for one-dimensional data
in the scatter plot follow a straight line. In case exceeding points exist, the
points will be situated around a straight line from which the exceeding points
deviate like in Figure 5.1.
Any other deviation from Normality results in a non-linear shape, as can be
seen in Figure 5.2. The ISO 13528 standard suggests identifying the points
with high z-scores individually. The Normal quantile plot fits for schemes
with few and with a lot of participants. For the former, it should be noted
that the normal quantile plot has a higher variability and that the tails of
the line may deviate from the straight line, even when the data do follow a
Normal distribution. In addition, EQA organizers can use the normal quan-
tile plot as a first step to assess the distribution of the reported data and
take necessary actions, like transforming data in case of skewness or splitting
peer groups in case of multimodality [87].
5.2.2 Histograms
Histograms are probably the best known and most frequently used graphi-
cal representation of univariate data series. The range of the data series is
partitioned into non-overlapping intervals of equal width and for each inter-
val bars are graphed of which the height is proportional to the number of
data inside the corresponding interval. The histogram may be extended with
lines representing action limits, for example at + 2s and + 3s from the mean
value. The ISO 13528 standard suggests to draw histograms of the z-scores.
In this way the x-axis is standardized with usually a fixed range and lines at Z
= + 2 and + 3 can be drawn to represent the proficiency assessment criterion.
Although algorithms exist to calculate the optimal interval width, there is
ample choice of how intervals are set. The latter may result in histograms
showing a different shape, although they are made from the same data (see
Figure 5.3). The position of the line of an individual participant informs
about the position of the result of the laboratory with respect to the results
of the other participants. Histograms also allow EQA organizers to evaluate
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Figure 5.1 Normal quantile plot of reported EQA data for
Total protein from one sample by laboratories belonging
to the same peer group, with z-scores outside [-3;3] in-
dicated (sample CP/10587 from survey 2010/3, method
VIS photometry - Biuret with blank on Cobas Integra
(Roche)).
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Figure 5.2 Three normal quantile plots, made of artificially generated data. The points
in graph A form a line with steadily increasing slope, indicating a skewed distribution.
On graph B, the points are situated on a straight line, although the extremes deviate,
indicating a leptokurtic distribution. The lines on graph C tend to lie on an S-shaped
curve, which is typical for bimodal distributions.
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the analytical methodology with respect to performance goals: in the most
optimal case, the histograms extend very slightly beyond the limits of the
performance goals. In case the limits are too wide and distant from the his-
togram, performance goals could be made stricter. On the other hand, when
the histograms extend too often beyond the limits of the performance goals,
the analytical methodology may not meet the required precision and action
should be taken as well, either by expanding the limits or by stimulating
laboratories to improve their analytical methodology.
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Figure 5.3 Four representations of a histogram of the same data reported
for Total protein (sample CP/10587 from survey 2010/3, method VIS pho-
tometry - Biuret with blank on Cobas Integra (Roche)). A and C are the
histograms made of the reported values, B and D from the derived z-scores.
C and D are built with a different choice of intervals than A and B. The
black dashed line helps interpreting an individual result.
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In case of large outliers, the X axis could be restricted such that extreme
observations are not represented on the graph. In this case, a brief indi-
cation should be added along the X-axis. Histograms can easily represent a
large amount of data, but are less effective for representing data from smaller
samples. In the later case, the number of data in each interval may be too
low to yield reliable bar heights.
5.2.3 Empirical Cumulative Distribution Function
In contrast with histograms, that show the density of data around a certain
value, cumulative distribution functions show the proportion of data smaller
than or equal to a certain value. Starting from a sample {x1,x2,...,xn}, the
function Fn(t) counts the number of data xi that are smaller than or equal
to t:
Fn(t) =
1
n
n∑
i=1
[xi ≤ t]
where [xi ≤ t] has the value 1 when x ≤ t and 0 otherwise.
The graph is made by plotting Fn(t) against each corresponding value of
the ordered data series, as shown in Figure 5.4.
Empirical Cumulative Distribution Functions (ECDF) can be drawn for any
n>1. They should be preferred to histograms for small sample sizes. When-
ever large outliers exist, the X-axis should be truncated to show the major-
ity of the data and a brief indication added along the X-axis. Cumulative
distribution functions can easily inform individual laboratories about their
position within the group of reported values: for every value along the hor-
izontal axis, the corresponding value along the X-axis shows the number of
values not larger than the corresponding value. Hence, these graphs are not
only useful for representing reported data, they can also be applied for the
visual representation of any kind of performance indicator, as discussed in
Chapter 3.
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Figure 5.4 An empirical cumulative distribution func-
tion for data reported for Total protein (sample
CP/10587 from survey 2010/3, method VIS photom-
etry - Biuret with blank on Cobas Integra (Roche)).
The dotted line helps interpreting an individual re-
sult, showing that there are about 75% laboratories
that have reported a value lower than or equal to the
individual result.
5.2.4 Box and whisker plots
Box plots are a useful and easy to draw visualization of a univariate series of
data. They are made up of the 25th, 50th and 75th percentile (P25, P50,P75).
A rectangle is drawn from P25 to P75. A line at P50 is drawn inside the rect-
angle. Subsequently, the following simple formula is used to identify outliers:
a result x is outlying if x > P75+1.5(IQR) or x <P25−1.5(IQR), where
IQR=P75−P25 is the interquartile range. The thresholds P25−1.5(IQR) and
P75+1.5(IQR) are named lower and upper inner fences and in case of a Nor-
mal distribution distribution correspond to a z-score of ±2.7. Lines, also
called whiskers, extend from P25 and P75 towards the most extreme values
inside the inner fences. As such, they represent the range of all the points,
not considered as outliers. Points outside this range are considered as out-
liers and represented by small dots. In addition, box plots may be used to
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position the individual value of a certain laboratory with respect to the other
values by plotting it as under the form of an extra symbol in or around the
box plot.
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Figure 5.5 Box plots obtained for two samples reported for To-
tal protein (sample C/9947 and C/9948 from survey 2010/1,
method VIS photometry - Biuret without blank, Beckman)
with similar concentration by laboratories using the same peer
group. The grey squares indicate the individual values ob-
tained by a certain laboratory.
Remark that the formula for detecting outliers are a simple and not wa-
tertight rule. Other rules exist, for example using limits at P25−3IQR and
P75+3IQR, also called inner and upper outer fences. Users of software that
draws box plots automatically are recommended to check the manual for in-
formation about the way how box plots are created.
Just as for histograms, box plots are sample size-independent and can be
easily adapted to the presence of large outliers by adjusting the axis and
adding a small symbol to indicate that values lie outside of the graph. Even
more, they are superior for representing different data series in one plot, be-
cause they can give a similar impression about the data distribution with
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less lines than histograms (see Figure 5.5) .
5.3 Graphs for combining variability and bias
Although not usually done in the clinical setting, EQA organizers may ask
the participants to report the uncertainty of the analytical result for a cer-
tain parameter. Uncertainties may be calculated in several ways. One may
identify all sources of laboratory error, which can be summed up to an un-
certainty measure for a certain result. Other measures of uncertainty may
be found by calculating a standard deviation on repeated measurements on
the same sample, as is often done for analytical method validation.
5.3.1 Normal quantile plot with added variability
A Normal quantile plot can be extended by drawing vertical lines represent-
ing the expanded uncertainty around each plotted value [60]. The expanded
uncertainty is usually taken as twice the uncertainty, expressed as a standard
deviation. Usually, the line is then drawn from the (reported value - 2 × the
standard deviation of the reported result) to (reported value + 2 × the stan-
dard deviation of the reported result). In addition, horizontal lines may be
drawn to represent the expanded uncertainty around the assigned value.
Figure 5.6 shows the resulting normal quantile plot. For correctly estimated
variability measures and obtained analytical results, the vertical lines should
intersect the horizontal boundary representing the uncertainty around the
assigned value.
Care should be taken however when interpreting the results, since the in-
tervals representing the expanded uncertainty could be seen as confidence
intervals and two estimates may be significantly different, even when their
confidence intervals overlap, as the following example illustrates.
Assume that there are two data series. Let us denote by x¯i and SEi the
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Figure 5.6 Normal quantile plot from reported data for Total
protein (sample CP/10587 from survey 2010/3, method VIS
photometry - Biuret with blank on Cobas Integra (Roche))
with extended variabilities, that were simulated. Laboratories
of which the extended uncertainty interval is completely out-
side of the extended uncertainty interval of the median have a
significant bias.
average and standard error of the mean of group i (i=1 to 2) and that the
standard deviations are known beforehand.
A significant difference is found when
|x¯1 − x¯2|√
SE21 + SE22
>QZ(0.975)
where QZ(0.975) is the upper 2.5.th percentile of the standard Normal dis-
tribution. Let us use 2 as an approximate value. Rewriting gives
(x¯1 − x¯2)2 > 4(SE21 + SE22),
On the other hand, two confidence intervals overlap when
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x¯1 + 2SE1 < x¯2 − 2SE2 or x¯1 − 2SE1 > x¯2 + 2SE2
This can be rewritten as
|x¯1 − x¯2| > 2(SE1 + SE2)
or
(x¯1 − x¯2)2 > 4(SE1 + SE2)2
Remark that (SE1 + SE2)2 is larger than (SE21 + SE22) and hence, the test
relying on the hypothesis test will find significance for smaller differences
between x¯1 and x¯2 than the test relying on confidence intervals. As a con-
sequence, the test displayed in Figure 5.6, as suggested by ISO [60], is non-
optimal due to a lack of power.
Other representations that are limited to the special case when uncertainties
have been reported and that are not extensions of known graphics, have been
reported in literature [48, 157]. They are not discussed in detail here because
they rely heavily on reported uncertainties, a practice that is often lacking
in EQAs in clinical settings.
5.4 Combining results of different samples
Just as they can give a fast visual impression of a single series of data,
graphical representations can be used for representing results obtained from
different samples, possibly from different surveys. They are a useful addition
to the graphs described before, in which the evaluation was done for each
sample separately.
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5.4.1 Bar plots of standardized laboratory biases
The ISO 13528 standard describes bar plots in order to give a visual im-
pression of the overall performance of the laboratory, in terms of bias or
variability. The results of the laboratories are represented by vertical lines
that extend from 0 towards the individual z-score obtained for a certain
parameter of a certain sample. Lines representing z-scores obtained from dif-
ferent sample are grouped together and the group of lines for each laboratory
are joined in one graph (see Figure 5.7).
Laboratories with high variability are identified by lines that exceed often
the + 2s, or + 3s limits, in the upper and lower direction, while laboratories
with high bias are identified by lines that point frequently into the same
direction. Hence, bar plots are able to represent different kinds of deviation
from optimality in one graph.
In our opinion, care should be taken however during the interpretation of
the bar plots, in particular when only a few samples are plotted. When the
laboratory suffers from an increased variability, there is a chance that several
lines exceeding z-limits will point in the same direction and hence, suggest
bias instead of variability. This chance decreases however with an increasing
number of samples taken into account in the graph.
In addition, this kind of representation becomes difficult to interpret for
large groups of participants or samples. The vertical axis however could be
limited in case of large outliers. In that case, an extra indication can be
added to the graph.
5.4.2 Youden plot
The Youden plot is an informative graph to represent data obtained for data
from two samples. It is based on a scatter plot, with the results obtained for
two samples by the same laboratories plotted against each other. This yields
usually an oval-shaped scattered cloud of points.
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Figure 5.7 Bar plots of one alcohol survey (2010/2) for labora-
tories that used Headspace chromatography (capillary-column).
Remark that laboratory 6 has all its lines far beneath the zero
line; the laboratory may suffer from exceeding bias. Laboratory
9 has exceeding lines of which one points upwards and one points
downwards. It may have exceeding variability.
A confidence ellipse can be obtained by using the Hotelling T2 statistic. The
ISO 13528 standard notes that the use of the Hotelling T2 is not robust and
hence, strongly influenced by a small fraction of outlying data. Surprisingly
enough, the standard mentions that the details of such a method has not yet
been worked out, althoug it was published 3 years after the appearance in
scientific literature of a robust Hotelling T2 test [189].
Therefore, we would advise to use the robust algorithm instead of the al-
gorithm mentioned in the ISO 13528 standard.
Depending on the position of the points on the scatter plot and with respect
to the confidence ellipse, different zones can be identified and linked to dif-
ferent deviations from the ideal analytical process. Points outside the ellipse
and along its major axis may indicate laboratory bias (zones A and B in Fig-
ure 5.8), points outside the ellipse and away from its major axis indicate high
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Figure 5.8 A Youden plot of reported values of Thyroid Stimulat-
ing Hormone of two samples ( T/8070 2 T/8071, survey 2007/4)
by laboratories using method “Non-Isotopic Roche-Elecsys /
Mod E / Cobas e”, with a robust confidence ellipse. Points in
Zone A and B are distant from the rest of the data along the ma-
jor axis and point to laboratories not following the test method
correctly. Points near zone C have been produced by laboratories
possibly suffering a large analytical variation.
analytical variability (Zone C). Note that the same remark holds as for the
bar plots: high analytical variability may also result in points in zone A or B.
EQA organizers may use Youden plots for reporting to participants and for
visually assessing homogeneity of peer groups as well. In case the peer group
consists of different subgroups with different means, the points will be scat-
tered in different clouds that are distant from each other.
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5.4.3 Plots of repeatability standard deviations
The results of multiple measurements of the same parameter on the same
sample may be used to obtain a measure of within-laboratory variability. A
graph can be made to evaluate the possible bias and variability of laborato-
ries by plotting the within-laboratory standard deviation for each laboratory
against the corresponding average value. In the absence of dependency of
measurements, a confidence region may be calculated by the following curve:
B(x) = spexp

±
√√√√Qχ2(1− α, ; 2)− n
(
x − x¯
sp
)2
√
2(n− 1)

where B is the boundary of the confidence region, Qχ2(1−α; 2) is the (1−α)−
quantile of a Chi-square distribution with 2 degrees of freedom, 1 − α is a
chosen significance level, n is the number of laboratories, x is the grand av-
erage of all results, sp is a standard deviation obtained by pooling all the
individual standard deviations. See the ISO standard for a robust algorithm
for pooling standard deviations. xi is a continuous variable, ranging from
x¯ − sp
√
Qχ2(1− α; 2)
n to x¯ + sp
√
Qχ2(1− α; 2)
n
The plot is shown in Figure 5.9 for a survey of alcohol determination. Re-
mark that the main axis of the shape of the cloud of points is orthogonal
to the main axis of the shape of the confidence regions, meaning that a
considerable between-laboratory variation exists, probably due to a small
laboratory-specific bias.
This representation is remarkably simple and helps not only identifying lab-
oratories with high bias or variability, it also helps to evaluate the method’s
ease to reproduce results between laboratories. The method is still reliable
in the presence of outlying observations and is applicable to groups of small
and large size.
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Figure 5.9 Plot of Standard deviation against average for
the 2010/1 alcohol EQA survey (samples E/10385, E/10387
and E/10388), reported by laboratories that used Headspace
chromatography (capillary-column), with confidence regions
at 95% and 99%.
5.4.4 Shewhart control chart for z-scores
Shewhart charts are well known from internal quality follow up and can be
applied to external quality assessment as well. The graph can be made by
plotting the z-scores obtained for different samples against time. Horizontal
lines at + 1s, + 2s and + 3s help to interpret the results. “Out-of-control”
points are found beyond the + 3s-limits. Other criteria for detecting deviant
processes in the laboratory may be applied as well, such as two out of three
successive points falling outside of the + 2s limits. An example is shown in
Figure 5.10 for the reported results for Ferritine from one particular labora-
tory.
Shewhart control charts are an excellent tool to monitor the performance
of a laboratory over a long time. They can be adapted to extremely outlying
150
5.4 Combining results of different samples
observations by controlling the limits of the vertical axis and putting a spe-
cial mark near the upper or lower horizontal boundary whenever values are
situated outside of the graph. There are however some drawbacks. When
different samples are sent in one survey, one has to make either a dot plot,
in which the z-scores of the different samples are plotted along a vertical
line and a line is drawn through the average value for each survey [60], or
make Shewhart charts per level of concentration. Then, the EQA organizer
should be aware to send each round samples from different concentration
ranges. The latter is not always easy to achieve. Moreover, the laboratory
may have changed analytical methods during the time spanned by the hori-
zontal axis. The plot should be limited to the periods for which results have
been obtained with the same methodology and this has an adverse effect on
the length of the time range for which Shewhart chart can be made.
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Figure 5.10 Shewhart chart for z-scores obtained for Ferritine, obtained
by the same laboratory from 1999 to 2011.
5.4.5 Cusum control charts for z-scores
The cusum control charts for z-scores start from the same model as the She-
whart control charts: the evolution of z-scores over time. A cumulative sum
of z-scores is produced over a certain time window, containing several EQA
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rounds (see Figure 5.11). The cumulative sum is then plotted against time.
The graph is mainly an effective method for detecting measurement bias.
The graph in Figure 5.11 for example shows that the laboratory may have
had a small tendency of a negative bias in 1999 and 2008. The Shewhart
z-score chart effectively also shows three consecutive z-scores below -1 for
these periods.
Advantages and disadvantages of this graphical representation are similar
to those of the Shewhart chart. It may be noted as well that the cumula-
tive sum is always taken over a time window, resulting in a lag for detecting
bias that becomes larger with increasing window size. Therefore, considering
the relatively low frequency of External Quality Control programmes, it may
take long before a bias is detected and hence the effectiveness of this kind of
graphs is not always assured.
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Figure 5.11 A Cusum chart for the results of Ferritine, obtained by the
same laboratory from 1999 to 2011. Z-scores were cumulated over three
consecutive surveys.
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5.4.6 Representation of the 3-step method
The 3-step method, as described in Chapters 3 and 4, is an evaluation tech-
nique that helps distinguishing between accidental mistakes, exceeding vari-
ability and bias. A visual representation of the method should inform the
laboratory about the frequency and nature of its accidental mistakes and give
an overview of its variability and bias and, simultaneously, compare the two
latter with the results found for other laboratories. Therefore, a graphical
representation has been developed consisting of three different graphs: a gen-
eral representation of the applied regression model, a histogram of variabili-
ties and a scatter plot of intercepts versus slopes, extended with a confidence
ellipse.
General representation of the applied regression model
A regression model is easily represented by a scatter plot with the regression
line between the non-outlying reported and target values. Specific modifica-
tions of the representation here are the addition of the 45°-line and a special
indication of outlying regression points, as shown in Figure 5.12. This rep-
resentation allows a rapid evaluation of measurements reported in a certain
time range. The vertical axis can be easily adapted in case of large outliers
and also here, a small symbol can be added to indicate that values are situ-
ated outside of the graph.
The outliers are supposed to result from accidental mistakes and hence their
distribution should be concentration independent. Whenever outliers are
more concentrated near the ends of the regression line, however, the linear
relation between reported and target values is not assured and laboratories
should investigate the departure of linearity in that zone. Comparing the
regression line with the 45°-line informs the laboratory about a possible bias
of its measurements. In case of a significant bias, a regression line parallel
but some distance below or above the 45°-line indicates a constant bias and a
regression line cutting the 45°-line indicates a concentration-dependent bias.
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Figure 5.12 The basis of the 3-step method: a linear regression line. The
full line is the ordinary least squares lines through all the points except the
outlier (indicated by the small triangle), the dashed line is the 45°-line.
ECDF of regression residual standard error
The second step compares the regression residual variability of an individual
laboratory with the regression residual variability obtained for other labora-
tories. An Empirical Cumulative Distribution function, as described before,
is one of the recommended ways of displaying a graphical summary of a uni-
variate series of data, in particular performance indicators.(see Figure 5.13).
Two extra indications may be added to the ECDF:
(1) lines representing residual variability of the individual laboratory (dashed
line in Figure 5.13)
(2) lines representing the upper threshold value for identifying regression
lines with exceeding variability (dotted line in Figure 5.13)
The most important comparison to be made here is between the positions
of the green and red line. A laboratory is flagged for exceeding variability
when the green vertical line (representing the laboratory’s individual resid-
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Figure 5.13 ECDF of regression residual standard error
values found for a group of laboratories using the Roche
enzymatic method in the alcohol EQA survey from survey
2007/1 to 2009/1. The vertical dotted line indicates the
upper threshold value for flagging exceeding variability,
the vertical dashed line represents the regression residual
standard error of a particular laboratory.
ual variability) is to the right of the red vertical line (representing the up-
per threshold). In addition, the green lines inform the laboratory about its
position in terms of residual variability within the whole population of lab-
oratories. The example in Figure 5.13 demonstrates that, although it is not
flagged for being exceedingly large, the regression residual variability of this
laboratory is relatively high, since more than 80 % of the laboratories have
a lower residual variability.
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Scatter plot of intercept versus slope
The intercept and slope of a simple linear regression model, with a fixed
population residual variance, intercept and slope, are negatively correlated.
This negative correlation is still visible when intercept and slope of different
variables are plotted against each other. In general, intercept and slope of
the regression lines of all laboratories can be considered as a bivariate Normal
sample. A robust confidence ellipse using the robust Hotelling T2 statistic
[189] can be calculated around the data made up by the intercepts and slopes
and delineate the area out of which regression lines are flagged for exceeding
bias (see Figure 5.14).
In addition, the value (0,1) may be drawn on the scatter plot, together with
the mean intercept and slope of all the laboratories not having exceeding bias.
The analytical method’s bias may be evaluated by considering a confidence
region around the mean intercept and slope: the method has a significant
bias when the (0,1) point is outside of the confidence region around the
mean intercept and slope. Note that the latter may loose power when there
is a large variability between the position of regression lines of the different
laboratories and/or regression lines are calculated over a small number of
points.
5.5 Towards interactive plots
Traditionally, reports of EQA surveys are produced on paper or more re-
cently, electronically, such as a Portable Document Format (PDF) file before
sending to the participants. The graphical representations discussed so far
have already demonstrated their efficacy in providing information about the
laboratory performance and can be easily drawn on paper or in a PDF. There
is however one major drawback of distributing graphs on paper or in a PDF:
they are rigid and lack any kind of interactivity. The kind, form and selec-
tion of data to be shown is a choice in the hands of the EQA organizer. As
a consequence, the laboratory, sometimes reporting results for many years
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Figure 5.14 Evaluation of the last step of the 3-step method:
bias, via a plot showing intercept versus slope for a group of lab-
oratories using the Roche enzymatic method in the alcohol EQA
survey from survey 2007/1 to 2009/1. The large grey quadrangle
represents the intercept and slope of an individual laboratory.
Grey round points represent the individual intercept and slope
of other laboratories using the same methodology. The triangle
represents the 45°-line (intercept 0, slope 1). The ellipse is the
robust confidence region for the (intercept,slope) combinations
of individual laboratories.
consecutively, has no way for a further graphical exploration of its results
than overviewing several graphs from different reports next to each other.
Interactive graphs on the contrary enable the laboratories to display results
from different rounds according to their own choice and may help them un-
derstanding their results in a better way. For example, the visualization of
the 3-step procedure uses a selection of consecutive surveys as a time frame
and a graph on paper follows the EQA’s organizer choice of length and posi-
tion of the time frame. The time frame length may also be important for the
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Figure 5.15 The evaluation of a method’s mean bias for a group of labora-
tories using the Roche enzymatic method in the alcohol EQA survey from
survey 2007/1 to 2009/1. The grey points are the (intercept,slope) combi-
nations of the individual laboratories. The black dot is the method’s mean
combination of intercept and slope, the ellipse is its confidence region. The
triangle is the point representing the 45°-line. Since the latter is outside the
confidence region of the method’s mean, the method has a significant bias.
cumulative z-score charts, where a laboratory may choose the time window
such that it contains solely results obtained with the same methodology. Of
course, graphs on paper or in a PDF file are not suited for this purpose but
a solution could be worked out within a web page.
Interaction with databases is supported by several programming languages
and applications within web pages are relatively easy to distribute and main-
tain. A solution should exist of graphics that are able to interact with the
user by means of event handlers, mainly triggered after a mouse event. Also,
an interaction with the HTML Document Object Model (DOM) is advisable,
such that an interaction between vector graphics and other HTML elements
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can be assured, for example offering text-based information, triggered by an
event in the graph. For example, a solution that allows the user to click in
a graph on a certain symbol, should trigger an action to show more infor-
mation about the data behind the symbol in text-based format elsewhere on
the page. Three possible technologies may be considered for this purpose:
Adobe Flash, Java and Scalable Vector Graphics.
(1) “Shockwave Flash format (SWF)” objects from Adobe Flash are widely
used. They are produced and compiled before being put on a web
server. With the help of an installed plug-in, they are loaded on the
client machine and can be ’played’. SWF files, however, consist of
a binary file, which doesn’t allow easy text-based searching. They
are able to access HTML DOM objects but the reverse is not always
possible.
(2) “Java applets”. They are small binaries written and compiled in Java
that can run in any browser on any hardware or software platform. Also
here, a plug in, the Java Virtual Machine (JVM), has to be installed be-
fore Java applets can be used. Java is a general-purpose language and
has a specific Application Programming Interface (API) for drawing
and interacting with 2D graphics. Also, it has an extensive database
integration. However, Java is a heavy-weight option, often character-
ized by slow loading. Just as SWF files, Java applets are binaries
that don’t allow easy text-based searching and lack an easy interactiv-
ity with the HTML DOM. An example of a Java applet for drawing
2D graphs are S-PLUS graphlets. The interaction they have with the
HTML DOM is unidirectional: HTML elements can be accessed and
modified from within the graphlets, but objects on the graph cannot
be accessed from within HTML objects or functions.
(3) “Scalable Vector Graphics (SVG)”. They are an open standard devel-
oped by the World Web Consortium (W3C) since 1999. They can be
briefly described as an Extensible Markup Language (XML) format for
describing two-dimensional vector graphics. From the three options,
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they are the only W3C recommendation and their XML format allows
easy text-search facilities. They have a complete integration with the
HTML DOM, so they can be embedded in any web page and inter-
act with any other HTML or function defined in the page. With the
use of AJAX technology, an easy integration with databases is possi-
ble and the graphics are able to respond quickly to user interactions.
Even more, in contrary with the other two suggestions, SVG is an of-
ficial standard supported by the W3C, which means that it should be
supported by the major browsers. Nowadays the most recent versions
of all the major browsers support SVG. The following paragraphs will
explore the SVG technology in further detail.
5.5.1 Scalable Vector Graphics
Information coded by XML is stored in text format. It should be written in
a structured way to be valid. The structure is made up of tags, which are
bounded by the ’<’ and ’>’ characters. There are three types of tags, begin
tags (<..>), end tags (</...>) and tags without elements (<.../>). For the
special case of SVG, every part of the graph, for example a line, polygon or
piece of text, is written down in a tag. The tag for the structure of a text
element for example looks like:
<text x="100" y="190">X</text>
The first word in the tag defines it type. In this example, the word ’text’
indicates a text element. In general, including a text element into an SVG file
will put a certain piece of text on a certain position on the graph. Between
the word text and the > several attributes can be specified. In the above
example, the x and y attribute indicate that the text should be written on
the (x,y) coordinate. Note that SVG coordinates are not like the coordinates
in a usual graph: while readers may be used to put the origin left beneath the
plotting area, SVG puts it in the upper left corner is (0,0). As a consequence,
the Y axis of the coordinate system points downwards. The content of the
text to be written is, in XML language, called the element and is to be found
between the start (<text...>) and end (</text>) tag.
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Example of an SVG document
An example of an SVG document can be found hereafter. Note that the line
numbers have to be removed before the file can be interpreted by a computer.
1. <svg xmlns="http://www.w3.org/2000/svg" version="1.1"
2. width="200" height="200" >
3. <g id="axes">
4. <line x1="20" x2="180" y1="180" y2="180" id="xaxis" stroke="black"/>
5. <line x1="20" x2="20" y1="20" y2="180" id="yaxis" stroke="black"/>
6. <text x="100" y="190" >X</text>
7. <text x="10" y="100" >Y</text>
8. </g>
9. <g id="points">
10. <circle cx="130" cy="130" r="2" stroke="black" fill="white"/>
11. <circle cx="30" cy="125" r="2" stroke="black" fill="white"/>
12. <circle cx="56" cy="135" r="2" stroke="black" fill="white"/>
13. <circle cx="60" cy="85" r="2" stroke="black" fill="white"/>
14. </g>
15. </svg>
The output of the file is visualized in an SVG interpreter as shown in Figure
5.16.
X
Y
Figure 5.16 An example SVG graph.
An SVG document is in fact an XML file with some specific tags. Every
SVG element should start with the <svg> tag. Specifications of the name
space, version, width and height are given. Note that any number of white
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spaces may be put in between different attributes. In this case, the SVG
file will have a width and height of 200 pixels. The 3rt to the 8th line con-
tains the first group of elements. Elements are grouped by the <g...></g>
tags. Grouping elements becomes interesting when one wants to add or re-
move them all together or apply geometrical transformations The 3rd and
4th lines contain the specifications of the horizontal and vertical line. Since
they don’t have elements specified, they are written down by the <.../> tag.
Lines 5 and 6 define the names of the lines as text elements. Lines 9-14 define
the groups of points that will be put on the graph. Each point is defined by
a separate <circle.../> tag. The center of each circle is defined in the cx and
cy specifications and the radius in the r-specification.
This example demonstrates that the specification of attributes is a crucial
part of writing SVG. In fact all location, shape, size and appearance specifi-
cations can be written down by specific attributes.
An extensive list of specifications can be found at the web page of the W3C
(http://www.w3org/Graphics/SVG)
Attributes are also used to describe behavior with respect to mouse events.
If, for example, we want the circle defined on line 12 to be blue inside when
the mouse moves over it and white otherwise, we can write:
<circle cx="60" cy="85" r="20" stroke="black" fill="white"
onmouseover="this.setAttribute(’fill’,’blue’)"
onmouseout="this.setAttribute(’fill’,’white’)"/>
The setAttribute function, as shown in the previous example, is a very useful
Javascript method to change dynamically attributes of an SVG element. In
fact, the function empowers an easy and elegant modification to the location,
shape, size or appearance of any SVG object. Moreover, SVG documents can
be completely integrated into an HTML page, while SVG elements can be
created and their attributes changed on the fly. For example, the following
piece of code describes an HTML page that contains an empty SVG element
and to which elements can be added, modified, or taken away:
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1. <html>
2. <script >
3. function drawcircle()
4. {
5. var D=document.getElementById("ob");
6. S=D.getSVGDocument();
7. ln=S.createElementNS("http://www.w3.org/2000/svg",
8. "circle");
9. ln.setAttribute("cx","150");
10. ln.setAttribute("cy","150");
11. ln.setAttribute("r","20");
12. ln.setAttribute("fill","black");
13. ln.addEventListener("mousemove",function(e){
14. this.setAttribute("stroke","red");
15. this.setAttribute("r","100")
16.},false);
17.ln.addEventListener("mouseout",function(e)
18.{
19. this.setAttribute("fill","black");
20. this.setAttribute("r","20")},false);
21. S.documentElement.appendChild(ln);
22.} ,false);}
23.</script>
24.<body>
25. <object id="ob" data=’svg.svg’
26. width="300" height="300" type="image/svg+xml">
27. </object>
28.<input type="button" value="Draw circle"
29. onclick="drawcircle()">
30. </body>
31. </html>
The file svg.svg contains an empty SVG document:
<svg xmlns="http://www.w3.org/2000/svg"></svg>
It is best to start reading the code on line 25, where an SVG object is defined
with a width and height of 300 pixels. On lines 28-29, an HTML element,
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a button, is defined that will start the function ’drawcircle’ when the user
clicks on it. The function drawcircle to be found at lines 3 to 22 subsequently
paints a black-filled circle on the SVG canvas. The circle becomes larger and
red when the user moves the mouse over it (lines 13-16). It becomes again
black and smaller when the user moves the mouse away from it (lines 17-22).
The above examples demonstrate the possibilities and flexibility of embed-
ding SVG into HTML: Javascript functions, that enable HTML elements to
react on the user’s behavior, can also be applied to SVG elements and a com-
plete interaction between SVG, Javascript and HTML elements is possible.
5.5.2 Long term evaluation of EQA results by SVG
Two examples are given to demonstrate the possible use of SVG for reporting
EQA data. The examples contain data from the Belgian External Quality
Assessment scheme of alcohol and could easily be adapted to other surveys
as well. The alcohol surveys of the Belgian EQA scheme are run twice a year.
At each survey, 5-6 fresh serum samples are sent. The two applications try to
support the pedagogical role of the EQA scheme, in providing a framework
to the participants for exploring their own results and to compare them with
the results obtained by the other laboratories.
A basic element of the two applications is the time selection element, as
shown in Figure 5.17. The surveys are identified by the year during which
they were executed and their ranking number within the year and are rep-
resented by two lines of text: the upper line represents the years, the lower
line the ranking. A selection of surveys is made by positioning a shaded
rectangle over them. The position and width of the rectangle is controlled
by four small triangles to the right of the two lines of text. Clicking on
the left or right triangle makes the grey rectangle to move, respectively,
to the left and the right and, as a consequence, another set of surveys is
selected. Clicking on the upper or lower triangles makes the rectangle, re-
spectively, to extend or shrink. As a consequence, the four rectangles allow
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the user to select surveys according to a moving time window, of which the
length can be adapted. The two examples given will change the data shown
in the graph according to the selected surveys. They can be accessed via
http://www.jewidaco.be/chapter5/examples.html.
2002  2003  2004  2005  2006  2007  2008  2009  2010  2011
     2   1   2   1   2   1   2   1   2   1   2   1   2   1   2   1   2   1   2  
Figure 5.17 Time selection element, used in the two SVG applications. The two
text lines represent the surveys, 2 per year. Surveys for which no data were
reported, such as 2002-1 in this case, are shown in grey.
An interactive environment to explore z-scores
Traditionally, z-scores are graphically accessed over time by displaying them
on Shewhart or Cusum charts (see Figure 5.10 and 5.11), in which they are
plotted against time. From the viewpoint of internal quality control pro-
cedures, plotting z-scores against time is an excellent way to evaluate the
measuring process and the right application of the rules allows a rapid in-
teraction in case the measuring process would be out of control. However,
internal and external quality control procedures differ in several aspects. The
frequency of measuring control samples in EQA, for example, is much lower
and it is not the basic purpose of external quality control to detect rapidly
anomalies in the analytical process.
As mentioned before, the education role of EQA programmes is becoming
more and more important and in the light of this, it may be important for
the laboratory to explore its results with respect to other variables than time,
like, for example, concentration. A plot of the z-scores with respect to the
assigned values (see Figure 5.18), for example, may reveal information about
a certain long-term bias that may be concentration-dependent.
Also, the number of times the z-scores exceed some limits in a particular con-
centration range may help the laboratory to search for appropriate actions.
The combination of this plot with the moving rectangle to select consec-
utive surveys, adds an extra dimension to the plot: the ability to rapidly
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Figure 5.18 An example of a graph of z-scores against concentration,
shown for one particular laboratory for selected surveys for alcohol de-
termination. Remark that about the half of the points (squares) exceeds
the 3s limits, indicating a poorly performing laboratory.
select different surveys allows to user to evaluate its z-scores with respect
to concentration and time simultaneously. In addition, the system reveals
extra information about certain z-scores when the user clicks on them. The
example that can be accessed from the web page. It has four built-in exam-
ples, which can be accessed by clicking on them on the right part of the page.
The z-scores are shown in green when they fit within the + 3s boundaries
and red when they are outside.
The first laboratory has a remarkable high frequency of z-scores outside of
the + 3s boundaries. Remark further that the laboratory has a high fre-
quency of negative z-scores in the beginning and a high frequency of positive
z-scores for more recent surveys.
The second laboratory is a very good performer: it has almost all its reported
results within the +/- 1s boundary. It is interesting for this laboratory to
increase the time frame size such that it covers all the surveys: all the green
points are situated randomly around and very closely to the zero line.
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For the third example, we can see that the frequency of z-scores beyond
+ 3s decreases for the recent surveys.
The fourth example, at last, should be explored by shrinking the size of
the time frame to one survey. Although the results rarely fall beyond the
+ 3s limits, it is clear that this laboratory has a small negative bias: for
several surveys, all z-score values are negative.
An interactive environment to explore the results of the 3-step
method
Long-term performance indicators, like the 3-step method described in Chap-
ters 3 and 4 of this work, assume a constant performance within the time
range under consideration. For this reason, the time frame for evaluation
should be as short as possible. On the other hand, several data are needed
to obtain a representative view of the laboratory performance and for this
reason, the time frame for evaluation should be large enough.
Whenever EQA organizers issue a report with the evaluation of results ob-
tained in several surveys, a time frame should be selected and unfortunately
enough, there is no general rule for calculating an ideal time frame to high-
light the performance of all individual laboratories. Sometimes laboratories
have recently renewed their methodology and they may prefer a short time
frame that contains only data from the surveys for which the new method-
ology has been used. Other laboratories may want to have an overview over
a longer time to check the stable performance of their method.
An application has been developed using the same time selection item de-
scribed before in which the user can freely select the surveys for which the
data will be plotted. The graphs depicting the results of the 3-step method
(see Figures 5.12, 5.13 and 5.14) are each time redrawn after a new selection
of surveys and in this way, a user-driven selection of surveys can be made.
Users are able to select the window such that it spans over a series of surveys
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for which a homogeneous methodology has been applied. The graphs also
allow to give extra, non-graphical information. For example, details about
sample and survey name are given when the user clicks on one of the points
in the regression graph. In addition, the graph showing the results of the
first step has a zoom-in function. By dragging the mouse inside the graph,
a rectangle is drawn. Releasing the mouse button rescales the graph such
that a zoom on the points inside the rectangle is created. Clicking on ’reset
zoom’ shows again the full graph.
The first example is a laboratory that suffers from a high frequency of out-
liers, mainly for concentrations above 1 g/L. The high frequency of outliers
can be visualized easily by extending the survey selection rectangle to all the
surveys.
The second example is a laboratory showing a high variability. The labo-
ratory is flagged for increased variability for as good as any subset of three
continuous surveys, except for data reported from end of 2009 on. This ex-
ample proves that moving the time selection frame forwards and backwards
enables the user to evaluate the evolution of laboratory performance over
time.
The last example shows a laboratory that showed exceeding bias in the be-
ginning of the period. However, it has been able to control bias and for the
latest surveys, not any deviation was found any more. When the time se-
lection frame is set at a width of four surveys, one can clearly see that the
point representing the intercept and slope of the regression line was at the
edge of the cloud of points and often situated outside the confidence region.
Starting from 2008 the data don’t show any bias any more.
5.6 Conclusion
Graphical representations of EQA data are useful tools to give a visual im-
pression of the reported results. They are not only a helpful part of the
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reports sent to the particapiting laboratories, they also serve to the EQA
organizer for quickly overviewing the reported results and searching for dis-
crepancies in the data, like violations of the distributional assumptions. Two
types of graphs can be distinguished.
The first type visualizes the distribution of the data and with the help of
some additional symbols, individual participants can position themselves
with respect to the other participants. They include normal quantile plots,
histograms and box plots, of which the two latter are the most popular and
can serve as each other alternatives. Histograms are easy to understand and
enable an easier positioning of an individual value with respect to the other
results; box plots are easier to be drawn and are more suitable to summarize
different data series in one graph.
The second type include graphical representations of specific questions. They
include the Shewhart type and Cusum charts, graphs that combine bias and
variability and the graphical representation of the 3-step method. For the
3-step method, a small comparison of output in Chapter 4 and Chapter 5
illustrates that the graphical representation of results yields a much better
understanding of the nature of mistakes. For this reason, the graphical rep-
resentation should be preferably used whenever the method is applied in an
individual report.
EQA data, however, have some specific characteristics that should be taken
care of in any kind of graphical representation, since heavy outliers may oc-
cur. A simple redesign of one of the axes may help and an indication will
be added as soon as a value has fallen outside the graph. In addition, the
interpretation of some graphs may be more cumbersome than at first naive
sight. When the expanded uncertainty is shown, for example, one should
bear in mind that significant differences between two populations are not
the equivalent to non-overlapping intervals set up by expanded uncertain-
ties. In addition, in particular for graphs showing bias and variability, care
has to be taken with the assumptions of possible dependency between data.
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Finally, robustness of specific curves should be an issue and implemented
everywhere. For the robust Youden plot, for example, the theoretical elabo-
rations are available.
A major improvement for reporting data to EQA participants, definitely
for displaying data obtained over a longer period, is the use of interactive
graphics. The technology to provide interactive graphical representations to
the participants, under the form of SVG, exists and is well fit for the purpose
of providing interactive graphs of EQA data. They enable a framework in
which the EQA organizer can decide the content and the form of the data
to be shown and the participant has the freedom to explore data in his/her
own way, for example by selecting various subsets of surveys, or by display-
ing textual information near the graphed points of interest. In this way, the
EQA participant is supported in the utilisation of exploring its own results
in order to find deviations from the ideal laboratory process. Also, the inter-
active use of graphics may raise the awareness of mistakes that are overseen
by EQA organizers and may stimulate participants to explore their results
in a much further extent than is nowadays possible.
170
Discussion and Conclusions
External Quality Assessment Programmes for clinical laboratories have been
running for more than half of a century [121]. In Europe, they have mainly
evolved towards programmes with an educational purpose as opposed to pro-
ficiency testing schemes with punitive sanctions as in the US. Today, External
Quality Assessment is considered as a crucial part in the total quality man-
agement of clinical laboratories. It is also a vivid scientific discipline with a
bunch of articles published monthly in peer-reviewed journals.
External Quality Assessment is facing major challenges; in particular novel
statistical approaches need to be developed to help improving the effective-
ness and service of EQA programmes [45]. Obviously, EQA programmes
should respond to changing needs in the field of laboratory medicine, which
has undergone considerable evolution in the last decades. Historically, EQA
focussed mainly on the analytical aspects of laboratory work [125]. Recently,
interest has shifted to assess pre-analytical and post-analytical phases as
well [82, 78]. We believe that major improvements in EQA schemes can be
achieved by being able to screen for pre-analytical and post analytical errors.
Currently, questionnaires and/or check lists are sent to the laboratories to
assess these two critical phases [147, 1, 73]. EQA organizers should try to
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close the gap between their current working processes and those in the clinical
laboratory by mimicking the laboratory processes of the pre-analytical and
post-analytical phases as well. For example, specific sample material could be
used to assess the behaviour of the laboratory staff with respect to handling
uncommon samples or clinical cases [177, 82, 121]. In addition, automatized
reporting systems [91] from the laboratory to the EQA organizer should be
implemented in order to assess post-analytical mistakes. Assessing mistakes
in the pre- and post-analytical phases should be done by modelling their fre-
quency [186]. Several statistical models can be utilized for assessing the ana-
lytical phase, where classical z-scores have proved to be an effective and well
understood concept to assess laboratory performance. Various algorithms for
calculating z-scores have been described [60, 50, 44, 30, 148, 191, 140] and
they can be divided into two categories: the first one consists of techniques
based on robust statistics, whereas methods of the second category proceed
with outlier searching algorithms prior to calculate classical means and stan-
dard deviations [57]. For small sample sizes (n less than 20), an approach
in which outliers are first removed using Grubbs’ test and then mean and
SD are calculated on the remaining values has shown to be superior to ro-
bust techniques. In presence of outliers, however, Tukey’s approach yielded
the least biased estimate of variability. Hence, when robust approaches are
preferred, we suggest Tukey’s approach. In any case, z-scores should not be
calculated for peer groups including less than 6 participating laboratories [26].
A second challenge of EQA programmes is to bring standardization among
methods [65]. Today, different analytical methods don’t necessarily deliver
the same test results for a particular sample, although directives, such as the
EU Directive on IVD products [36] that states that “methods should show
traceability to standards of higher order”, are one step towards standardiza-
tion. In our work, it has been demonstrated that standardization had not
been attained. For example, deviations were found in an EQA programme
for estradiol and progesterone for various methods [27]. In addition, EQA
organizers have to be aware of the quality of the control samples they use.
Often, the control material is treated before it is sent to the participants, so
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that it can be distributed on a large scale and preserved for a longer time
period. As a result, matrix effects problems occur, in the sense that differ-
ences in test results will appear between methods that could be attributed
to the preparation of the sample material and that would not occur for fresh
human samples [98]. Not only should EQA organizers strive towards the use
of material that is free of matrix effects for a large series of parameters, they
should also carefully select the peer groups and restrict themselves to make
comparisons between laboratories that use the same or equivalent method-
ology.
Further, whenever EQA organizers have historical data at their disposal,
they should consider the results from different samples as different variables
spanning in a multivariate space. Multivariate techniques can be applied
to reveal differences between groups of laboratories that may be too large
to obtain reliable estimates of standard deviation if the laboratories were
gathered into a single peer group. Whenever this occurs, EQA organizers
should split up peer groups according to more similar analytical methods.
To perform inter-method comparisons, a broad spectrum of possible tech-
niques can be found in literature. Orthogonal regression is usually preferred
to simple linear regression when analytical techniques are compared in the
same laboratory using various samples [89, 38]. When a target value has been
determined with a reference method, however, EQA organizers may compare
individual methods with the reference one [175]. Because of the possibility
of matrix effects whenever control samples have undergone preparatory steps
that routine samples don’t undergo, we suggest to check for linearity using a
technique that is based on the bootstrap and which can find deviations from
linearity, while allowing for a deviation from linearity that is not clinically
relevant [27]. Whenever matrix effects can be excluded, for example by using
fresh and untreated sample material, and target values for each sample can
be determined, we propose another approach which can distinguish different
types of deviations from the ideal process of laboratories reporting values
equal or close to the target values. This approach consists of three differ-
ent steps [28]. First, a regression model can be built for each laboratory
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separately and outliers against the regression model will be identified using
robust techniques. These outliers can often be linked to accidental mistakes,
which can in turn often be traced back to errors in the pre- or post-analytical
phase. For identifying errors in the analytical phase, the approach proceeds
in a second step after discarding regression outliers and it considers the resid-
ual standard error of the regression line as a measure of analytical variability.
A comparison of this measure between laboratories helps identifying labora-
tories with high analytical variability. In a third and last step, regression lines
with high analytical variability are discarded and the intercept and slope of
the regression lines are considered as indicators of bias. They can be viewed
as following a bivariate Normal distribution, and a robust approach can help
identify regression lines with excessive bias. In comparison to other tech-
niques that evaluate laboratory performance incorporating various samples
[35, 93, 19, 188], this technique has demonstrated superior performance in
estimating and handling outliers, and accurate estimation of bias and vari-
ability. This approach can also be applied for EQA surveys in which several
samples, by preference more than six, have been sent out in one survey or for
evaluation of laboratory performance over a long time period by combining
results from different EQA surveys. In the former case, it yields estimates of
intra-day accidental mistakes, variability and bias; in the latter case, it gives
an overview of long-term laboratory performance.
The approach can also be adapted to specific aspects of various parame-
ters. In case of lack of homogeneity of variances in the relation between
target and reported values, a weighing factor can be applied for the linear
regression model. In addition, when the distribution of the data around the
target value is markedly skewed to be approximated by the Normal distribu-
tion, a logarithmic transformation of the data may be used before applying
the method. The approach has been illustrated by EQA surveys for lithium
and ethanol determination in blood, leucocyte subset counting, and semen
analysis. For the three latter parameters, a long-term analysis was performed
and similar conclusions were drawn for all surveys. Laboratory performance
increased over time. The most obvious change was a decrease in acciden-
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tal mistakes, identified as outliers against the linear regression model. A
comparison of analytical variability and bias over time for laboratories that
used the same analytical methodology over the study period, however, did
not show any clear improvement, although performance differences between
methods were observed. As a consequence, an improvement over time of lab-
oratory performance for the parameters under consideration was explained
by a decrease in accidental mistakes and an increased use of more accurate
methods over time.
Reports that provide valuable feedback from EQA organizers to the par-
ticipants can be considered as a useful tool to support the educational role
of EQA [178, 60]. International standards emphasize the role of graphical
representations in these reports. It is of increasing importance for EQA
organizers to make deliberate decisions about the reporting of the data to
their participants and use novel techniques to improve the communication
channel with the laboratories. As far as the visual representation of data
is concerned, various graphical techniques exist to display the reported data
and to give the participants a visual appraisal of their position with respect
to the other laboratories Traditional visual representations, such as Normal
quantile plots [60, 87], histograms [60], box plots or empirical cumulative
distribution curves can be applied, although in presence of outliers specific
adaptations may be needed. Other visual representations that address spe-
cific questions may be given as well, such as plots that show the evolution of
z-scores, or plots that combine bias and standard deviation in a single graph
[48, 157, 60]. In addition, for the 3-step approach, a specific representation
exists, using a scatter plot to show the linear regression line, an empirical
distribution curve for displaying the regression residual standard error, and
a scatter plot with a confidence ellipse for displaying the distribution of in-
tercepts and slopes. Today, various technical solutions exist to display EQA
data. For example, interactive graphs can be accessed via a web page. This
allows the laboratories to find more textual information about a data point in
a graph, or to quickly change some characteristic of the graphs (e.g. graphs
including data obtained over several suveys, graphs where one can specify the
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time frame in which results should be seen). The graphs do not only allow
EQA organizers to enrich their feedback to the laboratories, they also afford
laboratories to explore their own results and help them to identify possible
sources of mistakes.
In conclusion, while EQA organizers are facing new challenges and oppor-
tunities, the use of novel computing, statistical and graphical tools in EQA
programmes can further enhance the quality and efficiency of clinical labo-
ratory work.
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A1. Linear regression
Consider a response variable Y and an explanatory variable X. Let {(xi,yi),
i=1,...n} be n observations of these variables. The linear regression model
writes
E (Y|x) = a + b.x
or
yi = a + b.xi + ei, i = 1, .., n
where a denotes the intercept, b the slope and ei the residual or error term,
assumed to be Normally distributed N(0,σ2). Estimates of a and b are ob-
tained by minimizing the residual sums of squares, namely
S =
n∑
i=1
e2i
Note that minimizing S is the cornerstone of the regression line calculation.
For this reason, linear regression is often called ’Least Squares Regression’.
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Taking partial derivatives of the above equation with respect to a and b
leads to the following results [152]
bˆ =
∑n
i=1(yi-y¯)(xi-x¯)∑n
i=1(xi − x¯)2
aˆ = y¯− bx¯
where x¯ = ∑ni=1 xi/n and y¯ = ∑ni=1 yi/n.
Linear regression may also be calculated giving different weights to each
pair (xi, yi). The formulas then become
bˆ =
∑n
i=1 wi(yi − y¯w)(xi − x¯w)∑n
i=1 wi(xi − x¯w)2
aˆ = y¯− b.¯x
where x¯w =
∑n
i=1 wixi/
∑n
i=1 wi and y¯w =
∑n
i=1 wiyi/
∑n
i=1 wi. The values wi
are the weights for (xi, yi) and may be taken as the inverse of variance esti-
mates.
The linear regression problem may also be written down in matrix notation.
Disregarding weights, the relation between x and y is then given by

y1
y2
...
yn
 =

1 x1
1 x2
... ...
1 xn

[
a
b
]
+

e1
e2
...
en

or, in shorter notation,
Y˜ = X˜B˜ + E˜
Solving for B˜ gives
180
Appendix
B˜ˆ = (X˜T X˜)−1X˜T Y˜
The matrix X˜ is also called the design matrix.
The estimator of σ2 is given by
s2=
∑n
i=1 eˆ2i
n− 2
where eˆi = yi −
(
aˆ + bˆxi
)
.
Now, two analytical methods, represented by variables X and Y, are equal if
the regression line is the 45°-line (a=0, b=1). Often, this test is assessed by
building a hypothesis test for a and b separately
H0: a=0 ↔H1: a 6=0
H0: b=1 ↔ H1: b 6=1
The solution is found by first calculating the standard errors of a and b:
SE(aˆ) = s
√√√√1
n +
x¯2∑n
i=1(xi − x¯)2
SE(bˆ) = s√∑n
i=1(xi − x¯)2
Then, the null hypotheses are accepted if
∣∣∣∣∣ aˆSE(aˆ)
∣∣∣∣∣<Qt(1− α2 ;n− 2) and
∣∣∣∣∣∣ bˆ− 1SE(bˆ)
∣∣∣∣∣∣<Qt(1− α2 ;n− 2)
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where Qt(1− α2 ; n−2) is the upper
α
2 quantile of the Student’s t distribution
with n-2 degrees of freedom and a is the probability of falsely rejecting the null
hypothesis, by convention set at 0.05. Note that standard statistical software
calculates the above equations by default. One should only be aware that
the null hypothesis concerning the slope tested by default by many statistical
software packages is whether b is equal to 0 and not to 1.
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A2. Orthogonal regression
Assume that the available data (yi,xi) are observations of the true values
(Yi,Xi), i.e.
yi = Yi + εi
xi = Xi + ηi
where Yi and Xi (i=1,...,n) are distributed N(µy,α2y) and N(µx,α2x), respec-
tively and εi and ηi are independent and distributed N(0,λ2ε) and N(0,λ2η),
respectively. The linear model writes
E (Y|X) = a + b.X
There is no simple algebraic solution to the problem of orthogonal regression,
although some solutions may be given if assumptions are made. In clinical
medicine one often assumes that the variabilities λ2ε and λ2η are known up to
a fixed ratio d, δ2 = λ
2
ε
λ2η
. Then, the regression coefficients are calculated as
bˆ =
syy − δ2sxx +
√
(syy − δ2sxx)2 + 4δ2s2xy
2.sxy
aˆ = y¯− bˆ.x¯
where, respectively, sxx =
1
n− 1
n∑
i=1
(xi − x¯)2, sxy = 1n− 1
n∑
i=1
(xi − x¯) (yi − y¯)
and syy =
1
n− 1
n∑
i=1
(yi − y¯)2.
This approach is often called Deming regression. It assumes that the mea-
surement uncertainty is constant over the whole measurement range. Since
this assumption cannot always be made, one can also consider the weighted
Deming regression [89]:
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bˆ =
∑n
i=1 wiziy
′
i∑n
i=1 wizix
′
i
aˆ = y¯w − b.¯xw
with wi= 1[vi + bˆ2ui] , ui =
1
n− 1
n∑
i=1
(xi − x¯)2,vi = 1n− 1
n∑
i=1
(yi − y¯)2,
x′i = xi − x¯w, y′i = yi − y¯w and zi = wi(vˆix′i + bˆuˆiy′i).
Because zi, wi, x¯w and y¯w are functions of b, an iterative calculation pro-
cedure is required. First a value of n−1 can be given to every wi. Next,
estimates of zi, b, x¯w and y¯w can be calculated, which can in turn be used
to update the values of wi. This iteration may converge until the new values
of wi obtained after each iteration don’t differ more than a predefined small
value. The sampling variability of the regression coefficients estimates, nec-
essary to build hypothesis testing like in the simple linear regression case,
are calculated as
Var(bˆ) = Q2
n∑
i=1
w2i [(x
′
i)vi + (y
′
i)ui]
Var(aˆ) =
( n∑
i=1
wi
)−1
+ 2(x¯w + 2z¯wQ)zwQ + (x¯w + 2z¯w)Var(bˆ)
where Q−1 = ∑ni=1 wi[x′iy′ibˆ + 4z′i(zi − x′i)] and z′i = zi−z¯w, z¯w =
∑n
i=1 wizi∑n
i=1 wi
Another assumption which can be made is the equality of the ratios of the
analytical error variance to the total variance:
λ2x
σ2x
=
λ2y
σ2y
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Then, the slope of the regression writes bˆ = ±
n∑
i=1
(xi − x¯)2
n∑
i=1
(yi − y¯)2
.
where the sign is equal to the correlation coefficient between X and Y. This
approach is called the standardized principal component [38].
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A3. Passing-Bablok regression
A3.1 Calculation of regression coefficients
A method that doesn’t require any special assumptions regarding the dis-
tribution of the data or the measurement errors of the two methods was
described by Passing and Bablok [9, 10].
Let
xi = Xi + εi
yi = Yi + ηi
where Xi and Yi (i=1,...,n) are random variables from an arbitrary, contin-
uous distribution and εi, ηi are random error terms, both coming from the
same type of distribution. Their variances λ2ε and λ2η need not to be constant
within the sampling range but should remain proportional, that is
δ2=
λ2η
λ2ε
The slopes of the straight lines between any two points are used for the es-
timation of b. They are given by Sij =
yi − yj
xi − xj , 1≤i<j≤n. There are C
n
2
possible ways to connect any two points. Any Sij with a value of −1, 0 or
+∞ is disregarded, so that in total there are m≤ Cn2 slopes Sij. Observe that,
since this method is only to be applied to continuous variables, the chance
of having Sij equal to −1, 0 or +∞ is low.
Then, let k be the number of values of Sij with Sij< −1 and S(k) the kth
slope in the sorted sequence of all the slopes, S(1)≤S(2)≤...≤S(n). Using k as
an offset, b is estimated by
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bˆ =

S(m+1
2 + k
) if m is odd
1
2
(
S(m2 + k) + S(
m
2 + 1 + k)
)
if m is even
Remark that the formulas for the calculation of bˆ differ slightly between the
first [9] and last [10] paper of Passing and Bablok. We opted to display the
formulas mentioned in the first paper.
A3.2 Confidence intervals for regression coefficients
For the construction of a two-sided confidence interval for b at the a level,
let QZ(1− α2 ) denote the upper α2 quantile of the standardized Normal dis-
tribution.
With Cα=QZ(1− α2 )
√
n(n− 1)(2n + 5)
18 and M1 =
m−Cα
2 , M2 = m−M1 + 1,
where M1 is rounded to an integer value, the confidence interval for b is given
by S(M1+k) ≤ b ≤ S(M2+k).
The intercept a is given by
aˆ = med
1≤i≤n
{
yi − bˆxi
}
If bL denotes the lower limit and bU the upper limit of the confidence interval
for b, then the corresponding limits for a are given by
aˆL = med1≤i≤n{yi − bˆUxi}
aˆU = med1≤i≤n{yi − bˆLxi}
It should be noted that the confidence intervals around the regression coeffi-
cients are usually wider than when classical linear regression is used [180, 9].
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A4. Method comparison for multiple analyses
of a limited number of samples
The assumption of linearity may be performed by a lack of fit test [105]. The
test compares an ANOVA-model, where each group of measurements for a
certain xi as target value is considered as a separate group, with a regression
model where the different values xi are considered to be continuous. If there
are n laboratories that have reported results for m samples, we can write the
ANOVA and regression design matrices as
ANOVA

x1 0 0 ... 0
... 0 0 ... 0
x1 0 0 ... 0
0 x2 0 ... 0
0 ... 0 ... 0
0 x2 0 ... 0
... ... ... ... ...
0 0 0 ... xm
0 0 0 ... ...
0 0 0 ... xm

Regression

1 x1
... ...
1 x2
... ...
1 xm

In both matrices, there are as much values xi as there are laboratories that
have reported values for the corresponding sample. For both models, the
residual sum of squares (SSE) is calculated.
For ANOVA, the Residual Sums of Squares writes SSEA=
∑m
i=1
∑n
j=1(yij − x¯i)2
and for regression, we have SSER=
∑m
i=1
∑n
j=1(yij − aˆ − bˆxi)2.
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Then, the quantity
F = SSER − SSEA
SSEA
.n−m
m− 2
follows an F(m−2,n−m) distribution. The null hypothesis, stating that there is
no lack of fit, is rejected if F is larger than a QF (1− α;m− 2, n−m) where
a is the false rejection rate. It is a very powerful test and may reject the
null hypothesis solely based on statistical and no clinical reasons. For this
reason, one may adopt it by allowing a minimal deviation from linearity for
each sample and use the bootstrap [34] to obtain the null distribution.
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A5. Multivariate Analysis of Variance
The matrix notation of a MANOVA model is similar to the notation of an
ANOVA model:
Y˜n×p = X˜n×p.B˜r×p + E˜r×p
Assuming we have p samples and n laboratories, Y˜ is an n×p matrix of re-
sponse variables, X˜ is a full-rank n×r matrix of group effects (for one-way
MANOVA, r is the number of groups to compare), B˜ is an r×p matrix of
group effects. E˜ is the n×p error matrix. The solution is found by calculat-
ing the between-group sum of squares and the within-group sum of squares
matrix. The two matrices are used to calculate an F-statistic under the null
hypothesis. Several versions of the test are available and there is no clear
agreement about the optimality of the tests. We follow the recommendation
of Olson [111, 110] and use the Pillai-Bartlett’s trace, which is calculated as
PB = tr(H˜T˜−1)
where H˜ is the between-group sum of squares matrix and reflects the differ-
ences between the groups. In general, its values increases with increasing
difference between groups. T˜ is the sum of the between-group and within-
group sum of squares matrix, the latter reflecting the variability between
values of the same group. The trace is the sum of the eigenvalues of a ma-
trix. Given s=rank of H˜, under the null hypothesis of no difference between
groups, the Pillai-Bartlett’s trace follows an F[p(r−1),s(n−r+s−p)] distribu-
tion. A hypothesis test compares PB with this F-distribution and rejects
the null hypothesis when PB>QF[1− α; p(r− 1); s(n− r + s− p))], where s
= min(p, r− 1).
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